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CONFORMATIONALLY STABILIZED HIV 
ENVELOPE IMMUNOGENS 
CROSS REFERENCE TO RELATED 
APPLICATION 
This application is a continuation application of U.S. 
patent application Ser. No. 13/232,775, filed Sep. 14, 2011, 
now U.S. Pat. No. 8,268.323, which is a divisional application 
of U.S. patent application Ser. No. 12/065,894, filed Mar. 5, 
2008, now U.S. Pat. No. 8,044,185, which is the U.S. S371 
National Stage of International Application No. PCT/ 
US2006/034681, filed Sep. 6, 2006, published in English 
under PCT Article 21(2), which in turn claims the benefit of 
U.S. Provisional Application No. 60/713,725, filed Sep. 6, 
2005: U.S. Provisional Application No. 60/729,878, filed 
Oct. 24, 2005: U.S. Provisional Application No. 60/731,627, 
filed Oct. 28, 2005; and U.S. Provisional Application No: 
60/832,458, filed Jul. 20, 2006. All of the prior applications 
are incorporated by reference herein in their entirety. 
FIELD 
The present disclosure relates to stabilized forms of human 
immunodeficiency virus gp120 envelope protein, specifically 
to crystalline forms of gp120, high resolution structures 
obtained from these crystals, and use thereof. 
BACKGROUND 
The primary immunologic abnormality resulting from 
infection by human immunodeficiency virus (HIV) is the 
progressive depletion and functional impairment of T lym 
phocytes expressing the CD4 cell Surface glycoprotein. The 
loss of CD4 helper/inducer T cell function probably underlies 
the profound defects in cellular and humoral immunity lead 
ing to the opportunistic infections and malignancies charac 
teristic of the acquired immunodeficiency syndrome (AIDS) 
(Lane et al., Ann. Rev. Immunol. 3:477, 1985). Studies of 
HIV-1 infection of fractionated CD4 and CD8 T cells from 
normal donors and AIDS patients have revealed that deple 
tion of CD4 T cells results from the ability of HIV-1 to 
selectively infect, replicate in, and ultimately destroy this T 
lymphocyte subset (Klatzmann et al., Science 225:59, 1984). 
The possibility that CD4 itself is an essential component of 
the cellular receptor for HIV-1 was first indicated by the 
observation that monoclonal antibodies directed against CD4 
block HIV-1 infection and syncytia induction (Dalgleish et 
al., Nature 312:767, 1984; McDougal et al., J. Immunol. 
135:3151, 1985). This hypothesis has been confirmed by the 
demonstration that a molecular complex forms between CD4 
and the major envelope glycoprotein of HIV-1 (McDougal et 
al., Science 231:382, 1986) 
The major envelope protein of HIV-1 is a glycoprotein of 
approximately 160 kD (160). During infection proteases of 
the host cell cleave gp160 into gp120 and gp41. gp41 is an 
integral membrane protein, while gp120 protrudes from the 
mature virus. Together gp120 and gp41 make up the HIV 
envelope spike. 
The HIV envelope spike mediates binding to receptors and 
virus entry (Wyatt and Sodroski, Science 280:188, 1998). The 
spike is trimeric and composed of three gp120 exterior and 
three gp41 transmembrane envelope glycoproteins. CD4 
binding to gp120 in the spike induces conformational 
changes that allow binding to a coreceptor, either CCR5 or 
CXCR4, which is required for viral entry (Dalgleish et al., 
Nature 312:763, 1984; Sattentau and Moore, J. Exp. Med. 
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174:407, 1991: Feng at al., Science 272:872, 1996; Wu et al., 
Nature 384:179, 1996; Trikola et al., Nature 384:184, 1996). 
The mature gp120 glycoprotein is approximately 470-490 
amino acids long depending on the HIV strain of origin. 
N-linked glycosylation at approximately 20-25 sites makes 
up nearly half of the mass of the molecule. Sequence analysis 
shows that the polypeptide is composed of five conserved 
regions (C1-C5) and five regions of high variability (V1-V5). 
With the number of individuals infected by HIV-1 
approaching 1% of the world's population, an effective vac 
cine is urgently needed. An enveloped virus, HIV-1 hides 
from humoral recognition behind a protective lipid bilayer. 
An available viral target for neutralizing antibodies is the 
envelope spike. Genetic, immunologic and structural studies 
of the HIV-1 envelope glycoproteins have revealed extraor 
dinary diversity as well as multiple overlapping mechanisms 
of humoral evasion, including self-masquerading glycan, 
immunodominant variable loops, and conformational mask 
ing. These evolutionarily honed bathers of diversity and eva 
sion have confounded traditional means of vaccine develop 
ment. It is believed that immunization with effectively 
immunogenic HIV gp120 envelope glycoprotein can elicit a 
neutralizing response directed against gp120, and thus HIV. 
The need exists for immunogens that are capable of eliciting 
an immunogenic response in a Suitable Subject. In order to be 
effective, the antibodies raised must be capable of neutraliz 
ing a broad range of HIV strains and Subtypes. 
SUMMARY OF THE DISCLOSURE 
Disclosed herein are gp120 polypeptides and nucleic acid 
molecules encoding gp120 polypeptides, which are useful to 
induce an immunogenic response to a lentivirus, such as SIV 
or HIV (for example HIV-1 and HIV-II) in a subject. In 
several embodiments, the gp120 polypeptides are stabilized 
in a CD4 bound conformation by the introduction of a plu 
rality of non-naturally occurring cross-linking cysteine resi 
dues. In other examples, the gp120 polypeptide has the V3 
loop in an extended conformation. 
Immunogenic compositions containing a therapeutically 
effective amount of gp120 polypeptides and nucleic acid 
molecules encoding gp120 polypeptides are also disclosed. 
Also disclosed are methods for eliciting and/or enhancing an 
immune response in a subject, for example by administering 
an immunogenic composition. 
Crystalline forms of gp120 are disclosed as are crystal 
structures of gp120 polypeptides obtained from these struc 
tures. Methods are also disclosed for identifying an immuno 
gen that induces an immune response to gp120 using these 
crystal structures. Also provided by this disclosure is a 
machine readable data storage medium including a data Stor 
age material encoded with machine readable data corre 
sponding to the coordinates of the crystal structures disclosed 
herein. A computer system is disclosed for displaying the 
coordinate data from these crystal structures of gp120. Such 
as the atomic positions, Surface, domain, or region of the 
gp120 polypeptide. 
The foregoing and other objects, features, and advantages 
of the invention will become more apparent from the follow 
ing detailed description, which proceeds with reference to the 
accompanying figures. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a schematic representation of the development 
cycle for gp120 immunogens stabilized in the CD4-bound 
conformation. Qualitative Biacore analysis was used as an 
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initial screen to determine if CD4 and the CD4 induced 
(CD4i) antibodies still bound. Isothermal titration calorim 
etry (ITC) and crystal structure determination were used to 
refine the gp120 immunogens. 
FIG. 2 is a set of computer generated images. The images 
show the modeled structures of wild-type gp120 compared 
with cavity-filling and double cysteine mutants. Each pair of 
panels shows the HXBc2 core wild-type structure (left pan 
els) and the mutant structure (right panels). Data ranged from 
minimum Bragg spacings of 1.9A to 2.5 A. 
FIG. 3 is a set of computer generated images. The images 
show the positions of conformationally stabilizing mutations 
in the CD4-bound structure of HIV-1 (left) and the unli 
ganded structure of SIV (right). Disulfide separations for each 
of the mutations in the CD4-bound and unliganded structure 
were calculated and are given in Table 3 below. 
FIG. 4 is tabulated date and plots of neutralization data 
obtained from rabbits immunized with four prime cycles of 
BSA or the indicated gp120. FIGS. 4A and 4B are tables 
showing the percent neutralization of the indicated viruses by 
sera obtained from rabbits immunized with the indicated 
stabilized forms of gp120, followed by immunization with a 
stabilized gp140 trimer. FIG. 4C is tabulated neutralization 
data from sera obtained from the indicated animals. The data 
show the effects of various peptides on the neutralization of 
HIV isolateYU2.SG3. This data demonstrates that the YUV3 
peptide blocks neutralization of HIV isolate YU2.SG3 by 
antibodies produced by the boost prime immunization 
scheme described in Example 5. FIGS. 4D-4M are graphical 
representations of the data shown in FIG. 4C. 
FIG. 5 is a computer generated image of the modeled 
structure of an HIV-1 gp120 core with V3 as defined by the 
coordinates in Table 2. The crystal structure of core gp120 
with an intact V3 is shown bound to the membrane-distal two 
domains of the CD4 receptor and the Fab portion of the X5 
antibody. In this orientation, the viral membrane would be 
positioned toward the top of the page and the target cell 
toward the bottom. 
FIG. 6 is an alignment of the V3 sequence from the indi 
cated HIV strains and clades and computer generated images 
of the structures of the V3 loop as set forth in Table 2. FIG. 6 
(A) V3 sequence. The sequences of JR-FL (SEQID NO: 21) 
and HXBc2 (SEQ ID NO: 22) are shown along with the 
consensus sequence of clades A (SEQID NO. 23), B (SEQID 
NO: 24), and C (SEQ ID NO: 25). For the consensus 
sequences, absolutely conserved residues are shown in upper 
case, with variable residues in lowercase. Single letter amino 
acid abbreviations: A, Ala; C, Cys; D, Asp; E, Glu, F, Phe: G, 
Gly; H. His; I, Ile; K, Lys: M, Met; N., Asn; P. Pro: Q, Gln: R, 
Arg; S, Ser: T. Thr, V. Val; Y. Tyr. The conserved (Arg-Pro) 
and (Gly-Pro-Gly-Arg) motifs indicated in grey FIG. 6 (D) 
and FIG. 6 (E). FIG. 6 (B) V3 electron density and B values. 
2Fobs-Fcalc density is shown for the entire V3 region and 
contoured at 1s. FIG. 6 (C) V3 structure. The entire V3 is 
shown. Regions corresponding to the fixed base, accordion 
like stem, and b-hairpin tip are labeled. FIG. 6 (D) Close-up 
view of the V3 base. From its N terminus (Cys296), V3 
extends the antiparallel sheet on the outer domain of gp120. 
After hydrogen bonding for three residues, additional sheet 
contacts are interrupted by two conserved residues: Arg298, 
whose side-chain hydrogen bonds to three carbonyl oxygens, 
including two on the neighboring outer domain strand; and 
Pro299, which initiates the separation of outgoing and return 
ing V3 Strands. In the returning strand, antiparallel b-sheet 
interactions with core gp120 recommence with the carbonyl 
of residue 297 and continue to the disulfide at Cys331. Main 
chain atoms are shown for the core and V3 base. Hydrogen 
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bonds are depicted with dashed lines, with select distances in 
A. All atoms of the highly conserved Arg298, Pro299, and 
Cys296-Cys331 disulfide are shown, with Arg and Pro car 
bons highlighted in yellow and disulfide in orange. FIG. 6 (E) 
Conformation of the V3 tip. From Ser306 to Gly312, the main 
chain assumes a standard b-conformation, which terminates 
in a Gly-Pro-Gly-Argb-turn (residues 312 to 315). After the 
turn, the returning density is less well defined, indicative of 
some disorder. All atoms of the tip are colored as in FIG. 6 
(C), with carbon atoms of the conserved tip highlighted in 
green. Hydrogen bonds that stabilize the Bhairpin are shown 
as in FIG. 6 (D). 
FIG. 7 is a computer generated image of a modeled gp120 
trimer and a coreceptor schematic. FIG. 7(A) V3 in the con 
text of a trimer at the target cell surface. The structure of the 
CD4-triggered gp120 with V3 was superimposed onto the 
structure of four-domain CD4 and the trimer model obtained 
by quantification of Surface parameters. In this orientation, 
the target cell membrane and coreceptor are expected to be 
positioned toward the bottom of the page. FIG. 7 (B) Sche 
matic of coreceptor interaction. CCR5 is shown with its 
tyrosine-sulfated N terminus (at residues 3, 10, 14, and 15) 
and three extracellular loops (ECLs). V3 is shown with its 
conserved base interacting with the sulfated CCR5 N termi 
nus and its flexible legs allowing its conserved V3 tip to reach 
the Second ECL of CCR5. 
FIG. 8 is a set of computer generated images modeling of 
the V3 loop bound to the indicated antibodies. The images 
show the configuration of the loops and the accessibility of V3 
to neutralizing antibodies. The molecular Surfaces of neutral 
izing antibodies that block coreceptor binding are shown 
superimposed onto gp120 in the context of V3; antibodies 
17b and X5 bind to the conserved coreceptor binding site on 
the core, whereas monoclonal antibodies 50.1, 58.2, 59.1, 
83.1, and 447-52D bind to V3. FIG.8 (A) Superposition of V3 
structures. Core with V3 is shown with V3 peptides as 
extracted from peptide-anti-V3 neutralizing antibody com 
plexes after superposition of the conserved V3 tip. FIG. 8 (B) 
Antibody accessibility of V3. Core gp120 with V3 (ribbon 
representation) is shown in two perpendicular views with Fab 
fragments (molecular Surface representation) of antibodies 
that bind at the coreceptor binding site on either core or V3. 
V3 is completely surrounded by neutralizing antibodies, Sug 
gesting a high degree of accessibility for generating an 
immune response. 
FIG.9 is a set of computer generated images demonstrating 
the induced fit of the X5 CDR H3 loop. FIG.9 (A) Bound X5 
structure. A stereo depiction is shown for all atoms of the 
CDR H3 loop of X5. Electron density (Fo-Fc. 3O) is shown 
for the loop after simulated annealing to remove model bias. 
FIG. 9 (B) Free versus bound conformations of X5. Stereo 
depictions of the CO-traces are shown for the two conforma 
tions of the free X5 and of the X5 in the final refined structure 
of the complex with the V3-containing gp120 core. Co-shifts 
are shown, with the 17 A shift of Gly 100H labeled. (C)Same 
as (B), but rotated by 90; dotted lines connect equivalent 
amino acids of free and bound X5. 
FIG. 10 is a set of computer generated images and bar 
graphs showing the analysis of coreceptor binding to gp120. 
FIG. 10 (A) Surface chemistry. The gp120 core with V3 is 
shown in three orientations. The middle row shows an orien 
tation similar to that in FIGS. 5 and 6, an orientation in which 
the “outer face of the V3 loop is closest to the viewer. The top 
row is rotated 180° about a vertical axis (showing the “inner 
or core-proximal face) and the bottom row is rotated 90° 
about a horizontal axis. In the first column, a ribbon diagram 
shows gp120 colored in grey and V3 in red. The next columns 
US 8,715,686 B2 
5 
represent the surface of gp120 and V3 color-coded according 
to the properties of the underlying atoms. Column 2 shows the 
molecular Surface colored according to the sequence variabil 
ity of the underlying amino acids for Clade B, with variable 
regions in purple and conserved regions in white. Columns 3 
and 4 show the mutational effect of varying amino acids on 
CCR5 binding (column3) or on the binding of sulfated CCR5 
Nterminal peptides (column 4). Black defines surfaces that 
were not tested, yellow regions that when altered do not affect 
binding, and green areas where alterations significantly affect 
binding. Column 5 depicts the electrostatic potential at the 
Solvent accessible Surface, with blue showing electropositive, 
red electronegative, and white apolar. Column 6 depicts the 
gp120 surface with modeled N-linked glycans (Nacetylglu 
cosamine) 20mannose)3 cores in orange-yellow, with the 
301 glycan highlighted in purple. The molecular Surface cor 
responding to positions “11” and "25", suggested to be 
important in distinguishing between CXCR4 and CCR5, are 
highlighted, as well as residue 440 which sequence analysis 
indicates is also of some significance in this regard. FIG. 10 
(B) V3 sequence variation. The sequence variation was quan 
tified (see methods) and is expressed as an entropy score: a 
score of Zero indicates absolute conservation, a score of 4.4 
indicates complete randomness. The V3 in B clade viruses 
which use CCR5 is comparable in terms of overall variation 
with other regions of gp120. The median entropy of each 
position within V3 is 0.21, and the interquartile range is 
0-0.59. If one excludes the named variable domains, the rest 
of gp120 has a median entropy of 0.2, with an interquartile 
range of 0.-0.44. There is no statistical difference between 
these two distributions (Wilcoxon rank-Sump value=0.14). In 
contrast, V1,V2, V4 and V5 are much more variable (median 
entropy=1.24, interquartile range 0.67-1.70, p value com 
pared to V3, <10-9.) Graphed in red and blue, respectively, 
are the position-dependent entropy score from 242 CCR5 
using isolates (R5) and 47 CXCR4-using isolates (X4). 
Twenty positions were found to be significantly more variable 
in X4 than R5 viruses after correction for multiple tests. In 
particular, the N-linked glycosylation site (NNT) is highly 
conserved in R5 viruses, with 238/242 viruses reported to be 
R5 in the Los Alamos database carrying the potential glyco 
sylation site at position 301, whereas only 17/47 X4 viruses 
retain the site (p<10-10). This glycan has been previously 
observed to influence overall neutralization sensitivity. 
Finally, insertions were found with higher frequency in X4 
viruses. The consensus R5 and X4 sequences are shown. The 
entropy scores from 64 R5 and 19 X4 Clade B isolates are 
shown, along with the respective consensus sequences. Aster 
isks denote where the consensus X4 sequence is the same as 
the consensus R5 sequence. 
FIG.11 is a set of computer generated images that show the 
alignment of V3 peptide:antibody structures with V3 in the 
context of core gp120. FIG. 11 (A) X-ray structures. The 
structures of V3 are shown either in the context of core gp120 
or bound to antibody 50.1,447-52D, 59.1, 83.1, or 58.2. FIG. 
11 (B) Nuclear magnetic resonance (NMR) structures. The 
NMR ensembles are shown for free V3), as well as for V3 
peptides bound to antibodies, 0.5 B and 447-52D. All struc 
tures are aligned with the conserved Pro-Gly of the tip. 
FIG. 12 is a set of computer generated images showing the 
modeled structure of the V1/2 for HXBc29c mutant. 
FIG. 13 is an alignment of the amino acid sequences of the 
HXBc2 core (SEQID NO: 20) with the New HXBc29c (SEQ 
ID NO: 1). 
FIG. 14 are nucleotide sequences that encode HXBc2 
gp120 WT and stabilized forms thereof. FIG. 14A is a nucle 
otide sequence of gp120 HXBc2 DM (SEQ ID NO:3), a 
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nucleotide sequence of gp120 HXBc2 Core4a (SEQID NO: 
4), and a nucleotide sequence of gp120 HXBc2 Core 4b (SEQ 
ID NO. 5). FIG. 14 B is a nucleotide sequence of gp120 
HXBc2 Core4c (SEQ ID NO: 6), a nucleotide sequence of 
gp120 HXBc2 Core(6a (SEQ ID NO: 7), and a nucleotide 
sequence of gp120 HXBc2 Coreób (SEQ ID NO: 8). FIG. 
14C is a nucleotide sequence of gp120 HXBc2 Core8a (SEQ 
ID NO: 9), a nucleotide sequence of gp120 HXBc2 Core8b 
(SEQ ID NO: 10), and a nucleotide sequence of gp120 
HXBc2 Core8c (SEQ ID NO: 11). FIG. 14D is a nucleotide 
sequence of gp120 HXBc2 Core.9a (SEQ ID NO: 12), a 
nucleotide sequence of gp120 HXBc2 Core.9b (SEQ ID NO: 
13), and a nucleotide sequence of gp120 HXBc2 Core9c 
(SEQID NO: 14). FIG.14E is a nucleotide sequence of gp120 
HXBc2 Core10a (SEQID NO: 15), a nucleotide sequence of 
gp120 HXBc2 Core10b (SEQID NO: 16), and a nucleotide 
sequence of gp120 HXBc2 Core 10c (SEQID NO: 17). FIG. 
14F is a nucleotide sequence of gp120 HXBc2 Corella (SEQ 
ID NO: 18), a nucleotide sequence of wild type (WT) gp120 
HXBc2 (SEQ ID NO: 19), and a nucleotide sequence of 
gp120 HXBc2 Core New 9c. 
FIG.15 is an example of an isothermal titration calorimetry 
curve for the binding of a soluble form of CD4 to a gp120 
polypeptide. Thermodynamic properties describing this 
molecular interaction can be extracted from such a curve. The 
table shows the extracted thermodynamic parameters of a 
selected set of gp120 polypeptides binding to a soluble form 
of gp120. The collection of such data and the extraction 
thermodynamic parameters is well known in the art. 
FIG. 16 is a set a plots of neutralization data for various 
HIV isolates in the presence and absence of CD4, showing the 
effect of CD4 triggering on viral neutralization. FIG.16A is a 
bar graph showing the percent neutralization by SCD4 trig 
gering of the V3 loop epitope. Data shown are percent neu 
tralization of pseudovirus YU2 by the monoclonal antibodies 
(mAb) or sera listed under each set of bar graphs. The white 
bar shows neutralization by SCD4 alone. The first hatched bar 
shows neutralization by the specified antibody alone. The 
second hatched bar shows the calculated (expected) neutral 
ization by a combination of sGD4 and the specified antibody. 
The stippled bar shows the observed (actual) neutralization 
by the combination of SCD4 and the specified antibody. 447 
and 39F are anti-V3 mAbs. 17b is a mAb to the co-receptor 
binding site. 82-2 is an individual guinea pig Sera derived 
from immunization with dCFIdV12 (Ball). 9427 is an indi 
vidual baboon sera derived from immunization with 
gp140GCN-4 (YU2). Observed is measured percent neutral 
ization with sGD4+Antibody. Expected=calculated additive 
effect of the two antibodies assuming they act independently. 
This effect is the product of the fraction remaining virus for 
each Ab; e.g. an antibody that produces 50% neutralization 
leaves 0.5 virus remaining. A second antibody with 50% 
neutralization would reduce that by 50%, leaving 0.25 frac 
tion remaining virus. Thus, the effect of the two antibodies is 
0.5x0.5–0.25. And 0.25 remaining is 75% neutralization. 
FIG. 16B is a bar graph of the actual luciferase (RLU) data 
plotted in FIG.16A. The figure legend describes each bar. The 
antibodies and sera used are as described for FIG.16A. FIG. 
16C is a bargraph of the actualluciferase (RLU) data for HIV 
strain JRFL. The antibodies tested are indicated. FIG.16 Dis 
a line graph shows percent neutralization of mAb 447 with the 
indicated amount of SCD4 present (X-axis), calculated after 
affect of sGD4 is taken into account. The diamonds (0) show 
the affect of sGD4 alone. The circles (O) show the combined 
effect of SCD4 plus mAb 447. The diamonds (0) show the 
percent neutralization calculated based on the level of virus 
entry with SCD4 present. FIG. 16E is a line graph of the 
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neutralization of JRFL by two guinea pig sera as shown (A. 
). The diamonds (0) show the effect ofsCD4 alone. The line 
graphs show the neutralization of each Sera, calculated based 
on the virus entry with SCD4 present. FIG.16F is a line graph 
of the neutralization ofYU2 by mAbs 447, 17b, and 39F. FIG. 
16G is a line graph of the neutralization of YU2 by the two 
animal sera that were described in FIG. 16A. FIG. 16 H is a 
line graph of the neutralization of virus 6535 by mabs 447 
and 17b. FIG. 16I is a line graph of the neutralization of virus 
6535 by two guinea pig sera as shown (0, ). The diamonds 10 
(0) show the effect of SCD4 alone. FIG.16J is a line graph of 
the neutralization of virus ADA by mAbs 447. FIG. 16K is a 
line graph of the neutralization of virus ADA by two guinea 
pig sera as shown (0, ). FIG. 16L is a line graph of the 
Mutant Name 
WT core 
neutralization of the clade C virus TV1 by mAbs 447 and 17b. 
FIG. 16M is a line graph of the neutralization of the clade C 
virus TV1 by guinea pig Sera derived from animals immu 
nized with clade CdCFI Env. FIG. 16N is a line graph of the 
neutralization of the clade C virus ZA12 by mab 17b. FIG. 
16O is a line graph of the neutralization of the clade C virus 
ZA12 by guinea pig Sera derived from animals immunized 
with clade C dCFI Env. FIG. 16P is a line graph of the 
neutralization of the clade C virus Z109 by mabs 447 and 
17b. FIG.16Q is a line graph of the neutralization of the clade 
C virus Z109 by guinea pig sera derived from animals immu 
nized with clade CdCFI Env. 
SEQUENCE LISTING AND NOMENCLATURE 
The nucleic and amino acid sequences listed in the accom 
panying sequence listing are shown using standard letter 
abbreviations for nucleotide bases, and three letter code for 
amino acids, as defined in 37 C.F.R. 1.822. Only one strand of 
each nucleic acid sequence is shown, but the complementary 
strand is understood as included by any reference to the 
displayed strand. 
SEQID NO: 1 is the amino acid sequence of gp120 HXBc2 
Core New 9c. 
SEQID NO: 2 the amino acid sequence of the gp120 with an 
extended V3 loop. 
SEQ ID NO: 3 is a nucleotide sequence of gp120 HXBc2 
DM. 
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SEQ ID NOs: 4-18 are nucleotide sequences of stabilized 
HXBc2 Core gp120. 
SEQ ID NO: 19 is a nucleotide sequence of wild type (WT) 
HXBC2. 
SEQID NO:20 is the amino acid sequence of wildtype (WT) 
HXBC2. 
SEQID NO: 21-25 are amino acid sequences of V3 loops. 
SEQ ID NO: 26 is a nucleotide sequence of gp120 HXBc2 
Core New 9c. 
SEQ ID NO: 27 is the amino acid sequence of gp120 
HXB2CG. 
Nomenclature Conversion for Conformationally Stabilized 
HXBc2 Mutants 
Mutant location 
X 
X 
X 
X 
DETAILED DESCRIPTION 
I. Terms 
Unless otherwise noted, technical terms are used according 
to conventional usage. Definitions of common terms in 
molecular biology can be found in Benjamin Lewin, Genes V. 
published by Oxford University Press, 1994 (ISBN 0-19 
854287-9); Kendrew et al. (eds.), The Encyclopedia of 
Molecular Biology, published by Blackwell Science Ltd., 
1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), 
Molecular Biology and Biotechnology: a Comprehensive 
Desk Reference, published by VCH Publishers, Inc., 1995 
(ISBN 1-56081-569-8). Terms describing protein structure 
and structural elements of proteins can be found in Creighton, 
Proteins, Structures and Molecular Properties, W.H. Freeman 
& Co., New York, 1993 (ISBN 0-717-7030) which is incor 
porated by reference herein in its entirety. 
Unless otherwise explained, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which this 
disclosure belongs. The singular terms “a,” “an and “the 
include plural referents unless context clearly indicates oth 
erwise. Similarly, the word 'or' is intended to include “and” 
unless the context clearly indicates otherwise. It is further to 
be understood that all base sizes or amino acid sizes, and all 
molecular weight or molecular mass values, given for nucleic 
acids or polypeptides are approximate, and are provided for 
description. Although methods and materials similar or 
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equivalent to those described herein can be used in the prac 
tice or testing of this disclosure, Suitable methods and mate 
rials are described below. The term “comprises' means 
“includes.” The abbreviation, "e.g. is derived from the Latin 
exempligratia, and is used herein to indicate a non-limiting 
example. Thus, the abbreviation “e.g. is synonymous with 
the term “for example.” 
All publications, patent applications, patents, and other 
references mentioned herein are incorporated by reference in 
their entirety. In case of conflict, the present specification, 
including explanations of terms, will control. In addition, all 
the materials, methods, and examples are illustrative and not 
intended to be limiting. In order to facilitate review of the 
various embodiments of the disclosure, the following expla 
nations of specific terms are provided: 
Adjuvant: A vehicle used to enhance antigenicity; such as 
a Suspension of minerals (alum, aluminum hydroxide, alumi 
num phosphate) on which antigen is adsorbed; or water-in-oil 
emulsion in which antigen solution is emulsified in oil (MF 
59, Freund's incomplete adjuvant), sometimes with the inclu 
sion of killed mycobacteria (Freund's complete adjuvant) to 
further enhance antigenicity (inhibits degradation of antigen 
and/or causes influx of macrophages). Adjuvants also include 
immunostimulatory molecules, such as cytokines, costimu 
latory molecules, and for example, immunostimulatory DNA 
or RNA molecules, such as CpG oligonucleotides. 
Administration: The introduction of a composition into a 
Subject by a chosen route. For example, if the chosen route is 
intravenous, the composition is administered by introducing 
the composition into a vein of the Subject. 
Antibody: A polypeptide substantially encoded by an 
immunoglobulin gene or immunoglobulin genes, or frag 
ments thereof, which specifically binds and recognizes an 
analyte (antigen) Such as gp120 or an antigenic fragment of 
gp120. Immunoglobulin genes include the kappa, lambda, 
alpha, gamma, delta, epsilon and mu constant region genes, as 
well as the myriad immunoglobulin variable region genes. 
Antibodies exist, for example as intact immunoglobulins 
and as a number of well characterized fragments produced by 
digestion with various peptidases. For instance, Fabs, FVS, 
and single-chain Fvs (SCFVs) that bind to gp120 or fragments 
of gp120 would be gp120-specific binding agents. This 
includes intact immunoglobulins and the variants and por 
tions of them well known in the art, such as Fab' fragments, 
F(ab)' fragments, single chain Fv proteins (“scFv'), and dis 
ulfide stabilized FV proteins (“dsFv'). A scFv protein is a 
fusion protein in which a light chain variable region of an 
immunoglobulin and a heavy chain variable region of an 
immunoglobulin are bound by a linker, while in dsEvs, the 
chains have been mutated to introduce a disulfide bond to 
stabilize the association of the chains. The term also includes 
genetically engineered forms such as chimeric antibodies 
(such as humanized murine antibodies), heteroconjugate 
antibodies such as bispecific antibodies). See also, Pierce 
Catalog and Handbook, 1994-1995 (Pierce Chemical Co., 
Rockford, Ill.); Kuby, J., Immunology, 3" Ed., W.H. Freeman 
& Co., New York, 1997. 
Antibody fragments are defined as follows: (1) Fab, the 
fragment which contains a monovalent antigen-binding frag 
ment of an antibody molecule produced by digestion of whole 
antibody with the enzyme papain to yield an intact light chain 
and a portion of one heavy chain; (2) Fab', the fragment of an 
antibody molecule obtained by treating whole antibody with 
pepsin, followed by reduction, to yield an intact light chain 
and a portion of the heavy chain; two Fab' fragments are 
obtained per antibody molecule; (3) (Fab'), the fragment of 
the antibody obtained by treating whole antibody with the 
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enzyme pepsin without Subsequent reduction; (4) F(ab')2, a 
dimer of two Fab' fragments held together by two disulfide 
bonds; (5) Fv, a genetically engineered fragment containing 
the variable region of the light chain and the variable region of 
the heavy chain expressed as two chains; and (6) single chain 
antibody (“SCA), a genetically engineered molecule con 
taining the variable region of the light chain, the variable 
region of the heavy chain, linked by a suitable polypeptide 
linker as a genetically fused single chain molecule. The term 
'antibody, as used herein, also includes antibody fragments 
either produced by the modification of whole antibodies or 
those synthesized de novo using recombinant DNA method 
ologies. 
Typically, a naturally occurring immunoglobulin has 
heavy (H) chains and light (L) chains interconnected by dis 
ulfide bonds. There are two types of light chain, lambda (W) 
and kappa (K). There are five main heavy chain classes (or 
isotypes) which determine the functional activity of an anti 
body molecule: IgM, Ig), IgG, IgA and IgE. 
Each heavy and light chain contains a constant region and 
a variable region, (the regions are also known as “domains'). 
In combination, the heavy and the light chain variable regions 
specifically bind the antigen. Light and heavy chain variable 
regions contain a “framework” region interrupted by three 
hyperVariable regions, also called “complementarity-deter 
mining regions” or “CDRs. The extent of the framework 
region and CDRs have been defined (see, Kabat et al., 
Sequences of Proteins of Immunological Interest, U.S. 
Department of Health and Human Services, 1991, which is 
hereby incorporated by reference). The Kabat database is 
now maintained online. The sequences of the framework 
regions of different light or heavy chains are relatively con 
served within a species. The framework region of an antibody, 
that is the combined framework regions of the constituent 
light and heavy chains, serves to position and align the CDRS 
in three-dimensional space. 
The CDRs are primarily responsible for binding to an 
epitope of an antigen. The CDRS of each chain are typically 
referred to as CDR1, CDR2, and CDR3, numbered sequen 
tially starting from the N-terminus, and are also typically 
identified by the chain in which the particular CDR is located. 
Thus, a V, CDR3 is located in the variable domain of the 
heavy chain of the antibody in which it is found, whereas a V, 
CDR1 is the CDR1 from the variable domain of the light 
chain of the antibody in which it is found. Light chain CDRs 
are sometimes referred to as CDRL1, CDRL2, and CDRL3. 
Heavy chain CDRs are sometimes referred to as CDR H1, 
CDR H2, and CDR H3. 
References to “V” or “VH refer to the variable region of 
an immunoglobulin heavy chain, including that of an Fv, 
scEv, dsFv or Fab. References to “V,” or “VL refer to the 
variable region of an immunoglobulin light chain, including 
that of an Fv, scFv, dsFv or Fab. 
A "monoclonal antibody' is an antibody produced by a 
single clone of B-lymphocytes or by a cell into which the light 
and heavy chain genes of a single antibody have been trans 
fected. Monoclonal antibodies are produced by methods 
known to those of skill in the art, for instance by making 
hybrid antibody-forming cells from a fusion of myeloma cells 
with immune spleen cells. These fused cells and their progeny 
are termed “hybridomas.” Monoclonal antibodies include 
humanized monoclonal antibodies. 
A "humanized' immunoglobulin is an immunoglobulin 
including a human framework region and one or more CDRS 
from a non-human (Such as a mouse, rat, or synthetic) immu 
noglobulin. The non-human immunoglobulin providing the 
CDRs is termed a “donor,” and the human immunoglobulin 
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providing the framework is termed an “acceptor.” In one 
embodiment, all the CDRs are from the donor immunoglo 
bulin in a humanized immunoglobulin. Constant regions need 
not be present, but if they are, they must be substantially 
identical to human immunoglobulin constant regions, such as 
at least about 85-90%, such as about 95% or more identical. 
Hence, all parts of a humanized immunoglobulin, except 
possibly the CDRs, are substantially identical to correspond 
ing parts of natural human immunoglobulin sequences. A 
"humanized antibody' is an antibody comprising a human 
ized light chain and a humanized heavy chain immunoglobu 
lin. A humanized antibody binds to the same antigen as the 
donor antibody that provides the CDRs. The acceptor frame 
work of a humanized immunoglobulin or antibody may have 
a limited number of substitutions by amino acids taken from 
the donor framework. Humanized or other monoclonal anti 
bodies can have additional conservative amino acid substitu 
tions which have Substantially no effect on antigenbinding or 
other immunoglobulin functions. Humanized immunoglobu 
lins can be constructed by means of genetic engineering (for 
example, see U.S. Pat. No. 5,585,089). 
Antigenic gp120 polypeptide: An 'antigenic gp120 
polypeptide' includes a gp120 molecule or a portion thereof 
that is capable of provoking an immune response in a mam 
mal, such as a mammal with or without an HIV infection. 
Administration of an antigenic gp120 polypeptide that pro 
Vokes an immune response preferably leads to protective 
immunity against HIV. 
Antigenic Surface: A Surface of a molecule, for example a 
protein Such as a gp120 protein or polypeptide, capable of 
eliciting an immune response. An antigenic Surface includes 
the defining features of that surface, for example the three 
dimensional shape and the Surface charge. An antigenic Sur 
face includes both Surfaces that occur on gp120 polypeptides 
as well as Surfaces of compounds that mimic the Surface of a 
gp120 polypeptide (mimetics). 
CD4: Cluster of differentiation factor 4 polypeptide, a 
T-cell surface protein that mediates interaction with the MHC 
class II molecule. CD4 also serves as the primary receptor site 
for HIV on T-cells during HIV-1 infection. 
The known sequence of the CD4 precursor has a hydro 
phobic signal peptide, an extracellular region of approxi 
mately 370 amino acids, a highly hydrophobic stretch with 
significant identity to the membrane-spanning domain of the 
class II MHC beta chain, and a highly charged intracellular 
sequence of 40 resides (Maddon, Cell 42:93, 1985). 
The term “CD4” includes polypeptide molecules that are 
derived from CD4 include fragments of CD4, generated 
either by chemical (for example enzymatic) digestion or 
genetic engineering means. Such a fragment may be one or 
more entire CD4 protein domains. The extracellular domain 
of CD4 consists of four contiguous immunoglobulin-like 
regions (D1, D2, D3, and D4, see Sakihama et al., Proc. Natl. 
Acad. Sci. 92:6444, 1995: U.S. Pat. No. 6,117,655), and 
amino acids 1 to 183 have been shown to be involved in gp120 
binding. For instance, a binding molecule or binding domain 
derived from CD4 would comprise a sufficient portion of the 
CD4 protein to mediate specific and functional interaction 
between the binding fragment and a native or viral binding 
site of CD4. One such binding fragment includes both the D1 
and D2 extracellular domains of CD4 (D1D2 is also a frag 
ment of soluble CD4 or SCD4 which is comprised of D1 D2 
D3 and D4), although Smaller fragments may also provide 
specific and functional CD4-like binding. The gp120-binding 
site has been mapped to D1 of CD4. 
CD4 polypeptides also include “CD4-derived molecules” 
which encompasses analogs (non-protein organic mol 
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ecules), derivatives (chemically functionalized protein mol 
ecules obtained starting with the disclosed protein sequences) 
or mimetics (three-dimensionally similar chemicals) of the 
native CD4 structure, as well as proteins sequence variants or 
geneticalleles that maintain the ability to functionally bind to 
a target molecule. 
CD4ES antibodies: Antibodies that bind to or substantially 
overlap the CD4 binding surface of a gp120 polypeptide. The 
antibodies interfere with or prevent CD4 from binding to a 
gp120 polypeptide. 
CD4i antibodies: Antibodies that bind to a conformation of 
gp120 induced by CD4 binding. 
Contacting: Placement in direct physical association; 
includes both in solid and liquid form. 
Computer readable media: Any medium or media, which 
can be read and accessed directly by a computer, so that the 
media is suitable for use in a computer system. Such media 
include, but are not limited to: magnetic storage media Such as 
floppy discs, hard disc storage medium and magnetic tape; 
optical storage media such as optical discs or CD-ROM; 
electrical storage media such as RAM and ROM; and hybrids 
of these categories such as magnetic/optical storage media. 
Computer system: Hardware that can be used to analyze 
atomic coordinate data. The minimum hardware of a com 
puter-based system typically comprises a central processing 
unit (CPU), an input device, for example a mouse, keyboard, 
and the like, an output device, and a data storage device. 
Desirably a monitor is provided to visualize structure data. 
The data storage device may be RAM or other means for 
accessing computer readable. Examples of Such systems are 
microcomputer workstations available from Silicon Graphics 
Incorporated and Sun Microsystems running Unix based 
Windows NT or IBM OS/2 operating systems. 
Degenerate variant and conservative variant: A polynucle 
otide encoding a polypeptide or an antibody that includes a 
sequence that is degenerate as a result of the genetic code. For 
example, a polynucleotide encoding a gp120 polypeptide or 
an antibody that binds gp120 that includes a sequence that is 
degenerate as a result of the genetic code. There are 20 natural 
amino acids, most of which are specified by more than one 
codon. Therefore, all degenerate nucleotide sequences are 
included as long as the amino acid sequence of the gp120 
polypeptide or antibody that binds gp120 encoded by the 
nucleotide sequence is unchanged. Because of the degen 
eracy of the genetic code, a large number of functionally 
identical nucleic acids encode any given polypeptide. For 
instance, the codons CGU, CGC, CGA, CGG, AGA, and 
AGG all encode the amino acid arginine. Thus, at every 
position where anarginine is specified withina protein encod 
ing sequence, the codon can be altered to any of the corre 
sponding codons described without altering the encoded pro 
tein. Such nucleic acid variations are “silent variations.” 
which are one species of conservative variations. Each 
nucleic acid sequence herein that encodes a polypeptide also 
describes every possible silent variation. One of skill will 
recognize that each codon in a nucleic acid (except AUG, 
which is ordinarily the only codon for methionine) can be 
modified to yield a functionally identical molecule by stan 
dard techniques. Accordingly, each 'silent variation of a 
nucleic acid which encodes a polypeptide is implicit in each 
described sequence. 
Furthermore, one of ordinary skill will recognize that indi 
vidual substitutions, deletions or additions which alter, add or 
delete a single amino acid or a small percentage of amino 
acids (for instance less than 5%, in Some embodiments less 
than 1%) in an encoded sequence are conservative variations 
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where the alterations result in the substitution of an amino 
acid with a chemically similar amino acid. 
Conservative amino acid Substitutions providing function 
ally similar amino acids are well known in the art. The fol 
lowing six groups each contain amino acids that are conser 
vative substitutions for one another: 
1) Alanine (A), Serine (S). Threonine (T); 
2) Aspartic acid (D), Glutamic acid (E); 
3) Asparagine (N). Glutamine (Q); 
4) Arginine (R), Lysine (K); 
5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 
and 
6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W). 
Not all residue positions within a protein will tolerate an 
otherwise “conservative' substitution. For instance, if an 
amino acid residue is essential for a function of the protein, 
even an otherwise conservative Substitution may disrupt that 
activity. 
Epitope: An antigenic determinant. These are particular 
chemical groups or peptide sequences on a molecule that are 
antigenic, such that they elicit a specific immune response. An 
antibody binds a particular antigenic epitope, Such as an 
epitope of a gp120 polypeptide. 
Expression: Translation of a nucleic acid into a protein. 
Proteins may be expressed and remain intracellular, become a 
component of the cell Surface membrane, or be secreted into 
the extracellular matrix or medium. 
Expression Control Sequences: Nucleic acid sequences 
that regulate the expression of a heterologous nucleic acid 
sequence to which it is operatively linked. Expression control 
sequences are operatively linked to a nucleic acid sequence 
when the expression control sequences control and regulate 
the transcription and, as appropriate, translation of the nucleic 
acid sequence. Thus expression control sequences can 
include appropriate promoters, enhancers, transcription ter 
minators, a start codon (ATG) in front of a protein-encoding 
gene, splicing signal for introns, maintenance of the correct 
reading frame of that gene to permit proper translation of 
mRNA, and stop codons. The term “control sequences” is 
intended to include, at a minimum, components whose pres 
ence can influence expression, and can also include additional 
components whose presence is advantageous, for example, 
leader sequences and fusion partner sequences. Expression 
control sequences can include a promoter. 
A promoter is a minimal sequence Sufficient to direct tran 
Scription. Also included are those promoter elements which 
are sufficient to render promoter-dependent gene expression 
controllable for cell-type specific, tissue-specific, or induc 
ible by external signals or agents; Such elements may be 
located in the 5' or 3' regions of the gene. Both constitutive 
and inducible promoters are included (see for example, Bitter 
et al., Methods in Enzymology 153:516-544, 1987). For 
example, when cloning in bacterial systems, inducible pro 
moters such as pil of bacteriophage lambda, plac, ptrp, ptac 
(ptrp-lac hybrid promoter) and the like may be used. In one 
embodiment, when cloning in mammalian cell systems, pro 
moters derived from the genome of mammalian cells (such as 
metallothionein promoter) or from mammalian viruses (such 
as the retrovirus long terminal repeat; the adenovirus late 
promoter; the vaccinia virus 7.5K promoter) can be used. 
Promoters produced by recombinant DNA or synthetic tech 
niques may also be used to provide for transcription of the 
nucleic acid sequences. 
A polynucleotide can be inserted into an expression vector 
that contains a promoter sequence which facilitates the effi 
cient transcription of the inserted genetic sequence of the 
host. The expression vector typically contains an origin of 
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replication, a promoter, as well as specific nucleic acid 
sequences that allow phenotypic selection of the transformed 
cells. 
gp120: The envelope protein from Human Immunodefi 
ciency Virus (HIV). The envelope protein is initially synthe 
sized as a longer precursor protein of 845-870 amino acids in 
size, designated gp160. Gp160 forms a homotrimer and 
undergoes glycosylation within the Golgi apparatus. It is then 
cleaved by a cellular protease into gp120 and gp41. Gp41 
contains a transmembrane domain and remains in a trimeric 
configuration; it interacts with gp120 in a non-covalent man 
ner. Gp120 contains most of the external, Surface-exposed, 
domains of the envelope glycoprotein complex, and it is 
gp120 which binds both to the cellular CD4 receptor and to 
the cellular chemokine receptors (such as CCR5). 
The mature gp120 wildtype polypeptides have about 500 
amino acids in the primary sequence. Gp120 is heavily N-gly 
cosylated giving rise to an apparent molecular weight of 120 
kD. The polypeptide is comprised of five conserved regions 
(C1-C5) and five regions of high variability (V1-V5). Exem 
plary sequence of wtgp160 polypeptides are shown on GEN 
BANK, for example accession numbers AAB05604 and 
AAD12142 
The gp120 core has a unique molecular structure, which 
comprises two domains: an “inner” domain (which faces 
gp41) and an "outer domain (which is mostly exposed on the 
Surface of the oligomeric envelope glycoprotein complex). 
The two gp120 domains are separated by a “bridging sheet” 
that is not part of either domain. The gp120 core comprises 25 
beta Strands, 5 alpha helices, and 10 defined loop segments. 
"Stabilized gp120” is a form of gp120 polypeptide from 
HIV-1, characterized by an increase in Tover the wild type 
gp120. In some examples the gp120 is stabilized by the 
replacement of at least two amino acids of gp120 with cys 
teines such that a disulfide bond can form, wherein the gp120 
protein has a T of greater than about 53.8°C. The stabilized 
gp120 mutants may contain amino acid substitutions that fill 
cavities present in the core of native gp120. The stabilized 
gp120 can bind CD4. Stabilized forms of gp120 may include 
forms that have synthetic amino acids. Several exemplary 
stabilized gp120 proteins are disclosed herein. 
Gp120 polypeptides also include gp120-derived mol 
ecules' which encompasses analogs (non-protein organic 
molecules), derivatives (chemically functionalized protein 
molecules obtained starting with the disclosed protein 
sequences) or mimetics (three-dimensionally similar chemi 
cals) of the native gp120 structure, as well as proteins 
sequence variants (such as mutants), genetic alleles, fusions 
proteins of gp120, or combinations thereof. 
The third variable region referred to herein as the V3 loop 
is a loop of about 35 amino acids critical for the binding of the 
co-receptor and determination of which of the co-receptors 
will bind. In certain examples the V3 loop comprises residues 
296-331. 
The numbering used in gp120 polypeptides disclosed 
herein is relative to the HXB2 numbering scheme as set forth 
in Numbering Positions in HIV Relative to HXB2CG Bette 
Korber et al., Human Retroviruses and AIDS 1998: A Com 
pilation and Analysis of Nucleic Acid and Amino Acid 
Sequences. Korber B, Kuiken C L. Foley B. Hahn B. 
McCutchan F. Mellors JW, and Sodroski J. Eds. Theoretical 
Biology and Biophysics Group, Los Alamos National Labo 
ratory, Los Alamos, N. Mex. which is incorporated by refer 
ence herein in its entirety. For reference, the amino acid 
sequence of HXB2CG is given below as SEQ ID NO: 27: 
lwVtvyygvpVwkeatttlfcasdakaydtevhnVwathacvptdpnpqeVV 
lvnvitenfnmwkindmveqmhedislwdqslkpcvkltplcvslkctdlk 
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ndtntnSSsgrmimekgeikncsfinistsirgkvokeyaffykldiipidndtt 
syklts.cntsvitdacpkVSfepipihycapagfailkcnnktfingtgpctnVStV 
qcthgirpVVStallingslaeeevvirSVnftdnaktiivalntsveinctrpnnn 
trkririqrgpgrafvtigkignmrqahcnisrak winntlkciasklreqfgnnk 
tifkassggdpeivthsfncggeffy.cnstclfnstwfnstwStegSnntegsdt 
itlpcrikdinmwckVgkamyapp isgqircSSnitglltraggins.nnese 
ifrpgggdmrdnwrselykykVVkieplgvaptkakrrvvarekr (SEQ ID 
NO: 27). HXB2 is also known as: HXBc2, for HXB clone 2: 
HXB2R, in the Los Alamos HIV database, with the R for 
revised, as it was slightly revised relative to the original 
HXB2 sequence; and HXB2CG in GenBank, for HXB2 com 
plete genome. 
Heavy atom derivatization: A method of producing a 
chemically modified form of a protein crystal, for example a 
crystal containing gp120. In practice, a crystal is soaked in a 
Solution containing heavy metal atom salts, or organometallic 
compounds, such as lead chloride, gold thiomalate, thimero 
sal or uranyl acetate, which can diffuse through the solvent 
channels of the crystal and bind the surface of the protein. The 
location(s) of the bound heavy metal atom(s) can be deter 
mined by X-ray diffraction analysis of the soaked crystal. 
This information, in turn, is used to generate the phase infor 
mation used to construct three-dimensional structure of the 
enzyme (see Blundel and Johnson, Protein Crystallography, 
Academic Press (1976). 
Host cells: Cells in which a vector can be propagated and 
its DNA expressed. The cell may be prokaryotic or eukary 
otic. The term also includes any progeny of the Subject host 
cell. It is understood that all progeny may not be identical to 
the parental cell since there may be mutations that occur 
during replication. However, Such progeny are included when 
the term "host cell' is used. 
In silico: A process performed virtually within a computer. 
For example, using a computer, a virtual compound can be 
screened for Surface similarity or conversely surface comple 
mentarity to a virtual representation of the atomic positions at 
least a portion of a gp120 polypeptide, for example as stabi 
lized gp120, such as defined in Table 1 or a gp120 with an 
extended V3 loop, such as defined in Table 2. 
Immune response: A response of a cell of the immune 
system, Such as a B cell, T cell, or monocyte, to a stimulus. In 
one embodiment, the response is specific for a particular 
antigen (an 'antigen-specific response'). In one embodiment, 
an immune response is a T cell response, such as a CD4+ 
response or a CD8+ response. In another embodiment, the 
response is a B cell response, and results in the production of 
specific antibodies. 
Immunogenic peptide: A peptide which comprises an 
allele-specific motif or other sequence, such as an N-terminal 
repeat, such that the peptide will bind an MHC molecule and 
induce a cytotoxic T lymphocyte (“CTL) response, or a B 
cell response (for example antibody production) against the 
antigen from which the immunogenic peptide is derived. 
In one embodiment, immunogenic peptides are identified 
using sequence motifs or other methods, such as neural net or 
polynomial determinations known in the art. Typically, algo 
rithms are used to determine the “binding threshold” of pep 
tides to select those with scores that give them a high prob 
ability of binding at a certain affinity and will be 
immunogenic. The algorithms are based either on the effects 
on MHC binding of a particular amino acid at a particular 
position, the effects on antibody binding of a particular amino 
acid at a particular position, or the effects on binding of a 
particular Substitution in a motif-containing peptide. Within 
the context of an immunogenic peptide, a "conserved resi 
due is one which appears in a significantly higher frequency 
than would be expected by random distribution at a particular 
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position in a peptide. In one embodiment, a conserved residue 
is one where the MHC structure may provide a contact point 
with the immunogenic peptide. In one specific non-limiting 
example, an immunogenic polypeptide includes a region of 
gp120, or a fragment thereof. 
Immunogenic composition: A composition comprising an 
immunogenic peptide that induces a measurable CTL 
response against virus expressing the immunogenic peptide, 
or induces a measurable B cell response (such as production 
of antibodies) against the immunogenic peptide. In one 
example an “immunogenic composition' is composition 
comprising a gp120 polypeptide that induces a measurable 
CTL response against virus expressing gp120 polypeptide, or 
induces a measurable B cell response (such as production of 
antibodies) against a gp120 polypeptide. It further refers to 
isolated nucleic acids encoding an immunogenic peptide, 
Such as a nucleic acid that can be used to express the gp120 
polypeptide (and thus be used to elicit an immune response 
against this polypeptide). 
For in vitro use, an immunogenic composition may consist 
of the isolated protein, peptide epitope, or nucleic acid encod 
ing the protein, or peptide epitope. For in vivo use, the immu 
nogenic composition will typically comprise the protein or 
immunogenic peptide in pharmaceutically acceptable carri 
ers, and/or other agents. Any particular peptide. Such as a 
gp120 polypeptide, or nucleic acid encoding the polypeptide, 
can be readily tested for its ability to induce a CTL or B cell 
response by art-recognized assays. Immunogenic composi 
tions can include adjuvants, which are well known to one of 
skill in the art. 
Immunologically reactive conditions: Includes reference 
to conditions which allow an antibody raised against a par 
ticular epitope to bind to that epitope to a detectably greater 
degree than, and/or to the Substantial exclusion of binding to 
Substantially all other epitopes. Immunologically reactive 
conditions are dependent upon the format of the antibody 
binding reaction and typically are those utilized in immu 
noassay protocols or those conditions encountered in vivo. 
The immunologically reactive conditions employed in the 
methods are “physiological conditions” which include refer 
ence to conditions (such as temperature, osmolarity, pH) that 
are typical inside a living mammal or a mammalian cell. 
While it is recognized that some organs are subject to extreme 
conditions, the intra-organismal and intracellular environ 
ment is normally about pH 7 (such as from pH 6.0 to pH 8.0, 
more typically pH 6.5 to 7.5), contains water as the predomi 
nant solvent, and exists at a temperature above 0° C. and 
below 50° C. Osmolarity is within the range that is supportive 
of cell viability and proliferation. 
Immunotherapy: A method of evoking an immune 
response against a virus based on their production of target 
antigens. Immunotherapy based on cell-mediated immune 
responses involves generating a cell-mediated response to 
cells that produce particular antigenic determinants, while 
immunotherapy based on humoral immune responses 
involves generating specific antibodies to virus that produce 
particular antigenic determinants. 
Inhibiting or treating a disease: Inhibiting the full develop 
ment of a disease or condition, for example, in a Subject who 
is at risk for a disease Such as acquired immune deficiency 
syndrome (AIDS), AIDS related conditions, HIV-1 infection, 
or combinations thereof. “Treatment” refers to a therapeutic 
intervention that ameliorates a sign or symptom of a disease 
or pathological condition after it has begun to develop. The 
term “ameliorating with reference to a disease or pathologi 
cal condition, refers to any observable beneficial effect of the 
treatment. The beneficial effect can be evidenced, for 
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example, by a delayed onset of clinical symptoms of the 
disease in a susceptible Subject, a reduction in severity of 
Some or all clinical symptoms of the disease, a slower pro 
gression of the disease, a reduction in the number of 
metastases, an improvement in the overall health or well 
being of the subject, or by other parameters well known in the 
art that are specific to the particular disease. A "prophylactic' 
treatment is a treatment administered to a subject who does 
not exhibit signs of a disease or exhibits only early signs for 
the purpose of decreasing the risk of developing pathology. 
Isolated: An "isolated' biological component (such as a 
nucleic acid, peptide or protein) has been Substantially sepa 
rated, produced apart from, or purified away from other bio 
logical components in the cell of the organism in which the 
component naturally occurs, such as, other chromosomal and 
extrachromosomal DNA and RNA, and proteins. Nucleic 
acids, peptides and proteins which have been "isolated thus 
include nucleic acids and proteins purified by standard puri 
fication methods. The term also embraces nucleic acids, pep 
tides, and proteins prepared by recombinant expression in a 
host cell as well as chemically synthesized nucleic acids. 
K: The dissociation constant for a given interaction, Such 
as a polypeptide ligand interaction. For example, for the 
bimolecular interaction of CD4 and gp120 it is the concen 
tration of the individual components of the bimolecular inter 
action divided by the concentration of the complex. 
Leukocyte: Cells in the blood, also termed “white cells.” 
that are involved in defending the body against infective 
organisms and foreign Substances. Leukocytes are produced 
in the bone marrow. There are 5 main types of white blood 
cell. Subdivided between 2 main groups: polymorphonuclear 
leukocytes (neutrophils, eosinophils, basophils) and mono 
nuclear leukocytes (monocytes and lymphocytes). 
Ligand: Any molecule which specifically binds a protein, 
Such as a gp120 protein, and includes, interalia, antibodies 
that specifically bind a gp120 protein. In alternative embodi 
ments, the ligand is a protein or a small molecule (one with a 
molecular weight less than 6 kiloDaltons). 
Mimetic: A molecule (such as an organic chemical com 
pound) that mimics the activity of an agent, such as the 
activity of a gp120 protein, for example by inducing an 
immune response to gp120. Peptidomimetic and organomi 
metic embodiments are within the scope of this term, 
whereby the three-dimensional arrangement of the chemical 
constituents of such peptido- and organomimetics mimic the 
three-dimensional arrangement of the peptide backbone and 
componentamino acid side chains in the peptide, resulting in 
Such peptido- and organomimetics of the peptides having 
Substantial specific activity. For computer modeling applica 
tions, a pharmacophore is an idealized, three-dimensional 
definition of the structural requirements for biological activ 
ity. Peptido- and organomimetics can be designed to fit each 
pharmacophore with computer modeling software (using 
computer assisted drug design or CADD). See Walters, 
“Computer-Assisted Modeling of Drugs, in Klegerman & 
Groves, eds., 1993, Pharmaceutical Biotechnology, Inter 
pharm Press: Buffalo Grove, Ill., pp. 165-174 and Principles 
of Pharmacology (ed. Munson, 1995), chapter 102 for a 
description of techniques used in computer assisted drug 
design. 
Molecular Replacement: A method that involves generat 
ing a preliminary model. Such as a model of a gp120 polypep 
tide, whose structure coordinates are unknown, by orienting 
and positioning a molecule whose structure coordinates are 
known (such as coordinates from Table 1) within the unit cell 
of the unknown crystal so as best to account for the observed 
diffraction pattern of the unknown crystal. Phases can then be 
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calculated from this model and combined with the observed 
amplitudes to give an approximate Fourier synthesis of the 
structure whose coordinates are unknown. This, in turn, can 
be subject to any of the several forms of refinement to provide 
a final, accurate structure of the unknown molecule (see Latt 
man, Methods in Enzymology, 115:55-77, 1985; Rossmann, 
ed., “The Molecular Replacement Method’, Int. Sci. Rev. 
Ser. No. 13, Gordon & Breach, New York, 1972). Using the 
structure coordinates of gp120. Such as a stabilized gp120 
provided herein; molecular replacement may be used to deter 
mine the structure coordinates of a crystalline mutant or 
homologue of gp120, a different crystal form of gp120, or 
gp120 in complex with another molecule. Such as an anti 
body, cell surface receptor, or combination thereof. 
Naturally Occurring Amino Acids: L-isomers of the natu 
rally occurring amino acids. The naturally occurring amino 
acids are glycine, alanine, Valine, leucine, isoleucine, serine, 
methionine, threonine, phenylalanine, tyrosine, tryptophan, 
cysteine, proline, histidine, aspartic acid, asparagine, 
glutamic acid, glutamine, gamma-carboxyglutamic acid, 
arginine, ornithine and lysine. Unless specifically indicated, 
all amino acids referred to in this application are in the 
L-form. “Synthetic amino acids’ refers to amino acids that 
are not naturally found in proteins. Examples of synthetic 
amino acids used herein, include racemic mixtures of seleno 
cysteine and selenomethionine. In addition, unnatural amino 
acids include the D or L forms of nor-leucine, para-nitrophe 
nylalanine, homophenylalanine, para-fluorophenylalanine, 
3-amino-2-benzylpropionic acid, homoarginine, and D-phe 
nylalanine. The term “positively charged amino acid refers 
to any naturally occurring or synthetic amino acid having a 
positively charged side chain under normal physiological 
conditions. Examples of positively charged naturally occur 
ring amino acids are arginine, lysine and histidine. The term 
“negatively charged amino acid refers to any naturally 
occurring or synthetic amino acid having a negatively 
charged side chain under normal physiological conditions. 
Examples of negatively charged naturally occurring amino 
acids are aspartic acid and glutamic acid. The term "hydro 
phobic amino acid refers to any amino acid having an 
uncharged, nonpolar side chain that is relatively insoluble in 
water. Examples of naturally occurring hydrophobic amino 
acids are alanine, leucine, isoleucine, Valine, proline, pheny 
lalanine, tryptophan and methionine. The term “hydrophilic 
amino acid refers to any amino acid having an uncharged, 
polar side chain that is relatively soluble in water. Examples 
of naturally occurring hydrophilic amino acids are serine, 
threonine, tyrosine, asparagine, glutamine, and cysteine. 
Nucleic acid: A polymer composed of nucleotide units 
(ribonucleotides, deoxyribonucleotides, related naturally 
occurring structural variants, and synthetic non-naturally 
occurring analogs thereof) linked via phosphodiester bonds, 
related naturally occurring structural variants, and synthetic 
non-naturally occurring analogs thereof. Thus, the term 
includes nucleotide polymers in which the nucleotides and 
the linkages between them include non-naturally occurring 
synthetic analogs, such as, for example and without limita 
tion, phosphorothioates, phosphoramidates, methyl phos 
phonates, chiral-methyl phosphonates, 2-O-methyl ribo 
nucleotides, peptide-nucleic acids (PNAS), and the like. Such 
polynucleotides can be synthesized, for example, using an 
automated DNA synthesizer. The term "oligonucleotide' 
typically refers to short polynucleotides, generally no greater 
than about 50 nucleotides. It will be understood that when a 
nucleotide sequence is represented by a DNA sequence (i.e., 
A, T, G, C), this also includes an RNA sequence (i.e., A., U.G., 
C) in which “U” replaces “T” 
US 8,715,686 B2 
19 
"Nucleotide' includes, but is not limited to, a monomer 
that includes a base linked to a Sugar, Such as a pyrimidine, 
purine or synthetic analogs thereof, or a base linked to an 
amino acid, as in a peptide nucleic acid (PNA). A nucleotide 
is one monomer in a polynucleotide. A nucleotide sequence 
refers to the sequence of bases in a polynucleotide. A gp120 
polynucleotide is a nucleic acid encoding a gp120 polypep 
tide. 
Conventional notation is used hereinto describe nucleotide 
sequences: the left-hand end of a single-stranded nucleotide 
sequence is the 5'-end; the left-hand direction of a double 
stranded nucleotide sequence is referred to as the 5'-direction. 
The direction of 5' to 3' addition of nucleotides to nascent 
RNA transcripts is referred to as the transcription direction. 
The DNA strand having the same sequence as an mRNA is 
referred to as the “coding strand;” sequences on the DNA 
Strand having the same sequence as an mRNA transcribed 
from that DNA and which are located 5' to the 5'-end of the 
RNA transcript are referred to as “upstream sequences: 
sequences on the DNA strand having the same sequence as 
the RNA and which are 3' to the 3' end of the coding RNA 
transcript are referred to as "downstream sequences.” 
“cDNA refers to a DNA that is complementary or identi 
cal to an mRNA, in either single stranded or double stranded 
form. 
“Encoding refers to the inherent property of specific 
sequences of nucleotides in a polynucleotide. Such as a gene, 
a cDNA, or an mRNA, to serve as templates for synthesis of 
other polymers and macromolecules in biological processes 
having eithera defined sequence of nucleotides (for example, 
rRNA, tRNA and mRNA) or a defined sequence of amino 
acids and the biological properties resulting therefrom. Thus, 
a gene encodes a protein if transcription and translation of 
mRNA produced by that gene produces the protein in a cellor 
other biological system. Both the coding strand, the nucle 
otide sequence of which is identical to the mRNA sequence 
and is usually provided in sequence listings, and non-coding 
Strand, used as the template for transcription, of a gene or 
cDNA can be referred to as encoding the protein or other 
product of that gene or cDNA. Unless otherwise specified, a 
“nucleotide sequence encoding an amino acid sequence' 
includes all nucleotide sequences that are degenerate versions 
of each other and that encode the same amino acid sequence. 
Nucleotide sequences that encode proteins and RNA may 
include introns. 
“Recombinant nucleic acid refers to a nucleic acid having 
nucleotide sequences that are not naturally joined together. 
This includes nucleic acid vectors comprising an amplified or 
assembled nucleic acid which can be used to transform a 
suitable host cell. A host cell that comprises the recombinant 
nucleic acid is referred to as a “recombinant host cell.” The 
gene is then expressed in the recombinant host cell to pro 
duce, such as a “recombinant polypeptide. A recombinant 
nucleic acid may serve a non-coding function (such as a 
promoter, origin of replication, ribosome-binding site, etc.) as 
well. 
A first sequence is an “antisense' with respect to a second 
sequence if a polynucleotide whose sequence is the first 
sequence specifically hybridizes with a polynucleotide whose 
sequence is the second sequence. 
Terms used to describe sequence relationships between 
two or more nucleotide sequences or amino acid sequences 
include “reference sequence.” “selected from.” “comparison 
window,” “identical.” “percentage of sequence identity.” 
“substantially identical.” “complementary,” and “substan 
tially complementary.” 
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For sequence comparison of nucleic acid sequences and 
amino acids sequences, typically one sequence acts as a ref 
erence sequence, to which test sequences are compared. 
When using a sequence comparison algorithm, test and ref 
erence sequences are entered into a computer, Subsequence 
coordinates are designated, if necessary, and sequence algo 
rithm program parameters are designated. Default program 
parameters are used. Methods of alignment of sequences for 
comparison are well known in the art. Optimal alignment of 
sequences for comparison can be conducted, for example, by 
the local homology algorithm of Smith & Waterman, Adv. 
Appl. Math. 2:482, 1981, by the homology alignment algo 
rithm of Needleman & Wunsch, J. Mol. Biol. 48:443, 1970, by 
the search for similarity method of Pearson & Lipman, Proc. 
Natl. Acad. Sci. USA 85:2444, 1988, by computerized imple 
mentations of these algorithms (GAP, BESTFIT. FASTA, and 
TFASTA in the Wisconsin Genetics Software Package, 
Genetics Computer Group, 575 Science Dr. Madison, Wis.), 
or by manual alignment and visual inspection (see for 
example, Current Protocols in Molecular Biology (Ausubel 
et al., eds 1995 supplement)). 
One example of a useful algorithm is PILEUP, PILEUP 
uses a simplification of the progressive alignment method of 
Feng & Doolittle, J. Mol. Evol. 35:351-360, 1987. The 
method used is similar to the method described by Higgins & 
Sharp, CABIOS 5:151-153, 1989. Using PILEUP, a reference 
sequence is compared to other test sequences to determine the 
percent sequence identity relationship using the following 
parameters: default gap weight (3.00), default gap length 
weight (0.10), and weighted end gaps. PILEUP can be 
obtained from the GCG sequence analysis Software package, 
such as version 7.0 (Devereaux et al., Nuc. Acids Res. 12:387 
395, 1984. 
Another example of algorithms that are suitable for deter 
mining percent sequence identity and sequence similarity are 
the BLAST and the BLAST 2.0 algorithm, which are 
described in Altschul et al., J. Mol. Biol. 215:403-410, 1990 
and Altschulet al., Nucleic Acids Res. 25:3389-3402, 1977. 
Software for performing BLAST analyses is publicly avail 
able through the National Center for Biotechnology Informa 
tion (ncbi.nlm.nih.gov). The BLASTN program (for nucle 
otide sequences) uses as defaults a word length (W) of 11, 
alignments (B) of 50, expectation (E) of 10, M-5, N=-4, and 
a comparison of both strands. The BLASTP program (for 
amino acid sequences) uses as defaults a word length (W) of 
3, and expectation (E) of 10, and the BLOSUM62 scoring 
matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 
89:10915, 1989). 
Another indicia of sequence similarity between two 
nucleic acids is the ability to hybridize. The more similar are 
the sequences of the two nucleic acids, the more stringent the 
conditions at which they will hybridize. The stringency of 
hybridization conditions are sequence-dependent and are dif 
ferent under different environmental parameters. Thus, 
hybridization conditions resulting in particular degrees of 
stringency will vary depending upon the nature of the hybrid 
ization method of choice and the composition and length of 
the hybridizing nucleic acid sequences. Generally, the tem 
perature of hybridization and the ionic strength (especially 
the Na" and/or Mg" concentration) of the hybridization 
buffer will determine the stringency of hybridization, though 
wash times also influence stringency. Generally, stringent 
conditions are selected to be about 5° C. to 20° C. lower than 
the thermal melting point (T) for the specific sequence at a 
defined ionic strength and pH. The T is the temperature 
(under defined ionic strength and pH) at which 50% of the 
target sequence hybridizes to a perfectly matched probe. Con 
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ditions for nucleic acid hybridization and calculation of strin 
gencies can be found, for example, in Sambrook et al., 
Molecular Cloning: A Laboratory Manual, Cold Spring Har 
bor Laboratory Press, Cold Spring Harbor, N.Y., 2001; Tijs 
sen, Hybridization With Nucleic Acid Probes, Part I. Theory 
and Nucleic Acid Preparation, Laboratory Techniques in 
Biochemistry and Molecular Biology, Elsevier Science Ltd., 
NY, N.Y., 1993 and Ausubel et al. Short Protocols in Molecu 
lar Biology, 4 ed., John Wiley & Sons, Inc., 1999. 
"Stringent conditions' encompass conditions under which 
hybridization will only occur if there is less than 25% mis 
match between the hybridization molecule and the target 
sequence. “Stringent conditions' may be broken down into 
particular levels of Stringency for more precise definition. 
Thus, as used herein, "moderate stringency' conditions are 
those under which molecules with more than 25% sequence 
mismatch will not hybridize; conditions of “medium strin 
gency” are those under which molecules with more than 15% 
mismatch will not hybridize, and conditions of “high strin 
gency” are those under which sequences with more than 10% 
mismatch will not hybridize. Conditions of “very high strin 
gency’ are those under which sequences with more than 6% 
mismatch will not hybridize. In contrast nucleic acids that 
hybridize under “low stringency conditions include those 
with much less sequence identity, or with sequence identity 
over only short Subsequences of the nucleic acid. For 
example, a nucleic acid construct can include a polynucle 
otide sequence that hybridizes under high Stringency or very 
high Stringency, or even higher stringency conditions to a 
polynucleotide sequence that encodes SEQID NO: 1. 
Operably linked: A first nucleic acid sequence is operably 
linked with a second nucleic acid sequence when the first 
nucleic acid sequence is placed in a functional relationship 
with the second nucleic acid sequence. For instance, a pro 
moter is operably linked to a coding sequence if the promoter 
affects the transcription or expression of the coding sequence. 
Generally, operably linked DNA sequences are contiguous 
and, where necessary to join two protein-coding regions, in 
the same reading frame. 
Peptide Modifications: The present disclosure includes 
mutant gp120 peptides, as well as synthetic embodiments. In 
addition, analogues (non-peptide organic molecules), deriva 
tives (chemically functionalized peptide molecules obtained 
starting with the disclosed peptide sequences) and variants 
(homologs) of gp120 can be utilized in the methods described 
herein. The peptides disclosed herein include a sequence of 
amino acids that can be either L- and/or D-amino acids, 
naturally occurring and otherwise. 
Peptides can be modified by a variety of chemical tech 
niques to produce derivatives having essentially the same 
activity as the unmodified peptides, and optionally having 
other desirable properties. For example, carboxylic acid 
groups of the protein, whether carboxyl-terminal or side 
chain, may be provided in the form of a salt of a pharmaceu 
tically-acceptable cation or esterified to form a C-C ester, 
or converted to an amide of formula NRR, wherein R and 
R2 are each independently H or C-C alkyl, or combined to 
form a heterocyclic ring, such as a 5- or 6-membered ring. 
Amino groups of the peptide, whetheramino-terminal or side 
chain, may be in the form of a pharmaceutically-acceptable 
acid addition salt, such as the HCl, HBr, acetic, benzoic, 
toluene Sulfonic, maleic, tartaric and other organic salts, or 
may be modified to C-C alkyl or dialkyl amino or further 
converted to an amide. 
Hydroxyl groups of the peptide side chains can be con 
Verted to C-C alkoxy or to a C-C ester using well 
recognized techniques. Phenyl and phenolic rings of the pep 
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tide side chains can be substituted with one or more halogen 
atoms, such as F, Cl, Br or I, or with C-C alkyl, C-C, 
alkoxy, carboxylic acids and esters thereof, oramides of Such 
carboxylic acids. Methylene groups of the peptide side chains 
can be extended to homologous C-C alkylenes. Thiols can 
be protected with any one of a number of well-recognized 
protecting groups, such as acetamide groups. Those skilled in 
the art will also recognize methods for introducing cyclic 
structures into the peptides of this disclosure to select and 
provide conformational constraints to the structure that result 
in enhanced stability. For example, a C- or N-terminal cys 
teine can be added to the peptide, so that when oxidized the 
peptide will contain a disulfide bond, generating a cyclic 
peptide. Other peptide cyclizing methods include the forma 
tion of thioethers and carboxyl- and amino-terminal amides 
and esters. 
Peptidomimetic and organomimetic embodiments are also 
within the scope of the present disclosure, whereby the three 
dimensional arrangement of the chemical constituents of 
Such peptido- and organomimetics mimic the three-dimen 
sional arrangement of the peptide backbone and component 
amino acid side chains, resulting in Such peptido- and orga 
nomimetics of the proteins of this disclosure. For computer 
modeling applications, a pharmacophore is an idealized, 
three-dimensional definition of the structural requirements 
for biological activity. Peptido- and organomimetics can be 
designed to fit each pharmacophore with current computer 
modeling Software (using computer assisted drug design or 
CADD). See Walters, “Computer-Assisted Modeling of 
Drugs’, in Klegerman & Groves, eds., 1993, Pharmaceutical 
Biotechnology, Interpharm Press: Buffalo Grove, Ill., pp. 
165-174 and Principles of Pharmacology Munson (ed.) 1995, 
Ch. 102, for descriptions of techniques used in CADD. Also 
included within the scope of the disclosure are mimetics 
prepared using Such techniques. In one example, a mimetic 
mimics the antigenic activity generated by gp120 a mutant, a 
variant, fragment, or fusion thereof. 
Pharmaceutical agent: A chemical compound or composi 
tion capable of inducing a desired therapeutic or prophylactic 
effect when properly administered to a subject or a cell. 
“Incubating includes a sufficient amount of time for a drug to 
interact with a cell. "Contacting includes incubating a drug 
in solid or in liquid form with a cell. An “anti-viral agent” or 
'anti-viral drug is an agent that specifically inhibits a virus 
from replicating or infecting cells. Similarly, an “anti-retro 
viral agent' is an agent that specifically inhibits a retrovirus 
from replicating or infecting cells. 
A “therapeutically effective amount' is a quantity of a 
chemical composition or an anti-viral agent Sufficient to 
achieve a desired effect in a subject being treated. For 
instance, this can be the amount necessary to inhibit viral 
replication or to measurably alter outward symptoms of the 
viral infection, Such as increase of T cell counts in the case of 
an HIV-1 infection. In general, this amount will be sufficient 
to measurably inhibit virus (for example, HIV) replication or 
infectivity. When administered to a subject, a dosage will 
generally be used that will achieve target tissue concentra 
tions (for example, in lymphocytes) that has been shown to 
achieve in vitro inhibition of viral replication. 
Pharmaceutically acceptable carriers: The pharmaceuti 
cally acceptable carriers of use are conventional. Reming 
ton's Pharmaceutical Sciences, by E. W. Martin, Mack Pub 
lishing Co., Easton, Pa., 15th Edition, 1975, describes 
compositions and formulations Suitable for pharmaceutical 
delivery of the fusion proteins herein disclosed. 
In general, the nature of the carrier will depend on the 
particular mode of administration being employed. For 
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instance, parenteral formulations usually comprise injectable 
fluids that include pharmaceutically and physiologically 
acceptable fluids Such as water, physiological saline, bal 
anced salt Solutions, aqueous dextrose, glycerol or the like as 
a vehicle. For Solid compositions (such as powder, pill, tablet, 
or capsule forms), conventional non-toxic solid carriers can 
include, for example, pharmaceutical grades of mannitol, 
lactose, starch, or magnesium Stearate. In addition to biologi 
cally neutral carriers, pharmaceutical compositions to be 
administered can contain minor amounts of non-toxic auxil 
iary Substances. Such as wetting or emulsifying agents, pre 
servatives, and pH buffering agents and the like, for example 
Sodium acetate or Sorbitan monolaurate. 
Polypeptide: Any chain of amino acids, regardless of 
length or post-translational modification (Such as glycosyla 
tion orphosphorylation). “Polypeptide' applies to amino acid 
polymers to naturally occurring amino acid polymers and 
non-naturally occurring amino acid polymer as well as in 
which one or more amino acid residue is a non-natural amino 
acid, for example an artificial chemical mimetic of a corre 
sponding naturally occurring amino acid. In one embodi 
ment, the polypeptide is a gp120 polypeptide, Such as a sta 
bilized gp120. A “residue' refers to an amino acid or amino 
acid mimetic incorporated in a polypeptide by an amide bond 
oramide bond mimetic. A polypeptide has an amino terminal 
(N-terminal) end and a carboxy terminal (C-terminal) end. 
“Polypeptide' is used interchangeably with peptide or pro 
tein, and is used interchangeably herein to refer to a polymer 
of amino acid residues. 
Protein core: The protein core refers to the interior of a 
folded protein, which is substantially free of solvent expo 
Sure, such as solvent in the form of water molecules in Solu 
tion. Typically, the protein core is predominately composed 
of hydrophobic or apolar amino acids. In some examples, a 
protein core may contain charged amino acids, for example 
aspartic acid, glutamic acid, arginine, and/or lysine. The 
inclusion of uncompensated charged amino acids (a compen 
sated charged amino can be in the form of a saltbridge) in the 
protein core can lead to a destabilized protein. That is, a 
protein with a lower T, then a similar protein without an 
uncompensated charged amino acid in the protein core. In 
other examples, a protein core may have a cavity with in the 
protein core. Cavities are essentially voids within a folded 
protein where amino acids or amino acid side chains are not 
present. Such cavities can also destabilize a protein relative to 
a similar protein without a cavity. Thus, when creating a 
stabilized form of a protein, for example a stabilized form of 
gp120, it may be advantageous to Substitute amino acid resi 
dues within the core in order to fill cavities present in the 
wild-type protein. 
Purified: The term purified does not require absolute 
purity; rather, it is intended as a relative term. Thus, for 
example, a purified protein is one in which the protein is more 
enriched than the protein is in its natural environment within 
a cell. Preferably, a preparation is purified such that the pro 
tein represents at least 50% of the protein content of the 
preparation. 
The gp120 polypeptides disclosed herein, or antibodies 
that specifically bind gp120, can be purified by any of the 
means known in the art. See for example Guide to Protein 
Purification, ed. Deutscher, Meth. Enzymol. 185, Academic 
Press, San Diego, 1990; and Scopes, Protein Purification: 
Principles and Practice, Springer Verlag, New York, 1982. 
Substantial purification denotes purification from other pro 
teins or cellular components. A substantially purified protein 
is at least 60%, 70%, 80%, 90%, 95% or 98% pure. Thus, in 
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one specific, non-limiting example, a Substantially purified 
protein is 90% free of other proteins or cellular components. 
Space Group: The arrangement of symmetry elements of a 
crystal. 
Structure coordinates: Mathematical coordinates derived 
from mathematical equations related to the patterns obtained 
on diffraction of a monochromatic beam of X-rays by the 
atoms (scattering centers) such as a gp120, a gp120:CD4 
complex, a gp120:antibody complex, or combinations 
thereof in a crystal in crystal form. The diffraction data are 
used to calculate an electron density map of the repeating unit 
of the crystal. The electron density maps are used to establish 
the positions of the individual atoms within the unit cell of the 
crystal. In one example, the term “structure coordinates' 
refers to Cartesian coordinates derived from mathematical 
equations related to the patterns obtained on diffraction of a 
monochromatic beam of X-rays, such as by the atoms of a 
stabilized form of gp120 in crystal form. 
Atomic coordinate data, such as that in Table 1 and Table 2 
lists each atom by a unique number (column 2); the atom 
name in the context of the residue to which it belongs (column 
3), for example CA refers to the alpha carbon of the peptide 
backbone (detailed descriptions of the atom identifiers for 
each residue can be found for example in Creighton, Proteins, 
Structures and Molecular Properties, W.H. Freeman & Co., 
New York, 1993); the amino acid residue in which the atom is 
located (column 4); the chain identifier (column 4) which 
may or may not be included, the number of the residue (col 
umn 5); the coordinates (for example, X, Y, Z) which define 
with respect to the crystallographic axes the atomic position 
(in A) of the respective atom (columns 6, 7, and 8); the 
occupancy of the atom in the respective position (column 9); 
the “B-factor, which is the isotropic displacement parameter 
(in A) and accounts for movement of the atom around its 
atomic center (column 10). 
Those of ordinary skill in the art understand that a set of 
structure coordinates determined by X-ray crystallography is 
not without standard error. For the purpose of this disclosure, 
any set of structure coordinates for a stabilized form of gp120 
or a gp120 with an extended V3 loop that have a root mean 
square deviation of protein backbone atoms (N, CO., C and 0) 
ofless than about 1.0 Angstroms when Superimposed, such as 
about 0.75, or about 0.5, or about 0.25 Angstroms, using 
backbone atoms, on the structure coordinates listed in Table 1 
or Table 2 shall (in the absence of an explicit statement to the 
contrary) be considered identical. 
Subject: Living multi-cellular vertebrate organisms, a cat 
egory that includes both human and Veterinary Subjects, 
including human and non-human mammals. 
T Cell: A white blood cell critical to the immune response. 
T cells include, but are not limited to, CD4 T cells and CD8" 
T cells. A CD4 T lymphocyte is an immune cell that carries 
a marker on its surface known as “cluster of differentiation 4 
(CD4). These cells, also known as helper T cells, help orches 
trate the immune response, including antibody responses as 
well as killer T cell responses. CD8" T cells carry the “cluster 
of differentiation 8” (CD8) marker. In one embodiment, a 
CD8 T cells is a cytotoxic T lymphocytes. In another embodi 
ment, a CD8 cell is a suppressor T cell. 
Therapeutic agent: Used in a generic sense, it includes 
treating agents, prophylactic agents, and replacement agents. 
T.: The temperature at which a change of state occurs. For 
example, the temperature at which gp120 undergoes a tran 
sition from the folded form to the unfolded form. Essentially 
this is the temperature at which the structure melts away. 
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Stabilized gp120 has a higher T, than native gp120. Another 
example would be the temperature at which a DNA duplex 
melts. 
Transformed: A transformed cell is a cell into which has 
been introduced a nucleic acid molecule by molecular biol 
ogy techniques. As used herein, the term transformation 
encompasses all techniques by which a nucleic acid molecule 
might be introduced into such a cell, including transfection 
with viral vectors, transformation with plasmid vectors, and 
introduction of DNA by electroporation, lipofection, and par 
ticle gun acceleration. 
Unit Cell: The smallest building block of a crystal. The 
entire Volume of a crystal may be constructed by regular 
assembly of such blocks. Each unit cell comprises a complete 
representation of the unit of pattern, the repetition of which 
builds produces a crystal lattice 
Vector: A nucleic acid molecule as introduced into a host 
cell, thereby producing a transformed host cell. Recombinant 
DNA vectors are vectors having recombinant DNA. A vector 
can include nucleic acid sequences that permit it to replicate 
in a host cell. Such as an origin of replication. A vector can 
also include one or more selectable marker genes and other 
genetic elements known in the art. Viral vectors are recombi 
nant DNA vectors having at least Some nucleic acid 
sequences derived from one or more viruses. 
Virus: Microscopic infectious organism that reproduces 
inside living cells. A virus consists essentially of a core of a 
single nucleic acid Surrounded by a protein coat, and has the 
ability to replicate only inside a living cell. “Viral replication' 
is the production of additional virus by the occurrence of at 
least one viral life cycle. A virus may subvert the host cells 
normal functions, causing the cell to behave in a manner 
determined by the virus. For example, a viral infection may 
result in a cell producing a cytokine, or responding to a 
cytokine, when the uninfected cell does not normally do so. 
“Retroviruses are RNA viruses wherein the viral genome 
is RNA. When a host cell is infected with a retrovirus, the 
genomic RNA is reverse transcribed into a DNA intermediate 
which is integrated very efficiently into the chromosomal 
DNA of infected cells. The integrated DNA intermediate is 
referred to as a provirus. The term “lentivirus' is used in its 
conventional sense to describe a genus of viruses containing 
reverse transcriptase. The lentiviruses include the “immuno 
deficiency viruses” which include human immunodeficiency 
virus (HIV) type 1 and type 2 (HIV-1 and HIV-2), simian 
immunodeficiency virus (SIV), and feline immunodeficiency 
virus (FIV). 
HIV-1 is a retrovirus that causes immunosuppression in 
humans (HIV disease), and leads to a disease complex known 
as the acquired immunodeficiency syndrome (AIDS). “HIV 
disease' refers to a well-recognized constellation of signs and 
symptoms (including the development of opportunistic infec 
tions) in persons who are infected by an HIV virus, as deter 
mined by antibody or western blot studies. Laboratory find 
ings associated with this disease are a progressive decline in 
T cells. 
X5: An antibody that bonds a conformation of gp120 
induced by the binding of CD4. Antibodies that bind to gp120 
in a conformation induced by CD4 binding are termed CD4i 
antibodies. 
AS: The change in entropy, such as the change in entropy 
upon the association of gp120 and CD4 or an antibody or 
antibody fragment, for example X5. 
AH: The change in the enthalpy, such as the change 
enthalpy upon the association of gp120 and CD4 or an anti 
body. 
10 
15 
25 
30 
35 
40 
45 
50 
55 
60 
65 
26 
II. Overview of Several Embodiments 
Provided herein in various embodiments are gp120 
polypeptides, which are useful to induce immunogenic 
response in Vertebrate animals (such as mammals, for 
example primates, such as humans) to lentivirus, such as SIV 
or HIV (for example HIV-1 and HIV-2). 
In several embodiments, the gp120 polypeptides are stabi 
lized in a CD4 bound conformation. In several disclosed 
examples, the gp120 polypeptides are stabilized by modifi 
cation. In certain examples, these modifications can be the 
introduction of a plurality of non-naturally occurring cross 
linking cysteine residues. In certain examples, the modifica 
tion can be the introduction of at least one amino acid Substi 
tution in the protein core of gp120. 
In several disclosed examples, cysteines are introduced 
into the gp120 polypeptide at position 96,109, 123,231, 267, 
275, 428,431 or in combinations thereof. In some examples 
of gp120 polypeptides disclosed herein, the plurality of non 
naturally occurring cross-linking cysteine residues are 
defined by the interaction and crosslinking of at least one of 
residue pairs 96 and 275: 109 and 428: 123 and 431; and 231 
and 267. In some embodiments, all of the residue pairs 96 and 
275; 109 and 428: 123 and 431; and 231 and 267 are 
crosslinked. 
In some embodiments, the stabilized gp120 polypeptide 
contains one or more amino acid Substitutions in the protein 
core. In several examples, the Substitution is made at position 
95, 257, 375, 433, or a combination thereof. In specific 
examples, the Substitution is a serine to tryptophan Substitu 
tion at position 95, a threonine to serine Substitution at posi 
tion 257, a serine to tryptophan substitution at position 375, 
an alanine to methionine Substitution at position 433, or a 
combination thereof. 
In specific examples, the Stabilized gp120 polypeptide 
includes the amino acid sequence set forth as SEQID NO: 1 
or is encoded by one of SEQID NO: 4, 5, 6, 7, 8, 10, 11, 12, 
13, 14, 15, 16, 17, 18, or degenerate variants thereof. In still 
other embodiments, the stabilized gp120 contains a portion of 
the amino acid sequence set forth as SEQ ID NO: 1 or as 
encoded by any one of SEQNOs: 4-18, for example, a domain 
Such as the outer domain, or a contiguous stretch of about 5 or 
more amino acids, such as about 6, about 7, about 8, about 9, 
about 10, about 15, about 20, about 25, or more amino acids. 
In other examples, the gp120 polypeptide has the V3 loop 
in an extended conformation. In one example, the gp120 
polypeptide with the V3 loop in an extended conformation 
contains the amino acid sequence set forth as SEQID NO: 2. 
In other embodiments, the gp120 polypeptide with an 
extended v3 loop contains a portion of the amino acid 
sequence set forth as SED ID NO: 2, for example, a domain 
Such as the outer domain, or a contiguous stretch of about 5 or 
more amino acids, such as about 6, about 7, about 8, about 9, 
about 10, about 15, about 20, about 25, or more amino acids 
wherein the domain or contiguous stretch of amino acids 
includes a portion of the V3 loop. 
Other embodiments are compositions containing a thera 
peutically effective amount of at least one gp120 polypeptide, 
Such as a stabilized gp120 polypeptide (such as set forth as 
SEQID NO: 1 or as encoded by the nucleotide sequence set 
forth as one of SEQID NO: 4, 5, 6, 7, 8, 10, 11, 12, 13, 1415, 
16, 17, and 18, or a degenerate variant thereof) or a gp120 
polypeptide with the V3 loop in an extended conformation, 
such as the amino acid sequence set forth as SEQ NO: 2. In 
Some embodiments, the composition can contain pharmaceu 
tically acceptable carriers, adjuvants, or combinations 
thereof. 
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This disclosure further provides methods for eliciting and/ 
or enhancing an immune response in a subject (such as a 
primate subject, for example a human Subject). In some 
embodiments, these methods involve administering to the 
Subject a composition including a gp120 polypeptide as dis 
closed herein, for example a stabilized gp120 such as set forth 
as SEQID NO: 1 or as encoded by the nucleotide sequence set 
forth as one of SEQID NO: 4, 5, 6, 7, 8, 10, 11, 12, 13, 1415, 
16, 17, and 18, or a degenerate variant thereof. In some 
embodiments, these methods involve administering to the 
Subject a composition including a gp120 polypeptide with an 
extended V3 loop such as set forth as SEQID NO: 2. In one 
specific, non-limiting example, the Subject is infected with a 
lentivirus, for example SIV or HIV, such as HIV-1 or HIV-2. 
In some embodiments, the immune response is a B cell 
response, a T cell response, or a combination thereof. 
In other embodiments, the subject is further administered a 
therapeutically effective amount of a monomeric or trimeric 
gp140 polypeptide, an unmodified monomeric or trimeric 
gp120 polypeptide, or a combination thereof. 
Other embodiments of this disclosure are isolated poly 
nucleotides (nucleic acid molecules) which encode the gp120 
polypeptides described herein. Specific examples of such 
nucleic acid molecules contain nucleic acids encoding the 
amino acid sequence set forth as one of SEQID NO: 1 or 2, 
the nucleotide sequences set forth as one of SEQ ID NOs: 
4-18, or degenerate variants thereof. In other embodiments, 
the isolated polynucleotides consist of nucleic acid molecules 
encoding the amino acid sequence set forth as one of SEQID 
NO: 1 or 2, the nucleotide sequences set forth as one of SEQ 
ID NOs: 4-18, or degenerate variants thereof. In certain 
embodiments, the nucleic acid encoding a gp120 polypeptide 
is operably linked to a promoter. Vectors comprising Such 
polynucleotides are also disclosed, as are host cells trans 
formed with such vectors. 
Other embodiments are compositions containing a thera 
peutically effective amount of a polynucleotide containing a 
nucleic acid encoding a gp120 polypeptide disclosed herein. 
In certain embodiments, the nucleic acid encodes the amino 
acid sequence set forth as SEQ ID NO: 1 and 2. In other 
embodiments the nucleic acid contains the one of the nucle 
otide sequences set forth as SEQID NO: 4-18 or a degenerate 
variant thereof. In some embodiments, the composition can 
contain pharmaceutically acceptable carriers, adjuvants, or 
combinations thereof. 
This disclosure further provides methods for eliciting and/ 
or enhancing an immune response in a subject (such as a 
primate Subject, for example a human Subject). The methods 
involve administering to the Subject a composition containing 
a nucleic acid encoding a gp120 polypeptide of this disclo 
Sure. In one specific, non-limiting example, the Subject is 
infected with a lentivirus, for example SIV or HIV, such as 
HIV-1 or HIV-2. In some embodiments, the immune response 
is a B cell response, a T cell response, or a combination 
thereof. 
In other embodiments, the subject is further administered a 
therapeutically effective amount of a plasmid vector express 
ing a polypeptide containing a monomeric or trimeric gp140 
polypeptide, an unmodified monomeric or trimeric gp120 
polypeptide; or combination thereof. 
Also disclosed herein are methods for identifying an 
immunogen that induces an immune response to gp120, for 
example gp120 from a lentivirus, such as SIV or HIV such as 
HIV-1 or HIV-2. Typically the immune response is a B cell 
response, a T cell response, or a combination thereof. These 
methods involve using a three-dimensional structure of 
gp120 as defined by atomic coordinates set forth in Table 1, 
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Table 2, or a portion thereof to design or select the immuno 
gen, synthesizing the immunogen, immunizing a subject with 
the immunogen; and determining if an immune response to 
gp120 is induced in the Subject. In some embodiments, the 
immunogen is designed from the gp120 amino acid sequence. 
In certain embodiments, the immunogen is designed or 
selected using a three-dimensional structure of gp120 as 
defined by atomic coordinates set forth in Table 1, Table 2, or 
a portion thereof and an amino acid sequence is assembled to 
provide an immunogen, for example by synthesizing the 
amino acid sequence or producing a nucleic acid encoding the 
immunogen. In other embodiments the is selected from a 
database of compounds or is designed de novo. 
Also provided by this disclosure is a machine readable data 
storage medium including a data storage material encoded 
with machine readable data corresponding to the coordinates 
of a stabilized form of gp120 as defined by Table 1 or a portion 
thereof or a form of gp120 having an extended conformation 
of the V3 loop as defined by Table 2 or a portion thereof. 
Also provided for are computer systems including data and 
a data processor, wherein the system forms a representation of 
the three-dimensional structure gp120 protein as defined by 
Table 1, Table 2, or a portion thereof, such as the atomic 
positions, Surface, domain, or region of the gp120 polypep 
tide. 
Also disclosed herein is the use of stabilized gp120 mol 
ecules as crystallization tools. A crystalline form of a stabi 
lized gp120 also is disclosed, for example the crystalline form 
of gp120 as defined by the coordinates as given in Table 1, or 
with coordinates having a root mean square deviation there 
from, wherein the distance between the residues is less than 
about 0.75A. A crystalline form of agp120 with an extended 
V3 loop also is disclosed, for example the crystalline form of 
gp120 as defined by the coordinates as given in Table 2, or 
with coordinates having a root mean square deviation there 
from, wherein the distance between the residues is less than 
about 0.75 A. 
III. gp120 Immunogens and Nucleic Acids Encoding gp120 
Immunogens 
The present disclosure relates to gp120 polypeptides and 
nucleic acids encoding these gp120 polypeptides. The gp120 
polypeptides of this disclosure are capable of eliciting an 
immune response to a gp120 protein in a subject, Such as a 
human Subject. In some embodiments, the gp120 polypep 
tides of this disclosure are stabilized in a CD4 bound confor 
mation. 
Using a combination of atomic level structural information 
with biophysical techniques novel gp120 polypeptides were 
designed that are stabilized in the conformation Substantially 
identical to the CD4 bound polypeptide. For example, the 
three-dimensional structure of the wild-type polypeptide was 
analyzed to determine where cysteine residues could be intro 
duced such that they would form disulfide bonds in the folded 
molecule. This methodology is not specific to cysteine resi 
dues; other natural or non-natural amino acids could be used. 
In some embodiments, the stabilized gp120 has a K for CD4 
of less than or equal to about 10 nM. Such as less than or equal 
to about 5 nM, less than or equal to about 3 nM, or less than 
or equal to about 1 nM. In some embodiments the stabilized 
gp120 has -TAS for CD4 binding of about less than or equal 
to 40kcal/mol, such as about less than or equal to 30kcal/mol, 
about less than or equal to 15 kcal/mol, or about less than or 
equal to 10 kcal/mol. 
The stability offolded polypeptides can be measured using 
techniques such as thermal denaturation. The temperature of 
the unfolding transition (T,) is an accepted measure of the 
stability of the folded polypeptide, where increases in T. 
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indicate an increase in the stability of the folded polypeptide. 
In some embodiments, the stabilized gp120 polypeptides has 
a T, value greater than about 52° C. Such as greater than 
about 53° C., greater than about 54°C. (such as 53.8° C.), 
greater than about 55° C., greater than about 56°C., greater 
than about 57°C., greater than about 58° C., or even greater 
than about 59° C. 
In some embodiments, the stabilized gp120 polypeptides 
are stabilized by a plurality of non-naturally occurring cross 
linking cysteine residues. By plurality it is meant that there 
are at least 2, Such as at least 4, at least 6, or at least 8 cysteines 
introduced by mutation into a gp120 polypeptide. Such that 
pairs of cysteines form at least 1, such as at least 2, at least 3, 
or at least 4 disulfide bonds. Each disulfide bond is formed by 
a pair of cysteines. 
In some embodiments, the mutationally introduced cys 
teines are introduced into the gp120 polypeptide at positions 
96, 109,123,231,267,275, 428,431, or in a sub-combination 
thereof. In some examples of the stabilized gp120 polypep 
tides, the plurality of non-naturally occurring cross-linking 
cysteine residues are defined by the interaction of at least one 
of residue pairs 96 and 275; 109 and 428: 123 and 431; and 
231 and 267. Thus, the stabilized gp120 polypeptides of this 
disclosure may have any combination of the crosslinked cys 
teines defined by the interaction of 96 and 275; 109 and 428; 
123 and 431; and 231 and 267. 
In some embodiments, the stabilized gp120 polypeptide 
contains one or more amino acid Substitutions in the protein 
core. In several disclosed examples, the Substitution is made 
at position 95,257,375, 433, or a combination thereof. Thus, 
a stabilized gp120 polypeptide may have one, two, three, or 
four Substitutions in the protein core. In specific examples, the 
Substitution is a serine to tryptophan substitution at position 
95, a threonine to serine substitution at position 257, a serine 
to tryptophan Substitution at position 375, an alanine to 
methionine Substitution at position 433, or various combina 
tions thereof. 
In one embodiment, the stabilized gp120 polypeptide 
(new 9c) includes the amino acid sequence set forth as: 
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sequence set forth as one of SEQID NO: 4, 5, 6, 7, 8, 10, 11, 
12, 13, 1415, 16, 17, and 18, or a degenerate variant thereof. 
In some embodiments, a stabilized gp120 polypeptide is an 
immunogenic fragment of SEQID NO: 1 or as encoded by the 
nucleotide sequence set forth as one of SEQID NO: 4, 5, 6, 7, 
8, 10, 11, 12, 13, 1415, 16, 17, and 18, or a degenerate variant 
thereof. Such that the immunogenic fragment is stabilized in 
a CD4 binding conformation. In some embodiments, the sta 
bilized gp120 includes the outer-domain. In one example, the 
outer domain includes residues 255-421 and 436-474 of 
gp120. Thus, the outer domain can contain residues 109-246 
and 261-299 of SEQ ID NO: 1, the amino acid sequence 
encoded by SEQID NO: 4-18 or a degenerate variant thereof. 
In some examples residues 246 and 261 are covalently linked, 
for example by a peptide linker. In some examples, the pep 
tide linker is residues 247-260 of SEQID NO: 1, the amino 
acid sequence encoded by SEQID NO: 4-18 or a degenerate 
variant thereof. Ideally the linker should be of sufficient 
length Such that the folded protein is a conformation that can 
be bound by CD4. In some embodiments, the linker is a 
peptide linker and the peptide linker is about 2 to about 20 
amino acids in length, Such as about 2, about 3, about 4, about 
5, about 6, about 7, about 8, about 10, about 12, about 15, or 
about 20 amino acids in length. In some embodiments, the 
immunogenic fragment of gp120 consists of residues 109 
246 and 261-299, and a linker In some embodiments the 
linker does not contain a sequence form gp120. 
In other embodiments, the stabilized gp120 fragment is 
truncated on the carboxy terminal end. For example, the 
carboxy terminal end can be truncated to about amino acid 
residue 433. In addition, portions of the amino terminus of 
gp120 can also be eliminated from the stabilized gp120 frag 
ment. The truncated gp120 sequence can be free from the 
carboxy terminus through amino acid residue 95. In one 
embodiment, the truncated gp120 sequence is free from the 
amino terminus of gp120 through residue 95 and residue 433 
through the carboxy terminus of gp120. Thus, in some 
embodiments the stabilized gp120 contains a portion of the 
1) 
EVVLVNVTENFNWCKNDMVEOMHEDICSLWDOSLKPCWKLCPLAGATSVITOACPKVSFEPIPIHY 
CAPAGFAILKCNNKTFNGTGPCTNVSTVOCTHGIRPVVSSOLLLNGSLAEEEWVIRSCNFTDNAKTII 
WOLNTSVEINCTRPNNGGSGSGGNMROAHCNISRAKWNNTLKOIASKLREOFGNNKTIIFKOSSGG 
DPEIVTHWFNCGGEFFYCNSTOLFNSTWFNSTWSTEGSNNTEGSDTITLPCRIKOIINMWCKVCKA 
MYAPPISGOIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWRSELYKYKVVKIE. 
In other embodiments, the stabilized gp120 includes the 
amino acid sequence encoded by one of SEQID NO: 4, 5, 6, 
7, 8, 10, 11, 12, 13, 14, 15, 16, 17, and 18, or degenerate 
variants thereof. In still other embodiments, the stabilized 
gp120 polypeptide consists of the amino acid sequence set 
forth as SEQ ID NO: 1 or as encoded by the nucleotide 
50 amino acid sequence set forth as SEQID NO: 1 or as encoded by any one of SED NOs:4-18. 
In other embodiments, the gp120 polypeptide has the V3 
loop in an extended conformation. An exemplary sequence of 
a gp120 with an extended loop is set forth as: 
(SEQ ID NO: 2) 
GARSEVVLENVTEHFNMWKNDMVEOMOEDIISLWDOSLKPCWKLTPLCVGAGSCDTSVITOACPKI 
SFEPIPIHYCAPAGFAILKCNDKTFNGKGPCKNWSTVOCTHGIRPVVSTOLLLNGSLAEEEWVIRSDNF 
TNNAKTI IVOLKESVEINCTRPNONTRKSIHIGPGRAFYTTGEIIGDIROAHCNISRAKWNDTLKOIVIK 
LREOFENKTIVFNHSSGGDPEIVMHSFNCGGEFFYCNSAOLFNSTWNNNTEGSNNTEGNTITLPCRIK 
OIINMWOEVGKAMYAPPIRGOIRCSSNITGLLLTRDGGINENGTEIFRPGGGDMRDNWRSELYKYKV 
WKIE. 
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Thus, a gp120 polypeptide with an extended V3 loop can 
contain the amino acid sequence set forth as SEQID NO: 2 or 
a fragment thereof. In one example, the gp120 polypeptide 
with the V3 loop in an extended conformation consists of the 
amino acid sequence set forth as SEQID NO: 2 or a fragment 
thereof. In still other embodiments, the gp120 polypeptide 
with an extended V3 loop contains a portion of the amino acid 
sequence set forth as SED ID NO: 2. In some embodiments, 
the stabilized gp120 includes the outer-domain. In one 
example, the outer domain includes residues 255-421 and 
436-474 of gp120. Thus, the outer domain can include resi 
dues 109-246 and 261-299 of SEQID NO: 2. 
In other embodiments, the gp120 polypeptide has the V3 
loop in an extended conformation is truncated on the carboxy 
terminal end. For example, the carboxy terminal end can be 
truncated to about amino acid residue 433. In addition, por 
tions of the amino terminus of gp120 can also be eliminated 
from the gp120 polypeptide has the V3 loop in an extended 
conformation fragment. The truncated gp120 sequence can 
be free from the carboxy terminus through amino acid residue 
95. In one embodiment, the truncated gp120 sequence is free 
from the amino terminus of gp120 through residue 95 and 
residue 433 through the carboxy terminus of gp120. Thus, in 
some embodiments the gp120 polypeptide has the V3 loop in 
an extended conformation contains a portion of the amino 
acid sequence set forth as SEQID NO: 2. 
In other embodiments, the gp120 polypeptide has an amino 
acid sequence least 90% identical to SEQID NO: 1, SEQID 
NO: 2, or the amino acid sequence encoded by any one of 
SEQID NO: 4-18, for example a polypeptide that has about 
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or even 
higher sequence identity to SEQID NO: 1, SEQID NO:2, or 
the amino acid sequence encoded by any one of SEQID NO: 
4-18. 
The immunogenic gp120 polypeptides or immunogenic 
fragments of the gp120 polypeptides disclosed herein can be 
chemically synthesized by standard methods, or can be pro 
duced recombinantly. An exemplary process for polypeptide 
production is described in Lu et al., Federation of European 
Biochemical Societies Letters. 429:31-35, 1998. They can 
also be isolated by methods including preparative chroma 
tography and immunological separations. 
In other embodiments, fusion proteins are provided includ 
ing a first and second polypeptide moiety in which one of the 
protein moieties includes an amino acid sequence as set forth 
in SEQID NO: 1 or 2, or a fragment thereof. In other embodi 
ments, fusion proteins are provided comprising a first and 
second polypeptide moiety in which one of the protein moi 
eties includes an amino acid sequence encoded by one of the 
nucleotide sequences as set forth as SEQID NO: 4-18, or a 
fragment thereof. The other moiety is a heterologous protein 
Such as can be a carrier protein and/or an immunogenic pro 
tein. Such fusions also are useful to evoke an immune 
response against gp120. In certain embodiments the gp120 
polypeptides disclosed herein are covalent or non-covalent 
addition of TLR ligands or dendritic cell or B cell targeting 
moieties. 
A gp120 polypeptide can be covalently linked to a carrier, 
which is an immunogenic macromolecule to which an anti 
genic molecule can be bound. When bound to a carrier, the 
bound polypeptide becomes more immunogenic. Carriers are 
chosen to increase the immunogenicity of the bound mol 
ecule and/or to elicit higher titers of antibodies against the 
carrier which are diagnostically, analytically, and/or thera 
peutically beneficial. Covalent linking of a molecule to a 
carrier can confer enhanced immunogenicity and T cell 
dependence (see Pozsgay et al., PNAS96:5194-97, 1999; Lee 
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et al., J. Immunol. 116:1711-18, 1976; Dintzis et al., PNAS 
73:3671-75, 1976). Useful carriers include polymeric carri 
ers, which can be natural (for example, polysaccharides, 
polypeptides or proteins from bacteria or viruses), semi-syn 
thetic or synthetic materials containing one or more func 
tional groups to which a reactant moiety can be attached. 
Bacterial products and viral proteins (such as hepatitis B 
Surface antigen and core antigen) can also be used as carriers, 
as well as proteins from higher organisms such as keyhole 
limpet hemocyanin, horseshoe crab hemocyanin, edestin, 
mammalian serum albumins, and mammalian immunoglobu 
lins. Additional bacterial products for use as carriers include 
bacterial wall proteins and other products (for example, Strep 
tococcal or staphylococcal cell walls and lipopolysaccharide 
(LPS)). 
Most antigenic epitopes of HIV proteins are relatively 
small in size, such as about 5 to 100 amino acids in size, for 
example about 5, about 6, about 7, about 8, about 9, about 10, 
about 15, about 20, about 25, about 30, about 40, about 50, 
about 60, about 70, about 80, about 90, or about 100. Thus, 
fragments (for example, epitopes or other antigenic frag 
ments) of a gp120 polypeptide, Such as any of the gp120 
polypeptides described herein or a fragment thereof, can be 
used as an immunogen. 
In some embodiments, the disclosed gp120 polypeptides 
are modified by glycosylation, for example by N-linked gly 
cans. Thus, the immune response can be focused on a region 
interestofagp120 polypeptide by masking other regions with 
non-immunogenic glycans. Glycosylation sites can be intro 
duced into the gp120 polypeptides by site directed mutagen 
esis. This straggly can be utilized to focus the immune 
response to regions of interest in the gp120 polypeptide, for 
example the CD4 binding site or the binding site for a neu 
tralizing antibody, for example a the b12 antibody. Examples 
of glycan masking can be found in Pantophlet and Burton, 
Trends Mol Med. 9(11):468-73, 2003, which is incorporated 
by reference herein in its entirety. 
Another strategy to focus the immune response on the CD4 
binding region or b12 epitope region is to use SIV and 
HIV gp120 core glycoproteins (such as the stabilized gp120 
polypeptides disclosed herein) that possess an endogenous 
CD4 binding site or to scaffold the heterologous HIV-1 CD4 
binding region onto cores derived from selected SIV or HIV-2 
strains. The gp120 core can be derived from the envelope 
glycoproteins of lentivirus, for example SIV such as SIV 
mac239 and HIV, such as HIV-2 7132A. The residues 
required for CD4BS antibody recognition, for example the 
site of b12 binding, are transplanted by site-directed 
mutagenesis of the appropriate codon-optimized plasmid 
sequences. In some embodiments, extra N-glycans are added 
to these cores to eliminate the elicitation of non-cross reactive 
antibodies directed against regions outside the antibody bind 
ing site, for example the binding site of a neutralizing anti 
body such as CD4ES antibody. 
The present disclosure concerns nucleic acid constructs 
including polynucleotide sequences that encode antigenic 
gp120 polypeptides of HIV-1. These polynucleotides include 
DNA, cDNA and RNA sequences which encode the polypep 
tide of interest. 
Methods for the manipulation and insertion of the nucleic 
acids of this disclosure into vectors are well known in the (see 
for example, Sambrook et al., Molecular Cloning, a Labora 
tory Manual, 2d edition, Cold Spring Harbor Press, Cold 
Spring Harbor, N.Y., 1989, and Ausubel et al., Current Pro 
tocols in Molecular Biology, Greene Publishing Associates 
and John Wiley & Sons, New York, N.Y., 1994). 
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Typically, the nucleic acid constructs encoding the gp120 
polypeptides of this disclosure are plasmids. However, other 
vectors (for example, viral vectors, phage, cosmids, etc.) can 
be utilized to replicate the nucleic acids. In the context of this 
disclosure, the nucleic acid constructs typically are expres 
sion vectors that contain a promoter sequence which facili 
tates the efficient transcription of the inserted genetic 
sequence of the host. The expression vector typically contains 
an origin of replication, a promoter, as well as specific nucleic 
acid sequences that allow phenotypic selection of the trans 
formed cells. 
More generally, polynucleotide sequences encoding the 
gp120 polypeptides of this disclosure can be operably linked 
to any promoter and/or enhancer that is capable of driving 
expression of the nucleic acid following introduction into a 
host cell. A promoter is an array of nucleic acid control 
sequences that directs transcription of a nucleic acid. A pro 
moter includes necessary nucleic acid sequences (which can 
be) near the start site of transcription, Such as in the case of a 
polymerase II type promoter (a TATA element). A promoter 
also can include distal enhancer or repressor elements which 
can be located as much as several thousand base pairs from 
the start site of transcription. Both constitutive and inducible 
promoters are included (see, for example, Bitter et al., Meth 
ods in Enzymology 153:516-544, 1987). 
To produce such nucleic acid constructs, polynucleotide 
sequences encoding gp120 polypeptides are inserted into a 
Suitable expression vector, Such as a plasmid expression vec 
tor. Procedures for producing polynucleotide sequences 
encoding gp120 polypeptides and for manipulating them in 
vitro are well known to those of skill in the art, and can be 
found, for example in Sambrook and Ausubel, supra. 
In addition to the polynucleotide sequences encoding the 
polypeptides set forth as SEQ ID NOs: 1-2 disclosed herein 
and nucleic acids encoding gp120 polypeptides as set forth as 
SEQID NOs:4-18 as disclosed herein, the nucleic acid con 
structs can include variant polynucleotide sequences that 
encode polypeptides that are substantially similar to SEQID 
NOS: 1-2 and nucleic acids encoding gp120 polypeptides as 
set forth as SEQ ID NOs: 4-18. Similarly, the nucleic acid 
constructs can include polynucleotides that encode chimeric 
polypeptides, for example fusion proteins. For enhanced 
immunogenicity, it may be advantageous to include the 
sequence encoding for heterologous T helper sequences 
derived from HIV or other heterologous sources. 
The similarity between amino acid (and polynucleotide) 
sequences is expressed in terms of the similarity between the 
sequences, otherwise referred to as sequence identity. 
Sequence identity is frequently measured interms of percent 
age identity (or similarity); the higher the percentage, the 
more similar are the primary structures of the two sequences. 
In general, the more similar the primary structures of two 
amino acid sequences, the more similar are the higher order 
structures resulting from folding and assembly. Thus, the 
nucleic acid constructs can include polynucleotides that 
encode polypeptides that are at least about 90%, or 95%, 
98%, or 99% identical to one of SEQ ID NOs: 1-2 with 
respect to amino acid sequence, or that have at least about 
90%. 95%, 98%, or 99% sequence identity to one or more of 
SEQ ID NOs: 4-18 and/or that differ from one of these 
sequences by the Substitution of degenerate codons. 
DNA sequences encoding an immunogenic gp120 
polypeptide can be expressed in vitro by DNA transfer into a 
suitable host cell. The cell may be prokaryotic or eukaryotic. 
The term also includes any progeny of the Subject host cell. It 
is understood that all progeny may not be identical to the 
parental cell since there may be mutations that occur during 
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replication. Methods of stable transfer, meaning that the for 
eign DNA is continuously maintained in the host, are known 
in the art. 
The polynucleotide sequences encoding an immunogenic 
gp120 polypeptide can be inserted into an expression vector 
including, but not limited to, a plasmid, virus or other vehicle 
that can be manipulated to allow insertion or incorporation of 
sequences and can be expressed in either prokaryotes or 
eukaryotes. Hosts can include microbial, yeast, insect, and 
mammalian organisms. Methods of expressing DNA 
sequences having eukaryotic or viral sequences in prokary 
otes are well known in the art. Biologically functional viral 
and plasmid DNA vectors capable of expression and replica 
tion in a host are known in the art. 
Transformation of a host cell with recombinant DNA can 
be carried out by conventional techniques that are well known 
to those of ordinary skill in the art. Where the host is prokary 
otic, such as E. coli, competent cells which are capable of 
DNA uptake can be prepared from cells harvested after expo 
nential growth phase and Subsequently treated by the CaCl2 
method using procedures well known in the art. Alternatively, 
MgCl, or RbCl can be used. Transformation can also be 
performed after forming a protoplast of the host cell if 
desired, or by electroporation. 
When the host is a eukaryote, such methods of transfection 
of DNA as calcium phosphate coprecipitates, conventional 
mechanical procedures Such as microinjection, electropora 
tion, insertion of a plasmid encased in liposomes, or virus 
vectors can be used. Eukaryotic cells can also be co-trans 
formed with polynucleotide sequences encoding an immuno 
genic gp120 polypeptide, and a second foreign DNA mol 
ecule encoding a selectable phenotype, such as the herpes 
simplex thymidine kinase gene. Another method is to use a 
eukaryotic viral vector, such as simian virus 40 (SV40) or 
bovine papilloma virus, to transiently infect or transform 
eukaryotic cells and express the protein (see for example, 
Eukaryotic Viral Vectors, Cold Spring Harbor Laboratory, 
Gluzman ed., 1982). 
IV. Immunogenic Compositions and Therapeutic Methods 
Any of the gp120 polypeptides and nucleic acid molecules 
encoding the gp120 polypeptides disclosed herein can be 
used as immunogens, or to produce immunogens to elicit an 
immune response (immunogenic compositions) to gp120 
Such as to a gp120 expressing virus, for example to reduce 
HIV-1 infection or a symptom of HIV-1 infection. Following 
administration of a therapeutically effective amount of the 
disclosed therapeutic compositions, the Subject can be moni 
tored for HIV-1 infection, symptoms associated with HIV-1 
infection, or both. Disclosed herein are methods of adminis 
tering the therapeutic molecules disclosed herein (Such as 
gp120 polypeptides and nucleic acids encoding gp120 
polypeptides) to reduce HIV-1 infection. In several examples, 
a therapeutically effective amount of a gp120 polypeptide 
including SEQID NO: 1, a therapeutically effective amount 
of a gp120 polypeptide including SEQID NO: 2, a therapeu 
tically effective amount of a gp120 polypeptide encoded by 
one of SEQID NOs: 4-18 or a degenerate variant thereof, or 
a combination thereof is administered to a subject. 
In certain embodiments, the immunogenic composition 
includes an adjuvant. An adjuvant can be a suspension of 
minerals, such as alum, aluminum hydroxide, aluminum 
phosphate, on which antigen is adsorbed; or water-in-oil 
emulsion in which antigen solution is emulsified in oil (MF 
59, Freund's incomplete adjuvant), sometimes with the inclu 
sion of killed mycobacteria (Freund's complete adjuvant) to 
further enhance antigenicity (inhibits degradation of antigen 
and/or causes influx of macrophages). In one embodiment, 
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the adjuvant is a mixture of stabilizing detergents, micelle 
forming agent, and oil available under the name PROVAX(R) 
(IDEC Pharmaceuticals, San Diego, Calif.). An adjuvant can 
also be an immunostimulatory nucleic acid, such as a nucleic 
acid including a CpG motif. 
In one example, the immunogenic composition is mixed 
with an adjuvant containing two or more of a stabilizing 
detergent, a micelle-forming agent, and an oil. Suitable sta 
bilizing detergents, micelle-forming agents, and oils are 
detailed in U.S. Pat. Nos. 5,585,103; 5,709,860: 5,270,202: 
and 5,695,770, all of which are incorporated by reference 
herein in their entirety. A stabilizing detergent is any deter 
gent that allows the components of the emulsion to remain as 
a stable emulsion. Such detergents include polysorbate 80 
(TWEEN) (Sorbitan-mono-9-octadecenoate-poly(oxy-1,2- 
ethanediyl; manufactured by ICI Americas, Wilmington, 
Dell), TWEEN 40TM, TWEEN 20TM, TWEEN 60TM, ZWIT 
TERGENTTM3-12, TEEPOLHB7TM, and SPAN85TM. These 
detergents are usually provided in an amount of approxi 
mately 0.05 to 0.5%, such as at about 0.2%. A micelle form 
ing agent is an agent which is able to stabilize the emulsion 
formed with the other components such that a micelle-like 
structure is formed. Such agents generally cause Some irrita 
tion at the site of injection in order to recruit macrophages to 
enhance the cellular response. Examples of Such agents 
include polymer surfactants described by BASF Wyandotte 
publications, for example, Schmolka, J. Am. Oil. Chem. Soc. 
54:110, 1977, and Hunter et al., J. Immunol 129:1244, 1981, 
PLURONICTM L62LF, L101, and L64, PEG1000, and 
TETRONICTM 1501, 150R1,701,901, 1301, and 130R1. The 
chemical structures of such agents are well known in the art. 
In one embodiment, the agent is chosen to have a hydrophile 
lipophile balance (HLB) of between 0 and 2, as defined by 
Hunter and Bennett, J. Immun. 133:31.67, 1984. The agent can 
be provided in an effective amount, for example between 0.5 
and 10%, or in an amount between 1.25 and 5%. 
The oil included in the composition is chosen to promote 
the retention of the antigen in oil-in-water emulsion, to pro 
vide a vehicle for the desired antigen, and preferably has a 
melting temperature of less than 65° C. such that emulsion is 
formed either at room temperature (about 20°C. to 25°C.), or 
once the temperature of the emulsion is brought down to room 
temperature. Examples of Such oils include squalene, 
Squalane, EICOSANETM, tetratetracontane, glycerol, and 
peanut oil or other vegetable oils. In one specific, non-limit 
ing example, the oil is provided in an amount between 1 and 
10%, or between 2.5 and 5%. The oil should be both biode 
gradable and biocompatible so that the body can break down 
the oil over time, and so that no adverse effects, such as 
granulomas, are evident upon use of the oil. 
Immunogenic compositions can be formulated with an 
appropriate solid or liquid carrier, depending upon the par 
ticular mode of administration chosen. If desired, the dis 
closed pharmaceutical compositions can also contain minor 
amounts of non-toxic auxiliary Substances, such as wetting or 
emulsifying agents, preservatives, and pH buffering agents 
and the like, for example sodium acetate or Sorbitan mono 
laurate. Excipients that can be included in the disclosed com 
positions include flow conditioners and lubricants, for 
example silicic acid, talc, Stearic acid or salts thereof. Such as 
magnesium or calcium Stearate, and/or polyethylene glycol, 
or derivatives thereof. 
Immunogenic compositions can be provided as parenteral 
compositions, such as for injection or infusion. Such compo 
sitions are formulated generally by mixing a disclosed thera 
peutic agent at the desired degree of purity, in a unit dosage 
injectable form (solution, Suspension, or emulsion), with a 
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pharmaceutically acceptable carrier, for example one that is 
non-toxic to recipients at the dosages and concentrations 
employed and is compatible with other ingredients of the 
formulation. In addition, a disclosed therapeutic agent can be 
Suspended in an aqueous carrier, for example, in an isotonic 
buffer solution at a pH of about 3.0 to about 8.0, preferably at 
a pH of about 3.5 to about 7.4, 3.5 to 6.0, or 3.5 to about 5.0. 
Useful buffers include sodium citrate-citric acid and sodium 
phosphate-phosphoric acid, and Sodium acetate/acetic acid 
buffers. The active ingredient, optionally together with 
excipients, can also be in the form of a lyophilisate and can be 
made into a solution prior to parenteral administration by the 
addition of suitable solvents. Solutions such as those that are 
used, for example, for parenteral administration can also be 
used as infusion solutions. 
A form of repository or “depot' slow release preparation 
can be used so that therapeutically effective amounts of the 
preparation are delivered into the bloodstream over many 
hours or days following transdermal injection or delivery. 
Such long acting formulations can be administered by 
implantation (for example Subcutaneously or intramuscu 
larly) or by intramuscular injection. The compounds can be 
formulated with suitable polymeric or hydrophobic materials 
(for example as an emulsion in an acceptable oil) or ion 
exchange resins, or as sparingly soluble derivatives, for 
example, as a sparingly soluble salt. 
Immunogenic compositions that include a disclosed thera 
peutic agent can be delivered by way of a pump (see Langer, 
supra: Sefton, CRC Crit. Ref. Biomed. Eng. 14:201, 1987: 
Buchwaldet al., Surgery 88:507, 1980: Saudeket al., N. Engl. 
J. Med. 321:574, 1989) or by continuous subcutaneous infu 
Sions, for example, using a mini-pump. An intravenous bag 
Solution can also be employed. One factor in selecting an 
appropriate dose is the result obtained, as measured by the 
methods disclosed here, as are deemed appropriate by the 
practitioner. Other controlled release systems are discussed in 
Langer (Science 249:1527-33, 1990). 
In one example, a pump is implanted (for example see U.S. 
Pat. Nos. 6,436,091; 5,939.380; and 5.993.414). Implantable 
drug infusion devices are used to provide patients with a 
constant and long-term dosage or infusion of a therapeutic 
agent. Such device can be categorized as either active or 
passive. 
Active drug or programmable infusion devices feature a 
pump or a metering system to deliver the agent into the 
patient’s system. An example of Such an active infusion 
device currently available is the Medtronic SYN 
CHROMEDTM programmable pump. Passive infusion 
devices, in contrast, do not feature a pump, but rather rely 
upon a pressurized drug reservoir to deliver the agent of 
interest. An example of such a device includes the Medtronic 
ISOMEDTM. 
In particular examples, immunogenic compositions 
including a disclosed therapeutic agent are administered by 
Sustained-release systems. Suitable examples of Sustained 
release systems include Suitable polymeric materials (such 
as, semi-permeable polymer matrices in the form of shaped 
articles, for example films, or microcapsules), Suitable hydro 
phobic materials (for example as an emulsion in an acceptable 
oil) or ion exchange resins, and sparingly soluble derivatives 
(such as, for example, a sparingly soluble salt). Sustained 
release compositions can be administered orally, parenterally, 
intracistemally, intraperitoneally, topically (as by powders, 
ointments, gels, drops or transdermal patch), or as an oral or 
nasal spray. Sustained-release matrices include polylactides 
(U.S. Pat. No. 3,773.919, EP 58.481), copolymers of 
L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et 
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al., Biopolymers 22:547-556, 1983, poly(2-hydroxyethyl 
methacrylate)); (Langer et al., J. Biomed. Mater. Res. 15:167 
277, 1981; Langer, Chem. Tech. 12:98-105, 1982, ethylene 
vinyl acetate (Langer et al., Id.) or poly-D-(-)-3-hydroxybu 
tyric acid (EP 133,988). 
Polymers can be used for ion-controlled release. Various 
degradable and nondegradable polymeric matrices for use in 
controlled drug delivery are known in the art (Langer, 
Accounts Chem. Res. 26:537, 1993). For example, the block 
copolymer, polaxamer 407 exists as a viscous yet mobile 
liquid at low temperatures but forms a semisolid gel at body 
temperature. It has shown to be an effective vehicle for for 
mulation and Sustained delivery of recombinant interleukin-2 
and urease (Johnston et al., Pharm. Res. 9:425, 1992; and Pec, 
J. Parent. Sci. Tech. 44(2):58, 1990). Alternatively, hydroxya 
patite has been used as a microcarrier for controlled release of 
proteins (Intema et al., Int. J. Pharm. 112:215, 1994). In yet 
another aspect, liposomes are used for controlled release as 
well as drug targeting of the lipid-capsulated drug (Betageriet 
al., Liposome Drug Delivery Systems, Technomic Publishing 
Co., Inc., Lancaster, Pa., 1993). Numerous additional systems 
for controlled delivery of therapeutic proteins are known (for 
example, U.S. Pat. Nos. 5,055.303; 5,188,837; 4,235,871; 
4,501,728; 4.837,028: 4,957,735; 5,019,369; 5,055.303; 
5,514,670; 5,413.797; 5,268,164; 5,004,697; 4,902,505; 
5,506,206: 5,271,961; 5,254,342; and 5,534,496). 
Immunogenic compositions can be administered for thera 
peutic treatments. In therapeutic applications, a therapeuti 
cally effective amount of the immunogenic composition is 
administered to a Subject Suffering from a disease, such as 
HIV-1 infection or AIDS. The immunogenic composition can 
be administered by any means known to one of skill in the art 
(see Banga, A., “Parenteral Controlled Delivery of Therapeu 
tic Peptides and Proteins.” in Therapeutic Peptides and Pro 
teins, Technomic Publishing Co., Inc., Lancaster, Pa., 1995) 
Such as by intramuscular, Subcutaneous, or intravenous injec 
tion, but even oral, nasal, or anal administration is contem 
plated. To extend the time during which the peptide or protein 
is available to stimulate a response, the peptide or protein can 
be provided as an implant, an oily injection, or as a particulate 
system. The particulate system can be a microparticle, a 
microcapsule, a microsphere, a nanocapsule, or similar par 
ticle (see, for example, Banga, Supra). A particulate carrier 
based on a synthetic polymer has been shown to act as an 
adjuvant to enhance the immune response, in addition to 
providing a controlled release. Aluminum salts can also be 
used as adjuvants to produce an immune response. 
Immunogenic compositions can be formulated in unit dos 
age form, Suitable for individual administration of precise 
dosages. In pulse doses, a bolus administration of an immu 
nogenic composition that includes a disclosed immunogen is 
provided, followed by a time-period wherein no disclosed 
immunogen is administered to the Subject, followed by a 
second bolus administration. A therapeutically effective 
amount of an immunogenic composition can be administered 
in a single dose, or in multiple doses, for example daily, 
during a course of treatment. In specific, non-limiting 
examples, pulse doses of an immunogenic composition that 
include a disclosed immunogen are administered during the 
course of a day, during the course of a week, or during the 
course of a month. 
Immunogenic compositions can be administered whenever 
the effect (Such as decreased signs, symptom, or laboratory 
results of HIV-1 infection) is desired. Generally, the dose is 
Sufficient to treat or ameliorate symptoms or signs of disease 
without producing unacceptable toxicity to the Subject. Sys 
temic or local administration can be utilized. 
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Amounts effective for therapeutic use can depend on the 
severity of the disease and the age, weight, general state of the 
patient, and other clinical factors. Thus, the final determina 
tion of the appropriate treatment regimen will be made by the 
attending clinician. Typically, dosages used in vitro can pro 
vide useful guidance in the amounts useful for in situ admin 
istration of the pharmaceutical composition, and animal mod 
els may be used to determine effective dosages for treatment 
of particular disorders. Various considerations are described, 
for example in Gilman et al., eds., Goodman and Gilman: The 
Pharmacological Bases of Therapeutics, 8th ed., Pergamon 
Press, 1990; and Remington’s Pharmaceutical Sciences, 17th 
ed., Mack Publishing Co., Easton, Pa., 1990. Typically, the 
dose range for a gp120 polypeptide is from about 0.1 ug/kg 
body weight to about 100 mg/kg body weight. Other suitable 
ranges include doses of from about 1 g/kg to 10 mg/kg body 
weight. In one example, the dose is about 1.0 ug to about 50 
mg, for example, 1 Lig to 1 mg. Such as 1 mg peptide per 
Subject. The dosing schedule can vary from daily to as seldom 
as once a year, depending on clinical factors, such as the 
subject’s sensitivity to the peptide and tempo of their disease. 
Therefore, a subject can receive a first dose of a disclosed 
therapeutic molecule, and then receive a second dose (or even 
more doses) at Some later time(s). Such as at least one day 
later, Such as at least one week later. 
The pharmaceutical compositions disclosed herein can be 
prepared and administered in dose units. Solid dose units 
include tablets, capsules, transdermal delivery systems, and 
Suppositories. The administration ofatherapeutic amount can 
be carried out both by single administration in the form of an 
individual dose unit or else several smallerdose units and also 
by multiple administrations of subdivided doses at specific 
intervals. Suitable single or divided doses include, but are not 
limited to about 0.01, 0.1, 0.5, 1, 3, 5, 10, 15, 30, or 50 ug 
protein/kg/day 
The nucleic acid constructs encoding antigenic gp120 
polypeptides described herein are used, for example, in com 
bination, as pharmaceutical compositions (medicaments) for 
use in therapeutic, for example, prophylactic regimens (such 
as vaccines) and administered to Subjects (for example, pri 
mate Subjects such as human Subjects) to elicit an immune 
response against one or more clade or strain of HIV. For 
example, the compositions described herein can be adminis 
tered to a human (or non-human) Subject prior to infection 
with HIV to inhibit infection by or replication of the virus. 
Thus, the pharmaceutical compositions described above can 
be administered to a Subject to elicit a protective immune 
response against HIV. To elicit an immune response, a thera 
peutically effective (for example, immunologically effective) 
amount of the nucleic acid constructs are administered to a 
Subject, Such as a human (or non-human) Subject. 
Immunization by nucleic acid constructs is well known in 
the art and taught, for example, in U.S. Pat. No. 5,643,578 
(which describes methods of immunizing vertebrates by 
introducing DNA encoding a desired antigen to elicit a cell 
mediated or a humoral response), and U.S. Pat. Nos. 5.593, 
972 and 5.817,637 (which describe operably linking a nucleic 
acid sequence encoding an antigen to regulatory sequences 
enabling expression). U.S. Pat. No. 5,880,103 describes sev 
eral methods of delivery of nucleic acids encoding immuno 
genic peptides or other antigens to an organism. The methods 
include liposomal delivery of the nucleic acids (or of the 
synthetic peptides themselves), and immune-stimulating 
constructs, or ISCOMSTM, negatively charged cage-like 
structures of 30-40 nm in size formed spontaneously on mix 
ing cholesterol and QUIL ATM (saponin). 
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For administration of gp120 nucleic acid molecules, the 
nucleic acid can be delivered intracellularly, for example by 
expression from an appropriate nucleic acid expression vec 
tor which is administered so that it becomes intracellular, 
such as by use of a retroviral vector (see U.S. Pat. No. 4,980, 
286), or by direct injection, or by use of microparticle bom 
bardment (Such as a gene gun; Biolistic, Dupont), or coating 
with lipids or cell-Surface receptors or transfecting agents, or 
by administering it in linkage to a homeobox-like peptide 
which is known to enter the nucleus (for example Joliot et al., 
Proc. Natl. Acad. Sci. USA 1991, 88:1864-8). The present 
disclosure includes all forms of nucleic acid delivery, includ 
ing synthetic oligos, naked DNA, plasmid and viral, inte 
grated into the genome or not. 
In another approach to using nucleic acids for immuniza 
tion, an immunogenic gp120 polypeptide can also be 
expressed by attenuated viral hosts or vectors or bacterial 
vectors. Recombinant vaccinia virus, adeno-associated virus 
(AAV), herpes virus, retrovirus, or other viral vectors can be 
used to express the peptide or protein, thereby eliciting a CTL 
response. For example, vaccinia vectors and methods useful 
in immunization protocols are described in U.S. Pat. No. 
4,722,848. BCG (Bacillus Calmette Guerin) provides another 
vector for expression of the peptides (see Stover, Nature 
351:456-460, 1991). 
In one example, a viral vector is utilized. These vectors 
include, but are not limited to, adenovirus, herpes virus, vac 
cinia, or an RNA virus such as a retrovirus. In one example, 
the retroviral vector is a derivative of a murine or avian 
retrovirus. Examples of retroviral vectors in which a single 
foreign gene can be inserted include, but are not limited to: 
Moloney murine leukemia virus (MoMuLV), Harvey murine 
sarcoma virus (HaMuSV), murine mammary tumor virus 
(MuMTV), and Rous Sarcoma Virus (RSV). When the sub ject is a human, a vector Such as the gibbonape leukemia virus 
(Gal. V) can be utilized. A number of additional retroviral 
vectors can incorporate multiple genes. All of these vectors 
can transfer or incorporate a gene for a selectable marker so 
that transduced cells can be identified and generated. By 
inserting a nucleic acid sequence encoding a gp120 polypep 
tide into the viral vector, along with another gene that encodes 
the ligand for a receptor on a specific target cell, for example, 
the vector is now target specific. Retroviral vectors can be 
made target specific by attaching, for example, a Sugar, a 
glycolipid, or a protein. Preferred targeting is accomplished 
by using an antibody to target the retroviral vector. Those of 
skill in the art will know of, or can readily ascertain without 
undue experimentation, specific polynucleotide sequences 
which can be inserted into the retroviral genome or attached 
to a viral envelope to allow target specific delivery of the 
retroviral vector containing the polynucleotide encoding a 
gp120 polypeptide. 
Since recombinant retroviruses are defective, they need 
assistance in order to produce infectious vector particles. This 
assistance can be provided, for example, by using helper cell 
lines that contain plasmids encoding all of the structural 
genes of the retrovirus under the control of regulatory 
sequences within the LTR. These plasmids are missing a 
nucleotide sequence that enables the packaging mechanism 
to recognizean RNA transcript for encapsidation. Helper cell 
lines that have deletions of the packaging signal include, but 
are not limited to Q2, PA317, and PA12, for example. These 
cell lines produce empty virions, since no genome is pack 
aged. If a retroviral vector is introduced into such cells in 
which the packaging signal is intact, but the structural genes 
are replaced by other genes of interest, the vector can be 
packaged and vector virion produced. 
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Suitable formulations for the nucleic acid constructs, 
include aqueous and non-aqueous Solutions, isotonic sterile 
Solutions, which can contain anti-oxidants, buffers, and bac 
teriostats, and aqueous and non-aqueous sterile Suspensions 
that can include Suspending agents, solubilizers, thickening 
agents, stabilizers, and preservatives. The formulations can 
be presented in unit-dose or multi-dose sealed containers, 
Such as ampules and vials, and can be stored in a freeze-dried 
(lyophilized) condition requiring only the addition of the 
sterile liquid carrier, for example, water, immediately prior to 
use. Extemporaneous solutions and Suspensions can be pre 
pared from sterile powders, granules, and tablets. Preferably, 
the carrier is a buffered saline solution. More preferably, the 
composition for use in the inventive method is formulated to 
protect the nucleic acid constructs from damage prior to 
administration. For example, the composition can be formu 
lated to reduce loss of the adenoviral vectors on devices used 
to prepare, store, or administer the expression vector, Such as 
glassware, Syringes, or needles. The compositions can be 
formulated to decrease the light sensitivity and/or tempera 
ture sensitivity of the components. To this end, the composi 
tion preferably comprises a pharmaceutically acceptable liq 
uid carrier, Such as, for example, those described above, and 
a stabilizing agent selected from the group consisting of 
polysorbate 80, L-arginine, polyvinylpyrrolidone, trehalose, 
and combinations thereof. 
In therapeutic applications, a therapeutically effective 
amount of the composition is administered to a subject prior 
to or following exposure to or infection by HIV. When admin 
istered prior to exposure, the therapeutic application can be 
referred to as a prophylactic administration (such as in the 
form of a vaccine). Single or multiple administrations of the 
compositions are administered depending on the dosage and 
frequency as required and tolerated by the Subject. In one 
embodiment, the dosage is administered once as a bolus, but 
in another embodiment can be applied periodically until a 
therapeutic result, such as a protective immune response, is 
achieved. Generally, the dose is sufficient to treat or amelio 
rate symptoms or signs of disease without producing unac 
ceptable toxicity to the subject. Systemic or local administra 
tion can be utilized. 
In the context of nucleic acid vaccines, naturally occurring 
or synthetic immunostimulatory compositions that bind to 
and stimulate receptors involved in innate immunity can be 
administered along with nucleic acid constructs encoding the 
gp120 polypeptides. For example, agents that stimulate cer 
tain Toll-like receptors (such as TLR7, TLR8 and TLR9) can 
be administered in combination with the nucleic acid con 
structs encoding gp120 polypeptides. In some embodiments, 
the nucleic acid construct is administered in combination 
with immunostimulatory CpG oligonucleotides. 
Nucleic acid constructs encoding gp120 polypeptides can 
be introduced in vivo as naked DNA plasmids. DNA vectors 
can be introduced into the desired host cells by methods 
known in the art, including but not limited to transfection, 
electroporation (for example, transcutaneous electropora 
tion), microinjection, transduction, cell fusion, DEAE dext 
ran, calcium phosphate precipitation, use of a gene gun, or use 
of a DNA vector transporter (See for example, Wu et al. J. 
Biol. Chem., 267:963-967, 1992; Wu and Wu J. Biol. Chem., 
263:14621-14624, 1988; and Williams et al. Proc. Natl. Acad. 
Sci. USA 88:2726-2730, 1991). As described in detail in the 
Examples, a needleless delivery device, such as a BIOJEC 
TOR(R) needleless injection device can be utilized to intro 
duce the therapeutic nucleic acid constructs in vivo. Recep 
tor-mediated DNA delivery approaches can also be used 
(Curieletal. Hum. Gene Then, 3:147-154, 1992; and Wu and 
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Wu, J. Biol. Chem., 262:4429-4432, 1987). Methods for for 
mulating and administering naked DNA to mammalian 
muscle tissue are disclosed in U.S. Pat. Nos. 5,580,859 and 
5,589,466, both of which are herein incorporated by refer 
ence. Other molecules are also useful for facilitating trans 
fection of a nucleic acid in Vivo, Such as a cationic oligopep 
tide (for example, WO95/21931), peptides derived from 
DNA binding proteins (for example, WO96/25508), or a cat 
ionic polymer (for example, WO95/21931). 
Another well-known method that can be used to introduce 
nucleic acid constructs encoding gp120 immunogens into 
host cells is particle bombardment (also known as biolistic 
transformation). Biolistic transformation is commonly 
accomplished in one of several ways. One common method 
involves propelling inert or biologically active particles at 
cells. This technique is disclosed in, for example, U.S. Pat. 
Nos. 4,945,050, 5,036,006; and 5,100,792, all to Sanford et 
al., which are hereby incorporated by reference. Generally, 
this procedure involves propelling inert or biologically active 
particles at the cells under conditions effective to penetrate 
the outer surface of the cell and to be incorporated within the 
interior thereof. When inert particles are utilized, the plasmid 
can be introduced into the cell by coating the particles with 
the plasmid containing the exogenous DNA. Alternatively, 
the target cell can be surrounded by the plasmid so that the 
plasmid is carried into the cell by the wake of the particle. 
Alternatively, the vector can be introduced in vivo by lipo 
fection. For the past decade, there has been increasing use of 
liposomes for encapsulation and transfection of nucleic acids 
in vitro. Synthetic cationic lipids designed to limit the diffi 
culties and dangers encountered with liposome mediated 
transfection can be used to prepare liposomes for in vivo 
transfection of a gene encoding a marker (Felgneret. al. Proc. 
Natl. Acad. Sci. USA 84:7413-7417, 1987: Mackey, et al. 
Proc. Natl. Acad. Sci. USA 85:8027-8031, 1988: Ulmer et al. 
Science 259:1745-1748, 1993). The use of cationic lipids can 
promote encapsulation of negatively charged nucleic acids, 
and also promote fusion with negatively charged cell mem 
branes (Felgner and Ringoid Science 337:387-388, 1989). 
Particularly useful lipid compounds and compositions for 
transfer of nucleic acids are described in WO95/18863 and 
WO96/17823, and in U.S. Pat. No. 5,459,127, herein incor 
porated by reference. 
As with the immunogenic polypeptide, the nucleic acid 
compositions may be administered in a single dose, or mul 
tiple doses separated by a time interval can be administered to 
elicit an immune response against HIV. For example, two 
doses, or three doses, or four doses, or five doses, or six doses 
or more can be administered to a subject over a period of 
several weeks, several months or even several years, to opti 
mize the immune response. 
It may be advantageous to administer the immunogenic 
compositions disclosed herein with other agents such as pro 
teins, peptides, antibodies, and other anti-HIV agents. 
Examples of such anti-HIV therapeutic agents include 
nucleoside reverse transcriptase inhibitors, such as abacavir, 
AZT, didanosine, emitricitabine, lamivudine, stavudine, teno 
fovir, Zalcitabine, Zidovudine, and the like, non-nucleoside 
reverse transcriptase inhibitors, such as delavirdine, 
efavirenz, nevirapine, protease inhibitors such as amprenavir, 
atazanavir, indinavir, lopinavir, nelfinavir osamprenavir, 
ritonavir, saquinavir, tipranavir, and the like, and fusion pro 
tein inhibitors such as enfuvirtide and the like. In certain 
embodiments, immunonogenic compositions are adminis 
tered concurrently with other anti-HIV therapeutic agents. In 
certain embodiments, the immunonogenic compositions are 
administered sequentially with other anti-HIV therapeutic 
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agents. Such as before or after the other agent. One of ordinary 
skill in the art would know that sequential administration can 
mean immediately following or after an appropriate period of 
time, such as hours days, weeks, months, or even years later. 
While not being bound by theory, it is believed that CD4 
binding to gp120 triggers the exposure of the immunodomi 
nant V3 loop. Thus, co-administration of soluble forms of 
CD4, such as the fragments described herein, or an antibody 
that binds to the CD4 binding site, can lead to enhanced 
elicitation of an immunogenic response to gp120. 
In certain embodiments, immunonogenic compositions 
disclosed herein are administered with a soluble portion of 
CD4, for example a sufficient portion of the CD4 to bind to the 
CD4 binding site on gp120. Such soluble fragments typically 
include both the D1 and D2 extracellular domains of CD4 
(D1D2) or SCD4 (which is comprised of D1 D2 D3 and D4 
domains of CD4), although Smaller fragments may also pro 
vide specific and functional CD4-like binding. In certain 
embodiments, the gp120 polypeptide with an extended V3 
loop or a nucleic acid encoding the same is administered 
concurrently with a soluble portion of CD4. In other embodi 
ments, the gp120 polypeptide with an extended V3 loop or a 
nucleic acid encoding the same is administered concurrently 
with an antibody that binds to the CD4 binding site on gp120. 
The immunogenic gp120 polypeptides and nucleic acid 
encoding these polypeptides (such as stabilized gp120 
polypeptides, gp120 polypeptides with an extended V3 loop) 
can be used in a novel multistep immunization regime. Typi 
cally, this regime includes administering to a Subject a thera 
peutically effective amount of a gp120 polypeptide as dis 
closed herein (the prime) and boosting the immunogenic 
response with stabilized gp140 trimer (Yang et al. J Virol. 
76(9):4634-42, 2002) after an appropriate period of time. The 
method of eliciting Such an immune reaction is what is known 
as “prime-boost.” In this method, a gp120 polypeptide is 
initially administered to a subject and at periodic times there 
after stabilized gp140 trimer boosts are administered. 
Examples of stabilized gp140 or gp120 trimers can be found 
for example in U.S. Pat. No. 6,911.205 which is incorporated 
herein in its entirely. 
The prime can be administered as a single dose or multiple 
doses, for example two doses, three doses, four doses, five 
doses, six doses or more can be administered to a subject over 
day week or months. The boost can be administered as a 
single dose or multiple doses, for example two to six doses, or 
more can be administered to a Subject over a day, a week or 
months. Multiple boosts can also be given, Such one to five, or 
O. 
The boosts can be an identical molecule or a somewhat 
different, but related, molecule. For example, one preferred 
strategy with the gp120 polypeptides of the present disclosure 
would be to prime using a stabilized gp120 polypeptide or a 
gp120 polypeptide with an extended V3 and boosting peri 
odically with stabilized trimers where the gp120 units are 
designed to come closer and closer to the wild type gp120 
over the succession of boosts. For example, the first prime 
could be a stabilized gp120 polypeptide, with a boost by a 
stabilized trimer form with the same stabilized gp120 or a 
trimer with less deletions or changes from the native gp120 
conformation, with Subsequent boosts using trimers that had 
still less deletions or changes from the native gp120 confor 
mation until the boosts were finally being given by trimers 
with a gp120 portion based on the native wild type HIV 
gp120. 
One can also use cocktails containing a variety of different 
HIV strains to prime and boost with trimers from a variety of 
different HIV strains or with trimers that are a mixture of 
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multiple HIV strains For example, the first prime could be 
with a gp120 polypeptide from one primary HIV isolate, with 
Subsequent boosts using trimers from different primary iso 
lates. 
In certain embodiments, the prime is a nucleic acid con 
struct comprising a nucleic acid sequence encoding a gp120 
immunogen as disclosed herein, for example an nucleotide 
sequence encoding the amino acid sequence set forth as SEQ 
ID NO: 1 or SEQID NO:2, or the nucleotide sequence as set 
forth as one of SEQ ID NO: 4-18 or a degenerate variant 
thereof. In certain embodiments the boost comprises a nucleic 
acid sequence encoding a stabilized gp140 trimer. 
V. Crystal Structures 
The stabilized gp120 polypeptides and the gp120 polypep 
tides with an extended V3 loop disclosed herein can be used 
to produce detailed models of gp120 polypeptide atomic 
structure. Exemplary coordinate data is given in Table 1 and 
Table 2. The atomic coordinate data is disclosed herein, or the 
coordinate data derived from homologous proteins may be 
used to build a three-dimensional model of a gp120 polypep 
tide or a portion thereof, for example by providing a sufficient 
number of atoms of the stabilized form of gp120 or the gp120 
with the V3 loop in the extended conformation as defined by 
the coordinates of Table 1 or Table 2 which represent a surface 
or three-dimensional region of interest, such as an antigenic 
Surface or ligand binding site. Thus, there can be provided the 
coordinates of at least about 5, such at least about 10, at least 
about 20, at least about 30, at least at least about 40, at least 
about 50, at least about 60, at least about 70, at least about 80, 
at least about 90, at least about 100, at least about 150, at least 
about 200, at least about 250, at least about 300, at least about 
350, at least about 400, at least about 450, at least about 500 
or more atoms of the structure. Such as defined by the coor 
dinates of Table 1 or Table 2. Thus, a sub-domain, region, or 
fragment of interest of the stabilized form of gp120 or the 
gp120 with the extended V3 loop which is in the vicinity of 
the antigenic Surface, can be provided for identifying or ratio 
nally designing a compound or drug. Such as an immunogen. 
A “sub-domain.” “region.” or “fragment can mean at least 
one, for example, one, two, three, four, or more, element(s) of 
secondary structure of particular regions of the stabilized 
form of gp120 or the gp120 with the extended V3 loop gp120 
with the extended V3 loop, and includes those set forth in 
Table 1 and Table 2. 
Any available computational methods may be used to build 
the three dimensional model. As a starting point, the X-ray 
diffraction pattern obtained from the assemblage of the mol 
ecules or atoms in a crystalline version of a gp120 polypep 
tide can be used to build an electron density map using tools 
well known to those skilled in the art of crystallography and 
X-ray diffraction techniques. Additional phase information 
extracted either from the diffraction data and available in the 
published literature and/or from Supplementing experiments 
may then used to complete the reconstruction. 
For an overview of the procedures of collecting, analyzing, 
and utilizing X-ray diffraction data for the construction of 
electron densities see, for example, Campbell et al., Biologi 
cal Spectroscopy, The Benjamin/Cummings Publishing Co., 
Inc., Menlo Park, Calif., 1984; Cantor et al., Biophysical 
Chemistry, Part II: Techniques for the study of biological 
structure and function, W.H. Freeman and Co., San Fran 
cisco, Calif. 1980; A. T. Brunger, X-plor Version 3.1: A sys 
tem for X-ray crystallography and NMR, Yale Univ. Pr., New 
Haven, Conn. 1993; M. M. Woolfson, An Introduction to 
X-ray Crystallography, Cambridge Univ. Pr. Cambridge, 
UK, 1997: J. Drenth, Principles of Protein X-ray Crystallog 
raphy (Springer Advanced Texts in Chemistry), Springer Ver 
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lag; Berlin, 1999: Tsirelson etal, Electron Density and Bond 
ing in Crystals: Principles. Theory and X-ray Diffraction 
Experiments in Solid State Physics and Chemistry, Inst. of 
Physics Pub., 1996; each of which is herein specifically incor 
porated by reference in their entirety. 
Information on molecular modeling can be found for 
example in, M. Schlecht, Molecular Modeling on the PC, 
1998, John Wiley & Sons; Gans et al., Fundamental Princi 
pals of Molecular Modeling, Plenum Pub. Corp., 1996; N.C. 
Cohen (editor), Guidebook on Molecular Modeling in Drug 
Design, Academic Press, 1996; and W. B. Smith, Introduction 
to Theoretical Organic Chemistry and Molecular Modeling, 
1996. 
Typically, a well-ordered crystal that will diffract X-rays 
strongly is used to solve the three-dimensional structure of a 
protein by X-ray crystallography. The crystallographic 
method directs a beam of X-rays onto a regular, repeating 
array of many identical molecules. The X-rays are diffracted 
from it in a pattern from which the atomic positions of the 
atom that make up the molecule of interest can be determined. 
Substantially pure and homogeneous protein samples are 
usually used for crystallization. Typically, crystals form when 
molecules are precipitated very slowly from Supersaturated 
Solutions. A typical procedure for making protein crystals is 
the hanging-drop method, in which a drop of protein Solution 
is brought very gradually to Supersaturation by loss of water 
from the droplet to the larger reservoir that contains salt, 
polyethylene glycol, or other solution that functions as a 
hydroattractant, although any other method that generates 
diffraction quality crystals can be used. In some examples 
diffraction quality crystals are obtained by seeding the super 
saturated Solution with Smaller crystals that serve as tem 
plates. 
Powerful x-ray beams can be produced from synchrotron 
storage rings where electrons (or positrons) travel close to the 
speed of light. These particles emit very strong radiation at all 
wavelengths from short gamma rays to visible light. When 
used as an X-ray Source, only radiation within a window of 
Suitable wavelengths is channeled from the storage ring. 
In diffraction experiments a narrow and parallel beam of 
X-rays is taken out from the X-ray source and directed onto the 
crystal to produce diffracted beams. The incident X-ray beam 
causes damage to both protein and solvent molecules. The 
crystal is, therefore, usually cooled to prolong its lifetime (for 
example to -220° to -50° C.). In some examples, single 
crystals are used to obtain a data set, while in other examples, 
multiple crystals are used to obtain a data set. The X-ray beam 
must strike the crystal from many different directions to pro 
duce all possible diffraction spots, thereby creating a com 
plete data set. Therefore, the crystal is rotated relative to the 
beam during data collection. The diffracted spots are 
recorded either on a film, or by an electronic detector, both of 
which are commercially available. 
When the primary beam from an x-ray source strikes the 
crystal, X-rays interact with the electrons on each atom in the 
crystal and cause them to oscillate. The oscillating electrons 
serve as a new Source of X-rays, which are emitted in almost 
all directions in a process referred to as scattering. When 
atoms (and hence their electrons) are arranged in a regular 
three-dimensional array, as in a crystal, the X-rays emitted 
from the oscillating electrons interfere with one another. In 
most cases, these X-rays, colliding from different directions, 
cancel each other out; those from certain directions, however, 
will add together to produce diffracted beams of radiation that 
can be recorded as a pattern on a photographic plate or detec 
tOr. 
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The diffraction pattern obtained in an X-ray experiment is 
related to the crystal that caused the diffraction. X-rays that 
are reflected from adjacent planes travel different distances, 
and diffraction only occurs when the difference in distance is 
equal to the wavelength of the X-ray beam. This distance is 
dependent on the reflection angle, which is equal to the angle 
between the primary beam and the planes. 
Each atom in a crystal scatters X-rays in all directions, and 
only those that positively interfere with one another, accord 
ing to Bragg's law (2d sin 0-w), give rise to diffracted beams 
that can be recorded as a distinct diffraction spot above back 
ground. Each diffraction spot is the result of interference of all 
X-rays with the same diffraction angle emerging from all 
atoms. To extract information about individual atoms from 
Such a system requires considerable computation. The math 
ematical tool that is used to handle such problems is called the 
Fourier transform. 
Each diffracted beam, which is recorded as a spot on the 
film, is defined by three properties: the amplitude, which is 
measured as the intensity of the spot; the wavelength, which 
is determined by the X-ray source; and the phase information, 
which is lost in X-ray experiments and must be calculated. All 
three properties are used for all of the diffracted beams, in 
order to determine the position of the atoms giving rise to the 
diffracted beams. Methods of determining the phases are well 
known in the art. 
For example, phase differences between diffracted spots 
can be determined from intensity changes following heavy 
atom derivatization. Another example would be determining 
the phases by molecular replacement. 
The amplitudes and the phases of the diffraction data from 
the protein crystals are used to calculate an electron-density 
map of the repeating unit of the crystal. A model of the 
particular amino acid sequence is built to approximate the 
electron density map. 
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The initial model will contain some errors. Provided the 
protein crystals diffract to high enough resolution (e.g., better 
than 3.5 A), most or substantially all of the errors can be 
removed by crystallographic refinement of the model using 
computer algorithms. In this process, the model is changed to 
minimize the difference between the experimentally 
observed diffraction amplitudes and those calculated for a 
hypothetical crystal containing the model. This difference is 
expressed as an R factor (residual disagreement) which is 0.0 
for exact agreement and about 0.59 for total disagreement. 
Typically, the R factor of a refined model is preferably 
between 0.15 and 0.35 (such as less than about 0.24-0.28) for 
a well-determined protein structure. The residual difference 
is a consequence of errors and imperfections in the data. 
These derive from various sources, including slight variations 
in the conformation of the protein molecules, as well as 
inaccurate corrections both for the presence of solvent and for 
differences in the orientation of the microcrystals from which 
the crystal is built. Thus, the final model represents an average 
of molecules that are slightly different in both conformation 
and orientation. 
In refined structures at high resolution, there are usually no 
major errors in the orientation of individual residues, and the 
estimated errors in atomic positions are usually around 0.1- 
0.2 A, provided the amino acid sequence is known. 
Most X-ray structures are determined to a resolution between 1.7 A. and 3.5 A. Electron-density maps with this 
resolution range are preferably interpreted by fitting the 
known amino acid sequences into regions of electron density 
in which individual atoms are not resolved. 
VI. Crystals Structure of Stabilized gp120 
The present disclosure also relates to the crystals obtained 
from stabilized forms of gp120, the crystal structures of the 
stabilized forms of gp120, the three-dimensional coordinates 
of the stabilized forms of gp120 polypeptide and three-di 
mensional structures of models of stabilized forms of gp120. 
Table 1 provides the atomic coordinates of the crystal struc 
ture of the polypeptide encoded by SEQID NO: 14. 
TABLE 1. 
The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
ATOM 
CB GLU 83 18.617 -44.257 86.334 OO O8.57 
CG GLU 83 17.192 -44.73S 86.515 OO O8.41 
CD GLU 83 16.205 -43.880 85.7SS OO O8.12 
OE1 GLU 83 16.358 -43.762 84.524 OO O8.57 
OE2 GLU 83 15.280 -43.327 86.385 OO O7.50 
C GLU 83 19.772 -46.457 86.717 OO O9.62 
O GLU 83 18.985 -47.321 87.117 OO 10.00 
N GLU 83 20.954 -44.298 87.129 OO O8.79 
CA GLU 83 19.642 -45.003 87.1.89 OO O9.16 
N VAL 84 20.768 -46.714 85.869 OO O9.52 
CA VAL 84 21.044 -48.053 85.341 OO O9.11 
CB VAL 84 20.172 -48-376 84.093 OO O8.87 
CG1 VAL 84 18.713 -48.542 84.498 OO O8.27 
CG2 VAL 84 2O.302 -47.271 83.061 OO O9.39 
C VAL 84 22.526 -48.185 84.964 OO O8.77 
O VAL 84 22.925 -47.846 83.851 OO O8.35 
N VAL 85 23.332 -48.684 85.900 OO O8.71 
CA VAL 85 24.774 -48.848 85.689 OO O8.45 
CB VAL 85 25.515 -49.032 87.038 OO O8.OS 
CG1 VAL 85 25.521 -47.724 87.807 OO O8.41 
CG2 VAL 85 24.837 -SO.11O 87.862 OO O7.81 
C VAL 85 25.175 -49.994 84.754 OO O8.29 
O VAL 85 24.757 -51.138 84.941 OO O8.64 
N LEU 86 25.997 -49.67O 83.7SS OO O7.51 
CA LEU 86 26.483 -50.644 82.774 OO 06.03 
CB LEU 86 26.839 -49.943 81.458 OO O4.36 
CG LEU 86 25.737 -49.391 80.SS2 OO O3.07 
CD1 LEU 86 24.750 -48.544 81.333 OO O2.61 
CD2 LEU 86 26.390 -48.57S 79.450 OO O1.71 
C LEU 86 27.720 -51.369 83.298 OO O5.81 
O LEU 86 28.354 -50.916 84.254 OO O5.88 
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US 8,715,686 B2 
The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
A TOM 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
S4 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
71 
72 
73 
74 
75 
76 
77 
78 
79 
8O 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
96 
97 
98 
99 
100 
101 
102 
103 
104 
105 
106 
107 
108 
109 
CA 
CB 
CG 
OD1 
ND2 
CA 
CB 
OG1 
CG2 
CA 
CB 
CG 
CD 
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CE3 
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28.06S 
29.231 
28.827 
28.OOO 
28.057 
30.119 
29.63S 
31.425 
32428 
32.360 
32.859 
33.953 
32.056 
32.252 
32.505 
31.822 
31.614 
30.231 
3O.O3S 
29.139 
32.679 
33.18O 
33.02O 
34.02O 
35.403 
36.380 
35.324 
33.551 
33.505 
33.196 
32.707 
31.343 
30.189 
30.231 
29.248 
31.249 
33.676 
34.317 
33.783 
34.683 
35.342 
36.358 
36.973 
36.568 
34.001 
33.114 
34.426 
33.870 
33.622 
32.495 
32.SS4 
31396 
31.537 
30.373 
3O446 
34.888 
36.094 
34.405 
35.277 
35.618 
36.609 
37.6O2 
36.351 
34.442 
33.882 
34.345 
33.579 
33.948 
35.277 
35.534 
36.913 
34.727 
36.474 
37.468 
37.513 
35.316 
36.696 
33.733 
-52.490 
-53.263 
-54.SS3 
-54.214 
-55.462 
-53.643 
-S3.933 
-53.652 
-53.982 
-SS.474 
-56.393 
-56.199 
-57.399 
-S3.117 
-S3.561 
-S1.875 
-50.931 
-SO.258 
-49.322 
-51.310 
-49.841 
-49.461 
-49.348 
-48.295 
-48.891 
-47.845 
-49.591 
-47.260 
-47.539 
-46.069 
-44.963 
-44.504 
-44.701 
-43.732 
-43.679 
-43.023 
-43.781 
-43.509 
-43.076 
-41928 
-41.832 
-42.903 
-43.404 
-43.252 
-40.602 
-40.198 
-39.915 
-38.608 
-38.429 
-39.245 
-40.629 
-38.629 
-41.393 
-39.382 
-40.768 
-37.568 
-37.8O1 
-36.436 
-35344 
-35.387 
-34.300 
-34.062 
-33.647 
-34.119 
-33.482 
-33.831 
-32.719 
-32.471 
-31.803 
-30.615 
-30.357 
-29.734 
-32.211 
-31.354 
-29.263 
-28.650 
-28.424 
–31.432 
82.668 
83.083 
83.8OS 
85.032 
82.857 
81.910 
80.813 
82166 
81.15S 
80.781 
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82.235 
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79.032 
79.127 
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79.151 
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80.113 
77.864 
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76.686 
7S.481 
77.177 
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76.86S 
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74.737 
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74.591 
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78.244 
78.781 
78.775 
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73.950 
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74.241 
72.422 
75.767 
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81246 
76.782 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OS.43 
O4.73 
O4.68 
O4.54 
OS.O3 
O4.29 
O3.86 
O4O1 
O3.78 
O4.65 
O5.20 
O4.86 
O4.99 
O2.44 
O1.94 
OO.88 
98.81 
98.28 
97.33 
98.08 
97.94 
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49.89 
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TABLE 1-continued 
The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
ATOM 10 O TRP 95 32.832 -30.588 76.793 OO 55.05 
ATOM 11 N CYS 96 34.876 -31.286 76.114 OO 55.79 
ATOM 12 CA CYS 96 35.183 -30.109 75.309 OO 56.39 
ATOM 13 C CYS 96 34.565 -30.210 73.922 OO 55.35 
ATOM 14 O CYS 96 35.144 - 29.76S 72.935 OO SS.34 
ATOM 15 CB CYS 96 36.705 - 29.935 75.183 OO 59.56 
ATOM 16 SG CYS 96 37.516 - 29.511 76.772 OO 65.71 
ATOM 17 N LYS 97 33.370 -30.781 73.863 OO S4.38 
ATOM 18 CA LYS 97 32.641 -30.968 72.619 OO 53.06 
ATOM 19 CB LYS 97 33.439 -31.832 71.6SS OO 54:39 
ATOM 2O CG LYS 97 34.407 -31.101 70.7SO OO 57.02 
ATOM 21 CD LYS 97 35.090 -32.103 69.834 OO 59.38 
ATOM 22 CE LYS 97 36.181 -31488 68.980 OO 60.34 
ATOM 23 NZ LYS 97 36.872 -32.SS4 68.187 OO 60.06 
ATOM 24 C LYS 97 31.366 -31.691 72.967 OO 52.61 
ATOM 25 O LYS 97 31042 -32.698 72.363 OO 53.46 
ATOM 26 N ASN 98 30.653 -31.195 73.96S OO 52.56 
ATOM 27 CA. ASN 98 29.410 -31.833 74.362 OO 52.14 
ATOM 28. CB ASN 98 29.300 -31911 75.889 OO 50.77 
ATOM 29 CG ASN 98 28.087 -32.706 76.342 OO 49.63 
ATOM 30 OD1 ASN 98 26.961 -32.4OS 75.957 OO 48.41 
ATOM 31 ND2 ASN 98 28.314 -33.723 77.168 OO 48.49 
ATOM 32 C ASN 98 28.232 -31.056 73.788 OO 52.73 
ATOM 33 O ASN 98 28.181 - 29.82S 73.873 OO 52.21 
ATOM 34 N ASP 99 27.286 -31.780 73.2O2 OO 53.95 
ATOM 3S CA. ASP 99 26.107 -31.16O 72.6O1 OO 55.38 
ATOM 36 CB ASP 99 25.354 -32.184 71.745 OO 58.50 
ATOM 37 CG ASP 99 25.615 -32.009 70.253 OO 6048 
ATOM 38 OD1 ASP 99 25.206 -32.892 69.462 OO 61.59 
ATOM 39 OD2 ASP 99 26.222 -30.982 69.877 OO 61.09 
ATOM 40 C ASP 99 25.142 -30.546 73.608 OO 54.26 
ATOM 41 O ASP 99 24.342 -29.676 73.260 OO 54.68 
ATOM 42 N. MET OO 25.208 -31.008 74.851 OO 51.85 
ATOM 43 CA MET OO 24.331 -30.496 75.889 OO 49.13 
ATOM 44 CB MET OO 24.357 -31424 77.094 OO 48.72 
ATOM 4S CG MET OO 24.159 -32.873 76.743 OO 49.12 
ATOM 46 SD MET OO 24.699 -33.947 78.077 OO 48.08 
ATOM 47 CE MET OO 23.233 -33.971 79.064 OO 49.17 
ATOM 48 C MET OO 24.783 - 29.11.O 76.308 OO 47.86 
ATOM 49 O MET OO 23.969 -28.274 76.678 OO 48.48 
ATOM 50 N. VAL O1 26.085 -28.867 76.253 OO 46.25 
ATOM 51 CA VAL O1 26.616 -27569 76.641 OO 4539 
ATOM 52 CB VAL O1 28.145 -27.522 76.472 OO 45.11 
ATOM S3 CG1 VAL O1 28.654 -26.126 76.755 OO 44.71 
ATOM S4 CG2 VAL O1 28.801 -28.517 77.4O1 OO 4394 
ATOM 55 C VA 
ATOM S6 O V. 
ATOM 57 N G 
ATOM S8 CA. G. 
ATOM S9 CB G 
ATOM 60 CG G 
ATOM 61 CD G 
ATOM 62 OE1 G 
ATOM 63 OE2 G 
ATOM 64 C G 
ATOM 6S O GL 
G 
G 
G 
G 
G 
G 
G 
G 
G 
O1 25.994 -26.45S 75.800 OO 45.33 
O1 25.579 -25.426 76.318 OO 45.54 
O2 25.918 -26.676 74.498 OO 45.19 
O2 25.371 -25.68S 73.599 OO 46.23 
O2 25.770 -26.016 72.167 OO 49.62 
O2 27.168 -26.621 72.070 OO SS-61 
O2 28.245 -25.679 72.588 OO 59.03 
O2 29.297 -26.166 73.077 OO 59.85 
O2 28.034 -24.448 72.489 OO 60.10 
O2 23.869 -25.627 73.715 OO 45.67 
O2 23.278 -24.568 73.567 OO 45.84 
O3 23.244 -26.764 73.982 OO 45.79 
O3 21.795 -26.786 74.101 OO 47.31 
O3 21.271 -28.220 74.156 OO 48.93 
O3 19.7SO -28.313 74.345 OO 52.63 
O3 18.929 -27.662 73.216 OO 53.89 
O3 17.703 -27.566 73.309 OO 54.70 
O3 19.6OO -27.222 72.154 OO 52.85 
ATOM 73 C O3 21416 -26.066 75.363 OO 47.02 
ATOM 74 O O3 20.494 -25.260 75.390 OO 46.84 
ATOM 75 N MET O4 22.146 -26.369 76.418 OO 48.58 
ATOM 76 CA MET O4 21.902 -25.752 77.703 OO 49.89 
ATOM 77 CB MET O4 22.985 -26.182 78.694 OO 52.33 
ATOM 78 CG MET O4 22.741 -25.743 80.137 OO 56.81 
ATOM 79 SD MET O4 22.286 -27.119 81.216 OO 60.04 
ATOM 80 CE MET O4 20.594 -27.574 80.517 OO S8.09 
ATOM 81 C MET O4 21.975 -24.2SS 77.483 OO 49.53 
ATOM 82 O MET O4 20.998 -23.53S 77.676 OO 50.52 
ATOM 66 N 
ATOM 67 CA 
ATOM 68 CB 
ATOM 69 CG 
ATOM 70 CD 
ATOM 71 OE1 
ATOM 72 NE2 
ATOM 83 N HIS 05 23.146 -23.8O8 77.048 OO 48.30 
ATOM 84 CA HIS 05 23.409 -22.403 76.807 OO 47.10 
ATOM 85 CB HIS 05 24.712 - 22.2SO 76.031 OO 46.50 
ATOM 86 CG HIS 05 25.181 -20.836 75.913 OO 45.38 
ATOM 87 CD2 HIS 05 25.468 -20.082 74.828 OO 44.97 
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TABLE 1-continued 
The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
ATOM 266 NE2 GLN 1.780 -18.411 76.764 OO 63.49 
ATOM 267 C GLN 1.441 - 13.953 80.321 OO 53.71 
ATOM 268 O GLN O.316 - 14.158 80.766 OO 54.68 
ATOM 269 N SER 2.449 - 13.547 81086 OO 52.50 
ATOM 27O CA. SER 
ATOM 271 CB SER 
ATOM 272 OG SER 
ATOM 273 C SER 
ATOM 274 O SER 
ATOM 275 N LEU 
ATOM 276 CA LEU 
ATOM 277 CB LEU 
ATOM 278 CG LEU 
ATOM 279 CD1 LEU 
ATOM 280 CD2 LEU 
2.265 - 13.308 82.519 OO S1.69 
3.038 - 14.336 83.348 OO 51.04 
2.621 -15.652 83.056 OO 52.93 
2.746 -11.913 82.901 OO 51.57 
2011 - 11.142 83.52O OO 52.69 
3.989 -11604 82.532 OO 49.90 
4.603 -10.315 82.825 OO 48.45 
6.022 - 10.529 83.343 OO 47.47 
6.268 -10.161 84.806 OO 48.17 
7.715 - 10.461 85.176 OO 47.96 
5.955 -8.686 8S.019 OO 47.70 
ATOM 281 C LEU 4.645 -9.431 81.581 OO 48.28 
ATOM 282 O LEU 5.644 -9.414 80.858 OO 48.83 
ATOM 283 N LYS 3.571 -8.682 81.345 OO 46.85 
ATOM 284 CA LYS 
ATOM 28S CB LYS 
ATOM 286 CG LYS 
ATOM 287 CD LYS 
ATOM 288 CE LYS 
ATOM 289 NZ LYS 
3.479 -7.817 80.170 OO 45.19 
2.012 -7.662 79.768 OO 45.35 
1.377 -8.958 79.341 OO 45.38 
9.987 -8.733 78.809 OO 45.69 
9.621 -9.864 77.882 OO 4539 
O.704 -10.041 76.876 OO 44.68 
ATOM 290 C LYS 4.1OO -6.44O 80.351 OO 43.15 
ATOM 291 O LYS 4.OO2 -5846 81.410 OO 43.84 
ATOM 292 N PRO 4.764 -5.920 79.315 OO 41.84 
ATOM 293 CD PRO S.467 -6.711 78.301 OO 41.18 
ATOM 294 CA PRO 
ATOM 295 CB PRO 
ATOM 296 CG PRO 
ATOM 297 C PRO 
ATOM 298 O PRO 
ATOM 299 N CYS 
ATOM 300 CA CYS 
ATOM 301 C CYS 
ATOM 3O2 O CYS 
ATOM 303 CB CYS 
ATOM 3O4 SG CYS 
S.377 -4.594 79.428 OO 42.68 
6.611 -4.708 78.532 OO 41.64 
6.852 -6.184 78.446 OO 41.32 
4.452 -3444 78.977 OO 44.OO 
3.547 -3631 78.15S OO 43.14 
4.688 -2.258 79.528 OO 44.26 
3.911 -1.082 79.177 OO 45.33 
4.328 -0.688 77.776 OO 44.84 
3.536 -0.157 76.996 OO 45.02 
4.212 O.OS9 80.148 OO 48.41 
4.OOO -0.390 81.904 OO SS.41 
ATOM 305 N VAL 2O S.S95 -0.946 77.476 OO 43.63 
ATOM 306 CA VAL 2O 6.165 -0.669 76.166 OO 42.72 
ATOM 307 CB VAL 2O 6.807 O.719 76.110 OO 40.94 
ATOM 308 CG1 VAL 2O 7.494 O.914 74.784 OO 38.51 
ATOM 309 CG2 VAL 2O 5.740 1.773 76.293 OO 40.48 
ATOM 310 C VAL 2O 7.217 - 1.734 75.897 OO 43.68 
ATOM 311 O VAL 2O 7.932 -2.162 76.811 OO 42.94 
ATOM 312 N LYS 21 7.292 -2.168 74.643 OO 44.39 
ATOM 313 CA LYS 21 8.232 -3.197 74.237 OO 45.78 
ATOM 314 CB LYS 21 7.498 -4530 74.119 OO 46.75 
ATOM 31S CG LYS 21 8.292 -5.667 73.498 OO 48.39 
ATOM 316 CD LYS 21 7.477 -6.942 73.525 OO 49.47 
ATOM 317 CE LYS 21 8.214 -8.075 72.855 OO 52.19 
ATOM 318 NZ LYS 21 7.391 -9.321 72.815 OO 54.57 
ATOM 319 C LYS 21 8.834 -2.829 72.897 OO 46.81 
ATOM 320 O LYS 21 8.119 -2.708 71.913 OO 47.70 
ATOM 321 N LEU 22 20.146 -2.641 72.864 OO 48.66 
ATOM 322 CA LEU 22 20.828 -2.293 71629 OO 51.53 
ATOM 323 CB LEU 22 21.795 - 1.138 71.841 OO SO.96 
ATOM 324 CG LEU 22 21.169 0.187 72.235 OO 51.52 
ATOM 325 CD1 LEU 22 22.2O2 1.272 72.015 OO 52.75 
ATOM 326 CD2 LEU 22 19930 O468 71.403 OO 51.31 
ATOM 327 C LEU 22 21.613 -3.454 71.075 OO 54.29 
ATOM 328 O LEU 22 22.385 -4.069 71.794 OO 55.82 
ATOM 329 N CYS 23 21422 -3.756 69.796 OO 57.66 
ATOM 330 CA CYS 23 22.156 -4.844 69.161 OO 61.99 
ATOM 331 C CYS 23 22.651 -4.4O1 67.790 OO 65.95 
ATOM 332 O CYS 23 21.868 -3.977 66.952 OO 66.42 
ATOM 333 CB CYS 23 21.261 -6.O68 69.001 OO 61.14 
ATOM 334 SG CYS 23 20.636 - 6.863 70.520 OO 64.65 
ATOM 335 N PRO 24 23.962 -4.486 67.543 OO 70.34 
ATOM 336 CD PRO 24 25.032 -4.644 68.538 OO 71.39 
ATOM 337 CA PRO 24 24.526 -4.079 66.255 OO 74.44 
ATOM 338 CB PRO 24 25.915 -3.586 66.640 OO 73.49 
ATOM 339 CG PRO 24 26.298 -4.577 67.678 OO 72.11 
ATOM 340 C PRO 24 24.6OO -S.151 65.170 OO 78.68 
ATOM 341 O PRO 24 25.007 -6.289 65435 OO 78.97 
ATOM 342 N. LEU 25 24.216 -4.754 63.952 OO 83.43 
ATOM 343 CA LEU 25 24.246 -5.602 62.755 OO 87.97 
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58.60 
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45.34 
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41.32 
42.65 
41.02 
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TABLE 1-continued 
The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
ATOM 422 C ILE 2O1 3.874 - 1810 72.577 OO 41.94 
ATOM 423 O ILE 2O1 4.654 - 1896 73.532 OO 41.41 
ATOM 424 N THR 2O2 2.690 -1.214 72.657 OO 41.95 
ATOM 425 CA 2O2 2.226 -0.601 73.889 OO 42.08 
ATOM 426 CB 2O2 1969 O.892 73.696 OO 41.25 
ATOM 427 OG1 2O2 3.082 1490 73.027 OO 40.91 
ATOM 428 CG2 2O2 1.788 1.56O 7SO31 OO 41.52 
ATOM 429 C 2O2 O.918 -1.251 74.318 OO 43.2O 
ATOM 430 O 2O2 9.948 -1.241 73.563 OO 43.24 
ATOM 431 N 2O3 O.890 -1.818 7S.S24 OO 44.57 
ATOM 432 CA 2O3 9.679 -2.464 76.037 OO 45.88 
ATOM 433 CB 2O3 9.752 -3.978 75.850 OO 45.18 
ATOM 434 CG 2O3 O.718 -4.63S 76.792 OO 46.99 
ATOM 435 CD 2O3 1.663 -SS79 76.093 OO 48.26 
ATOM 436 OE1 2O3 1.253 -6.602 75.541 OO 47.41 
ATOM 437 NE2 2O3 2.945 -S.236 76.109 OO 49.20 
ATOM 438 C 2O3 9.526 -2.169 77.515 OO 46.24 
ATOM 439 O 2O3 O.416 -157S 78.126 OO 46.33 
ATOM 440 N 204 8.395 -2.576 78.086 OO 46.69 
s 
N 
N 
N 
ATOM 441 CA LA 204 8.169 -2.376 79.510 OO 47.75 
ATOM 442 CB LA 204 6.754 -2.731 79.869 OO 47.77 
ATOM 443 C LA 204 9.155 -3.326 80.193 OO 49.20 
ATOM 444 O LA 204 9.282 -4.492 79.799 OO SO45 
ATOM 445 N CYS 205 9.854 -2.83O 81.209 OO 49.03 
ATOM 446 CA CYS 205 10.870 -3618, 81.895 OO 47.82 
ATOM 447 C CYS 205 10.596 -3.914 83.372 OO 47.OO 
ATOM 448 O CYS 205 11.342 -3.464 84.244 OO 47.48 
ATOM 449 CB CYS 205 12.214 -2.899 81.749 OO 49.40 
ATOM 450 SG CYS 205 12.089 -1097 82.038 OO 5240 
ATOM 451 N PRO 2O6 9.53S -4.692 83.671 OO 45.36 
ATOM 452 CD PRO 2O6 8.592 -S.258 82.690 OO 44.OO 
ATOM 453 CA PRO 2O6 9.142 -5.069 85.037 OO 43.93 
ATOM 454 CB PRO 2O6 8.083 -6.13S 84.797 OO 42.82 
ATOM 455 CG PRO 2O6 7.423 -5.660 83.SS2 OO 42.86 
ATOM 456 C PRO 2O6 O.294 -5.603 85.890 OO 43.70 
ATOM 457 O PRO 2O6 1.013 -6.495 85.458 OO 43.27 
ATOM 458 N LYS 2O7 O.471 -SOS9 87.094 OO 44.28 
ATOM 459 CA LYS 2O7 1.533 -S.S21 87.992 OO 45.36 
ATOM 460 CB LYS 2O7 1664 -4.626 89.235 OO 43.66 
ATOM 461 CG LYS 2O7 2.061 -3.179 89.019 OO 4240 
ATOM 462 CD LYS 2O7 3.436 -3.046 88.429 OO 41.07 
ATOM 463 CE LYS 2O7 4.481 -3.725 89.264 OO 40.58 
ATOM 464 NZ LYS 2O7 S.758 -3.685 88.S10 OO 40.89 
ATOM 46S C LYS 2O7 1.157 -6.913 88.481 OO 47.60 
ATOM 466 O LYS 2O7 O.126 - 7.086 89.126 OO 49.38 
ATOM 467 N VAL 208 1.975 -7.91O 88.185 OO 49.19 
ATOM 468 CA VAL 208 1.669 -9.248 88.654 OO SO40 
ATOM 469 CB VAL 208 1.317 - 10.192 87.512 OO 49.17 
ATOM 470 CG1 VAL 208 O.947 -11.548 88.072 OO 48.47 
ATOM 471 CG2 WAL 208 O.171 -9.621 86.720 OO 49.94 
ATOM 472 C VAL 208 2.867 -9.800 89.379 OO 52.48 
ATOM 473 O VAL 208 3.950 -9.895 88.82O OO 53.30 
ATOM 474 N SER 209 2.667 - 10.153 90.638 OO 55.82 
ATOM 47S CA. SER 209 3.744 -10.701 91.442 OO 59.23 
ATOM 476 CB SER 209 4.271 -9.657 92.433 OO 6O.OO 
ATOM 477 OG SER 209 3.294 -9.3OO 93.397 OO 59.59 
ATOM 478 C SER 209 3.251 - 11.912 92.205 OO 60.56 
ATOM 479 O SER 209 2.328 - 11.819 93.015 OO 61.51 
ATOM 480 N PHE 210 3.863 - 13.054 91.927 OO 61.88 
ATOM 481 CA PHE 210 3.509 - 14.293 92.596 OO 62.55 
ATOM 482 CB PHE 210 2.163 - 14831 92.088 OO 62.36 
ATOM 483 CG PHE 210 2.173 - 15.247 90.645 OO 62.8O 
ATOM 484 CD1 PHE 210 2.312 - 14.303 89.634 OO 63.22 
ATOM 485 CD2 PHE 210 2.044 - 16.588 90.295 OO 63.02 
ATOM 486 CE1 PHE 210 2.321 -14.690 88.294 OO 62.99 
ATOM 487 CE2 PHE 210 2.052 - 16.980 88.957 OO 63.02 
ATOM 488. CZ PHE 210 2.191 - 16.027 87.956 OO 6216 
ATOM 489 C PHE 210 4.624 - 15.285 92.317 OO 62.59 
ATOM 490 O PHE 210 5.231 -15.266 91.245 OO 62.81 
ATOM 491 N GLU 211 4.908 - 16.138 93.291 OO 62.66 
ATOM 492 CA GLU 211 S.963 -17.12O 93.127 OO 62.85 
ATOM 493 CB GLU 211 6.274 -17.768 94.490 OO 63.27 
ATOM 494 CG GLU 211 7.354 - 16.98S 95.278 OO 65.06 
ATOM 495 CD GLU 211 7.291 -17.16O 96.800 OO 65.99 
ATOM 496 OE1 GLU 211 7.OSS -18.299 97.267 OO 66.91 
ATOM 497 OE2 GLU 211 7.497 - 16.153 97.528 OO 63.93 
ATOM 498 C GLU 211 5.645 - 18.161 92.036 OO 61.85 
ATOM 499 O GLU 211 4.538 -18.703 91.96S OO 61.07 
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TABLE 1-continued 
The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
ATOM 500 N PRO 
ATOM SO1 CD PRO 
ATOM SO2 CA PRO 
ATOM SO3 CB PRO 
ATOM SO4 CG PRO 
ATOM 505 C PRO 
ATOM SO6 O PRO 
ATOM 507 N LE 
ATOM 508 CA LE 
ATOM SO9 CB LE 
ATOM S10 CG2 ILE 
ATOM S11 CG1 ILE 
ATOM S12 CD1 ILE 
ATOM 513 C LE 
ATOM S14 O LE 
ATOM 515 N PRO 
ATOM S16 CD PRO 
ATOM S17 CA PRO 
ATOM S18. CB PRO 
ATOM 519 CG PRO 
ATOM 520 C PRO 
ATOM S21 O PRO 
ATOM 522 N LE 
ATOM 523 CA LE 
ATOM 524 CB LE 
ATOM S2S CG2 ILE 
ATOM 526 CG1 ILE 
ATOM 527 CD1 ILE 
6.617 - 184O6 91.136 OO 60.73 
7.853 -17.606 91.033 OO 60.13 
6.529 -19.35S 90.019 OO 60.07 
7.865 -19.151 89.295 OO 60.56 
8.190 -17.724 89.579 OO 58.99 
6.318 -20.824 90.424 OO 59.13 
7.062 -21.371 91.241 OO 58.14 
5.308 -21.454 89.834 OO 58.39 
4.999 -22.851 90.111 OO 57.51 
3.582 -23.226 89.634 OO 57.45 
2.936 -24.123 90.645 OO S8.00 
2.716 -21.978. 89.461 OO 58.13 
2.426 -21.23O 90.750 OO 58.27 
5.995 -23.7OS 89.330 OO 57.45 
6.398 -23.33S 88.225 OO 57.51 
6.406 -24.863 89.888 OO 56.69 
6.153 -25.38O 91.240 OO 55.47 
7.361 -25.729 89.193 OO 55.78 
7.614 -26.845 90.197 OO 54.06 
7.405 -26.184 91.489 OO 54.24 
6.789 -26.257 87.894 OO 56.50 
S.620 -26.637 87.820 OO 55.06 
7.640 -26.271 86.878 OO 58.07 
7.286 -26.745 85.SSS OO 58.99 
7.892 -25.815 84.461 OO 60.28 
7.752 -26.442 83.088 OO 61.12 
7.218 -24.435 84.499 OO 6106 
5.713 -24.448 84.23O OO 60.70 
ATOM 528 C LE 7.846 -28.153 85.391 OO S941 
ATOM 529 O LE 8.987 -28.418 85.754 OO 58.13 
ATOM 530 N HIS 7.019 -29.051 84.866 OO 61.77 
ATOM 531 CA HIS 
ATOM 532 CB HIS 
ATOM 533 CG HIS 
ATOM 534. CD2 HIS 
ATOM S3S ND1 HIS 
ATOM S36 CE1 HIS 
ATOM 537 NE2 HIS 
7.403 -30.436 84.617 OO 63.93 
6.393 -31403 85.235 OO 64.72 
6.375 -31414 86.730 OO 67.28 
5.441 -30.977 87.609 OO 67.94 
7.375 -31.987 87.483 OO 68.72 
7.057 -31.908 88.766 OO 68.43 
5.890 -31.3OO 88.868 OO 69.02 
ATOM 538 C HIS 7.378 -30.6SS 83.1 OS OO 65.39 
ATOM 539 O. HIS 6.331 -30.504 82.474 OO 6SS1 
ATOM S4O N TYR 8.517 -31.002 82.517 OO 66.95 
ATOM 541 CA TYR 
ATOM 542 CB TYR 
ATOM 543 CG TYR 
ATOM 544 CD1 TYR 
ATOM 545 CE1 TYR 
ATOM 546 CD2 TYR 
ATOM 547 CE2 TYR 
ATOM 548 CZ TYR 
8.562 -31.26O 81.081 OO 67.77 
9.964 -30.971, 80.S30 OO 69.8O 
20.183 -31.36O 79.076 OO 72.85 
20.066 -32.688 78.656 OO 73.62 
2O.306 -33.062 77.332 OO 73.91 
20.543 -30.408 78.124 OO 74.21 
20.787 -30.774 76.791 OO 75.39 
20.664 -32.105 76.407 OO 75.03 
ATOM 549 OH TYR 20.905 -32.476 75101 OO 75.25 
ATOM 550 C TYR 8.198 -32.726 80.881 OO 67.53 
ATOM 551 O TYR 8.779 -33.611 81.512 OO 66.37 
ATOM 552 N CYS 7.220 -32.977 80.021 OO 68.26 
ATOM 553 CA CYS 
ATOM 554 C CYS 
ATOM 555 O CYS 
ATOM 556 CB CYS 
ATOM 557 SG CYS 
ATOM 558 N ALA 
ATOM 559 CA ALA 
6.801 -34.345 79.736 OO 69.95 
7.146 -34.676 78.291 OO 70.18 
7.368 -33.768 77483 OO 71.OO 
S.299 -34.S1S 79.952 OO 70.79 
4.717 -34.185 81.647 OO 73.86 
7.190 -35.969 77.972 OO 69.23 
7.525 -36.418 7 6.622 OO 67.68 
ATOM 56O CB ALA 7.950 -37.874 76.651 OO 68.44 
ATOM 561 C ALA 6.367 -36.224 75.644 OO 66.31 
ATOM S62 O ALA 2 5.224 -36.577 75.937 OO 64.91 
ATOM 563 N PRO 220 6.657 -3S.652 74.462 OO 65.58 
ATOM 564 CD PRO 220 7.955 -3S.O74 74.079 OO 65.63 
ATOM S6S CA PRO 220 S.657 -35.394 73.42O OO 64-40 
ATOM 566 CB PRO 220 6.352 -34.386 72.500 OO 64.51 
ATOM 567 CG PRO 220 7.515 -33.858 73.317 OO 65.89 
ATOM S68 C PRO 220 S.298 -36.67O 72.676 OO 63.38 
ATOM 569 O PRO 220 6.095 -37.609 72.625 OO 63.61 
ATOM 570 N ALA 221 4.104 -36.691. 72090 OO 61.61 
ATOM 571 CA ALA 221 3.645 -37.852 71.345 OO 59.16 
ATOM 572 CB ALA 221 2.397 -37.503 70.558 OO 57.25 
ATOM 573. C ALA 221 4.751 -38.323 70.407 OO 58.51 
ATOM 574. O ALA 221 5.303 -37.532 69.645 OO S8.11 
ATOM 575 N GLY 222 S.O92 -39.608 70.492 OO 58.44 
ATOM 576 CA GLY 222 6.121 -40.163 69.632 OO 58.13 
ATOM 577 C GLY 222 7.508 -40.316 70.229 OO 58.27 
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TABLE 1-continued 
The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
ATOM 578 O. GLY 222 18.405 -40.83O 69.560 OO 57.97 
ATOM 579 N PHE 223 17.700 -39.888 71.475 OO 58.69 
ATOM S80 CA PHE 223 19.02O -39.989 72.102 OO 58.31 
ATOM 581 CB PHE 223 19.711 -38.625 72.073 OO 59.64 
ATOM S82 CG PHE 223 2O.O3O -38.136 7.O.690 OO 60.13 
ATOM 583 CD1 PHE 223 19.032 -37.613 69.873 OO 59.78 
ATOM S84 CD2 PHE 223 21.330 -38.222 70.197 OO 59.77 
ATOM 585 CE1 PHE 223 19.323 -37.182 68.588 OO 60.31 
ATOM 586 CE2 PHE 223 21.632 -37.797 68.919 OO 60.24 
ATOM 587 CZ. PHE 223 20.626 -37.273 68.107 OO 61.40 
ATOM 588 C PHE 223 19.052 -40.53O 73.527 OO 57.51 
ATOM S89 O PHE 223 18.016 -40.708 74.165 OO 56.31 
ATOM 590 N ALA 224 2O.261 -40.787 74.021 OO 57.34 
ATOM 591 CA ALA 224 20.447 -41.309 75.373 OO 58.31 
ATOM 592 CB ALA 224 20.842 -42.773 75.311 OO S8.16 
ATOM 593 C ALA 224 21517 -40514 76.1.16 OO 58.54 
ATOM 594 O ALA 224 22.404 -39.945 75.491 OO 59.61 
ATOM 595 N LE 225 21436 -40.486 77.444 OO 57.96 
ATOM 596 CA LE 225 22.401 -39.751 78.255 OO 57.94 
ATOM 597 CB LE 225 21.699 -38.763 79.225 OO 58.15 
ATOM 598 CG2 ILE 225 22.734 -3.8O81 80.114 OO 58.23 
ATOM 599 CG1 ILE 225 2O.904 -37.712 78.444 OO S8.02 
ATOM 600 CD1 ILE 225 20.136 -36.737 79.329 OO 55.55 
ATOM 601 C LE 225 23.278 -40.666 79.101 OO 58.42 
ATOM 6O2 O LE 225 22.794 -41341 80.006 OO 59.16 
ATOM 603 N LEU 226 24.572 -40.686 78.815 OO 58.75 
ATOM 604 CA LEU 226 25.484 -41.509 79.597 OO 59.39 
ATOM 60S CB LEU 226 26.569 -42.109 78.699 OO 57.81 
ATOM 606 CG LEU 226 26.083 -42.866 77.461 OO 56.08 
ATOM 607 CD1 LEU 226 27.257 -43.SSO 76.8O2 OO 55.05 
ATOM 608 CD2 LEU 226 25.039 -43.886 77.838 OO 55.26 
ATOM 609 C LEU 226 26.101 -40.612 80.667 OO 60.63 
ATOM 610 O LEU 226 26.257 -39.412 80.453 OO 60.94 
ATOM 611 N LYS 227 26.448 -41.197 81810 OO 62.31 
ATOM 612 CA LYS 227 27.022 -40.452 82.930 OO 63.91 
ATOM 613 CB LYS 227 25.940 -40.23O 84.000 OO 63.10 
ATOM 614 CG LYS 227 26.440 -39.783 85.373 OO 62.19 
ATOM 615 CD LYS 227 25.292 -39.708 86.391 OO 61.38 
ATOM 616 CE LYS 227 25.767 -39.22O 87.765 OO 61.56 
ATOM 617 NZ LYS 227 24.653 -39.044 88.746 OO 59.42 
ATOM 618 C LYS 227 28.208 -41.169 83.560 OO 65.8O 
ATOM 619 O LYS 227 28.038 -42.199 84.205 OO 67.24 
ATOM 620 N CYS 228 29.409 -40.631. 83.387 OO 68.12 
ATOM 621 CA CYS 228 30.578 -41.262 83.983 OO 70.64 
ATOM 622 C CYS 228 30.444 -41.156 85.496 OO 7041 
ATOM 623 O CYS 228 30.085 -40.107 86.019 OO 70.19 
ATOM 624 CB CYS 228 31.871 -40.590 83.511 OO 73.46 
ATOM 625 SG CYS 228 33.366 -41.5O2 84.026 OO 78.70 
ATOM 626 N ASN 229 30.733 -42.243 86.200 OO 71.33 
ATOM 627 CA. ASN 229 30.600 -42.2SS 87.647 OO 71.92 
ATOM 628 CB ASN 229 29.857 -43.508 88.082 OO 72.45 
ATOM 629 CG ASN 229 28.411 -43492 87.652 OO 73.11 
ATOM 630 OD1 ASN 229 27.647 -42.61O 88.051 OO 72.87 
ATOM 631 ND2 ASN 229 28.022 -44.465 86.830 OO 72.92 
ATOM 632 C ASN 229 31867 -42.109 88.469 OO 72.51 
ATOM 633 O ASN 229 31.785 -42.O2S 89.688 OO 72.22 
ATOM 634 N ASN 230 33.033 -42089 87.829 OO 74.40 
ATOM 63S CA. ASN 230 34.272 -41.91O 88.582 OO 76.62 
ATOM 636 CB ASN 230 35.455 -41654 87.648 OO 77.04 
ATOM 637 CG ASN 230 35.879 -42.887 86.894 OO 78.06 
ATOM 638 OD1 ASN 230 36.745 -42.818 86.02O OO 78.68 
ATOM 639 ND2 ASN 230 35.278 -44.024 87.232 OO 78.86 
ATOM 640 C ASN 230 34.064 -40.685 89.458 OO 77.81 
ATOM 641 O ASN 230 33.496 -39.687 89.010 OO 78.44 
ATOM 642 N. LYS 231 34.507 -40.754 90.706 OO 79.OO 
ATOM 643 CA LYS 231 34.338 -39.623 91.608 OO 80.19 
ATOM 644 CB LYS 231 34.648 -40.048 93.049 OO 81.06 
ATOM 645 CG LYS 231 33.678 -41.098 93.576 OO 81.81 
ATOM 646 CD LYS 231 34.028 -41.6OO 94.968 OO 82.8O 
ATOM 647 CE LYS 231 33.081 -42.74O 95.376 OO 8345 
ATOM 648. NZ LYS 231 33.385 -43.321 96.720 OO 82.56 
ATOM 649 C LYS 231 35.235 -38.474 91.169 OO 80.35 
ATOM 6SO O LYS 231 35.008 -37.321 91.536 OO 80.46 
ATOM 651 N THR 232 36.245 -38.8O3 90.368 OO 80.83 
ATOM 652 CA THR 232 37.188 -37.817 89.843 OO 81.48 
ATOM 653 CB THR 232 38.552 -37.900 90.545 OO 81.81 
ATOM 654 OG1 THR 232 38.381 -37.66S 91.947 OO 82.72 
ATOM 6SS CG2 THR 232 39.515 -36.86S 89.96S OO 81.15 
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TABLE 1-continued 
The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
ATOM 656 C THR 232 37.399 -38.103 88.367 OO 81.71 
ATOM 657 O THR 232 38.174 -3.8.987 87.998 OO 82.58 
ATOM 658 N PHE 233 36.706 -37.3SO 87.526 OO 81.77 
ATOM 659 CA PHE 233 36.807 -37.537 86.089 OO 81.98 
ATOM 660 CB PHE 233 35.426 -37.881 85.532 OO 80.95 
ATOM 661 CG PHE 233 35.448 -38.347 84.117 OO 80.2O 
ATOM 662 CD1 PHE 233 36.242 -39.423 83.746 OO 79.86 
ATOM 663 CD2 PHE 233 34.675 -37.713 83.153 OO 80.45 
ATOM 664 CE1 PHE 233 36.269 -39.865 82.434 OO 8O.O1 
ATOM 665 CE2 PHE 233 34.692 -38.145 81840 OO 80.85 
ATOM 666 CZ PHE 233 35.493 -39.226 81.477 OO 80.97 
ATOM 667 C PHE 233 37.351 -36.276 85.428 OO 82.46 
ATOM 668 O PHE 233 36.918 -35.172 85.749 OO 82.61 
ATOM 669 N ASN 234 38.304 -36.432 84.513 OO 83.24 
ATOM 670 CA. ASN 234 38.874 -35.271 83.841 OO 84.16 
ATOM 671 CB ASN 234 40.354 -35.499 83.532 OO 86.83 
ATOM 672 CG ASN 234 40.574 -36.548 82.469 OO 90.OS 
ATOM 673 OD1 ASN 234 39.934 -36.527 81.421 OO 91.19 
ATOM 674 ND2 ASN 234 41.507 -37.457 82.725 OO 92.74 
ATOM 675 C ASN 234 38.117 -34.914 82.559 OO 83.56 
ATOM 676 O ASN 234 38.633 -34.196 81.697 OO 83.14 
ATOM 677 N. GLY 235 36.897 -35433 82.444 OO 82.91 
ATOM 678 CA GLY 235 36.049 -35147 81.300 OO 81.77 
ATOM 679 C GLY 235 36.479 -35.646 79.936 OO 80.76 
ATOM 680 O GLY 235 35.687 -35.623 78.996 OO 80.76 
ATOM 681 N THR 236 37.722 -36.095 79.808 OO 79.92 
ATOM 682 CA THR 236 38.2O3 -36.583 78.521 OO 78.75 
ATOM 683 CB THR 236 39.368 -35.722 77.992 OO 79.46 
ATOM 684 OG1 THR 236 39.526 -35.948 76.586 OO 79.72 
ATOM 685 CG2 THR 236 40.671 -36.091 78.698 OO 79.62 
ATOM 686 C THR 236 38.676 -38.020 78.618 OO 77.39 
ATOM 687 O THR 236 38.821 -38.564 79.706 OO 77.35 
ATOM 688 N GLY 237 38.926 -38.628 77.469 OO 76.8O 
ATOM 689 CA GLY 237 39.390 -39.998 7745S OO 76.72 
ATOM 690 C GLY 237 38.283 -40.994 77.729 OO 76.45 
ATOM 691 O GLY 237 37.106 -40.659 77.589 OO 76.57 
ATOM 692 N PRO 238 38.634 -42.235 78.113 OO 75.99 
ATOM 693 CD PRO 238 40.OOO -42.777 78.002 OO 75.67 
ATOM 694 CA PRO 238 37.689 -43.311 78.413 OO 75.71 
ATOM 695 CB PRO 238 38.456 -44.544 77.980 OO 75.43 
ATOM 696 CG PRO 238 39.824 -44.215 78.454 OO 75.46 
ATOM 697 C PRO 238 37.247 -43404 79.876 OO 75.60 
ATOM 698 O PRO 238 38.014 -43.116 80.795 OO 74.29 
ATOM 699 N CYS 239 35.996 -43.811 80.06S OO 76.23 
ATOM 700 CA CYS 239 35.401 -43.978. 81.386 OO 77.64 
ATOM 701 C CYS 239 35.078 -45.462 81.561 OO 77.75 
ATOM 702 O CYS 239 34.724 -46.151 80.6O2 OO 77.99 
ATOM 703 CB CYS 239 34.114 -43.136 81.511 OO 78.55 
ATOM 704 SG CYS 239 33.201 -43.307 83.092 OO 79.98 
ATOM 705 N THR 240 35.205 -45.9SO 82.789 OO 77.99 
ATOM 706 CA. THR 240 34.936 -47.352 83.086 OO 77.29 
ATOM 707 CB THR 240 36.156 -47.984 83.808 OO 77.48 
ATOM 708 OG1 THR 240 36.642 -47088 84.817 OO 77.79 
ATOM 709 CG2 THR 240 37.276 -48.2S3 82.812 OO 76.21 
ATOM 710 C THR 240 33.651 -47.SSS 83.914 OO 76.52 
ATOM 711 O THR 240 32.878 -48.482 83.653 OO 76.31 
ATOM 712 N ASN 241 33.427 -46.683 84.898 OO 74.90 
ATOM 713 CA. ASN 241 32.239 -46.740 85.760 OO 72.8O 
ATOM 714. CB ASN 241 32.617 -46.258 87.171 OO 72.8O 
ATOM 71S CG ASN 241 31.621 -46.691 88.241 OO 72.83 
ATOM 716 OD1 ASN 241 3O404 -46.657 88.031 OO 73.02 
ATOM 717 ND2 ASN 241 32.142 -47.O79 89.402 OO 71.56 
ATOM 718 C ASN 241 31.195 -45.797 85.132 OO 71.45 
ATOM 719 O ASN 241 31.185 -44.6O1 85.419 OO 70.59 
ATOM 720 N VAL 242 30.323 -46.333 84.278 OO 69.95 
ATOM 721 CA VAL 242 29.319 -45.512 83.591 OO 68.27 
ATOM 722 CB VAL 242 29.779 -45.171 82.153 OO 68.44 
ATOM 723 CG1 VAL 242 30.532 -46.343 81548 OO 68.10 
ATOM 724 CG2 VAL 242 28.574 -44.842 81.286 OO 68.72 
ATOM 725 C VAL 242 27.911 -46.091 83.494 OO 66.92 
ATOM 726 O VAL 242 27.736 -47.279 83.258 OO 67.05 
ATOM 727 N SER 243 26.908 -45.231 83.650 OO 65.86 
ATOM 728 CA. SER 243 25.513 -45.657 83.568 OO 65.72 
ATOM 729 CB SER 243 24.911 -45.773 84.975 OO 64.61 
ATOM 730 OG SER 243 25.167 -44.631 85.765 OO 62.69 
ATOM 731 C SER 243 24.6SS -44.729 82.700 OO 65.75 
ATOM 732 O SER 243 25.138 -43.719 82.195 OO 66.44 
ATOM 733 N THR 244 23.386 -45.089 82.523 OO 65.22 
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TABLE 1-continued 
The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
ATOM 734 CA. THR 244 22.440 -44.307 81.722 OO 64.94 
ATOM 735 CB THR 244 21.692 -45.202 80.714 OO 65.14 
ATOM 736 OG1 THR 244 22448 -45286 79.5O1 OO 65.13 
ATOM 737 CG2 THR 244 2O.294 -44.655 80.422 OO 64.17 
ATOM 738 C THR 244 21.408 -43.644 82.614 OO 6S.O3 
ATOM 739 O. THR 244 20.913 -44.262 83.550 OO 66.14 
ATOM 740 N VAL 245 21.065 -42.397 82.310 OO 64.75 
ATOM 741 CA VAL 245 20.089 -41.669 83.112 OO 64.42 
ATOM 742 CB VAL 245 20.777 -40.574 83.939 OO 64.72 
ATOM 743 CG1 VAL 245 21.922 -41.172 84732 OO 64.56 
ATOM 744 CG2 VAL 245 21.291 -39.477 83.019 OO 6S.OO 
ATOM 745 C VAL 245 9.008 -41.016 82.264 OO 64.37 
ATOM 746 O VAL 245 9.148 -40.887 81.052 OO 62.59 
ATOM 747 N GLN 246 7.927 -40.6OO 82.910 OO 65.67 
ATOM 748 CA GLN 246 6.839 -39.947 82.195 OO 67.31 
ATOM 749 CB GLN 246 S.S28 -40.083 82.972 OO 69.55 
ATOM 7SO CG GLN 246 S.OO9 -41.514 83.OSS OO 72.91 
ATOM 751 CD GLN 246 4.973 -42.189 81.691 OO 74.79 
ATOM 752 OE1 GLN 246 4.414 -41.645 80.737 OO 76.33 
ATOM 753 NE2 GLN 246 S.S68 -43.381 81.593 OO 74.80 
ATOM 754 C GLN 246 7.174 -38.477 81.991 OO 67.14 
ATOM 755 O GLN 246 7.049 -37.952 80.887 OO 6740 
ATOM 756 N. CYS 247 7.603 -37.819 83.064 OO 67.11 
ATOM 757 CA CYS 247 7.981 -36.408 83.009 OO 66.41 
ATOM 758 C CYS 247 9.173 -36.223 83.942 OO 64.14 
ATOM 759 O CYS 247 9.394 -37.048 84.834 OO 63.44 
ATOM 76O CB CYS 247 6.821 -35.516 83.465 OO 68.57 
ATOM 761 SG 247 5.192 -35.863 82.704 OO 72.95 
ATOM 762 N 248 9.943 -35.1SS 83.736 OO 61.65 
ATOM 763 CA 248 21.115 -34.882 84.571 OO 58.60 
ATOM 764 CB 248 22.015 -33.789 83.953 OO 58.51 
ATOM 765 OG1 248 21.401 -32.506 84.118 OO 58.42 
ATOM 766 CG2 248 22.224 -34.048 82.472 OO 57.39 
ATOM 767 C 248 20.649 -34.404 85.938 OO 56.78 
ATOM 768 O 248 1946O -34.479 86.248 OO 56.77 
ATOM 769 N 249 21.575 -33.914 86.759 OO 54.48 
ATOM 77O CA 249 21.204 -33.423 88.085 OO S232 
ATOM 771 CB 249 22.408 -33.4SS 89.036 OO 50.67 
ATOM 772 CG 249 23.SS7 -32.617 88.581 OO SO.88 
ATOM 773 CD2 249 23.960 -31.378 88.951 OO 51.06 
ATOM 774 ND1 249 24418 -33.O16 87.582 OO 52.07 
ATOM 775 CE1 249 25.300 -32.059 87.354 OO 52.55 
ATOM 776 NE2 249 25.043 -31.OS3 88.171 OO S1.62 
ATOM 777 C 249 20.648 -31.997 88.000 OO 51.12 
ATOM 778 O. 249 20.672 -31.366 86.943 OO SO41 
ATOM 779 N LY 250 2012O -31504 89.112 OO SO.12 
ATOM 780 CA LY 250 19.589 -30.158 89.128 OO 48.39 
ATOM 781 C LY 250 20.738 - 29.188 89.013 OO 47.71 
ATOM 782 O LY 250 21.720 - 29.274 89.754 OO 47.82 
ATOM 783 N ILE 251 20.631 -28.262 88.075 OO 47.08 
ATOM 784 CA ILE 251 21.692 -27.295 87.898 OO 47.14 
ATOM 785 CB ILE 251 22.386 -27.494 86.533 OO 46.53 
ATOM 786 CG2 ILE 251 23.380 -26.363 86.268 OO 46.08 
ATOM 787 CG1 ILE 251 23.1OO -28.845 86.534 OO 46.01 
ATOM 788 CD1 ILE 251 23.697 - 29.231 85.209 OO 46.76 
ATOM 789 C ILE 251 21.222 -25.856 88.OSO OO 47.08 
ATOM 790 O. ILE 251 O.219 -25.439 87.479 OO 46.45 
ATOM 791 N ARG 252 953 -25.114 88.868 OO 47.74 
ATOM 792 CA ARG 252 651 -23.722 89.1O1 OO 48.23 
ATOM 793 CB ARG 252 2.398 -23.209 90.335 OO 49.56 
ATOM 794 CG ARG 252 642 -23.363 91.631 OO 52.05 
ATOM 795 CD ARG 252 428 -24.816 91.987 OO SS.46 
ATOM 796 NE ARG 252 O.534 -24.934 93.127 OO 58.57 
ATOM 797 CZ ARG 252 O.800 -24.438 94.33O OO 6106 
ATOM 798 NH1 ARG 252 942 -23.796 94.547 OO 61.62 
ATOM 799 NH2 ARG 252 9.917 -24.568. 95.313 OO 62.98 
ATOM 800 C ARG 252 2.125 - 22.96S 87.877 OO 47.35 
ATOM 8O1 O ARG 252 3.322 - 22.949 87.577 OO 48.58 
ATOM 802 N PRO 253 194 -22.354 87.134 OO 45.23 
ATOM 8O3 CD PRO 253 9.728 - 22.423 87.233 OO 44.SS 
ATOM 804 CA PRO 253 595 -21.604 85.949 OO 43.24 
ATOM 80S CB PRO 253 O.288 -21483 85179 OO 4238 
ATOM 806 CG PRO 253 9.293 -21.3SO 86.272 OO 43.19 
ATOM 807 C PRO 253 2.182 -20.256 86.375 OO 41.47 
ATOM 808 O PRO 253 21744 -19.199 85.926 OO 42.48 
ATOM 809 N VAL 2S4 23.179 -20.3OS 87.255 OO 39.38 
ATOM 810 CA VAL 2S4 23.822 - 19.092 87.751 OO 37.91 
ATOM 811 CB VAL 2S4 24.819 -19.384 88.879 OO 37.89 
The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
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24.589 
25.346 
24.399 
25.090 
24.103 
24.783 
23.571 
26.16S 
25.878 
27.412 
28.486 
28.585 
29.018 
29.846 
30.047 
30.787 
32.159 
32.559 
32.592 
33.063 
32.629 
34.313 
35.327 
35.699 
35.659 
36.43O 
36.368 
37.163 
34.995 
35.661 
33.96S 
33.563 
33.304 
34.388 
33.952 
35.672 
32.295 
31.402 
32.236 
31.076 
31.528 
32.353 
32.904 
31.485 
30.306 
30.823 
29.076 
28.283 
27.611 
28.555 
27.784 
29.722 
27.233 
26.633 
27.022 
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24.627 
24.446 
25.131 
23.506 
26.107 
25.084 
27.328 
27.5O1 
27.889 
27.951 
28.148 
28.540 
28.367 
27.014 
29.992 
30.813 
30.301 
31.667 
31.689 
31.346 
-2O.199 
-21.570 
-21.522 
-22.888 
-21.036 
-2O347 
-2O.923 
-19847 
-19905 
-18. SSS 
-17.374 
-16.071 
-17433 
-21.004 
-21.362 
-21.538 
-22.589 
-21.988 
-20.825 
-2O.716 
-19.952 
-23.82O 
-24.400 
-24.226 
-25.384 
-26.635 
-26.638 
-27.704 
-28.977 
-30.119 
-30.289 
-28.926 
-28.339 
-29.537 
-29.588 
-29.585 
-28.271 
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22.73 
21.19 
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23.31 
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20.86 
23.53 
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24.34 
26.23 
2S47 
25.81 
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25.71 
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30.33 
29.97 
3O.OO 
31.78 
32.91 
32.66 
33.12 
33.65 
34.68 
34.04 
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TABLE 1-continued 
The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
ATOM 890 CD1 
ATOM 891. CD2 
ATOM 892 C 
ATOM 893 O 
ATOM 894 N 
ATOM 895 CA 
L E 26S 31.307 -28.477 98.352 OO 34.03 
26S 32.379 -27.219 96.520 OO 34.44 
26S 32.297 -30.869 94.098 OO 35.56 
26S 31.596 -31.751 93.6O7 OO 34:43 
266 33.622 -30.951 94.176 OO 38.30 
266 34.352 -32.128 93.725 OO 40.59 A 
ATOM 896 CB LA 266 35.769 -31.751 93.3O2 OO 38.89 
ATOM 897 C LA 266 34.372 -33.07O 94.9.20 OO 43.62 
ATOM 898 O 266 34.755 -32.677 96.O26 OO 44.O2 
ATOM 899 N 267 33.961 -34.314 94.691 OO 46.39 
ATOM 900 CA 
ATOM 901 CB 
ATOM 902 CG 
ATOM 903 CD 
ATOM 904 OE1 
ATOM 90S OE2 
ATOM 906 C 
ATOM 907 O 
ATOM 908 N 
ATOM 909 CA 
ATOM 910 CB 
ATOM 911 CG 
ATOM 912 CD 
ATOM 913 OE1 
ATOM 914 OE2 
ATOM 915 C 
ATOM 916 O 
ATOM 917 N 
ATOM 918 CA 
ATOM 919 CB 
ATOM 920 CG 
ATOM 921 CD 
ATOM 922 OE1 
ATOM 923 OE2 
ATOM 924 C 
ATOM 925 O 
267 33.868 -35.3O3 95.754 OO 49.11 
267 33.263 -36.593 95.198 OO 51.72 
267 32.103 -36.352 94.222 OO 56.02 
267 31.126 -37.527 94.130 OO 57.75 
267 30.292 -37.68O 95.053 OO 58.56 
267 31.190 -38.294 93.139 OO 58.03 
267 35.125 -35.625 96.554 OO 49.70 
267 35.031 -35.933 97.736 OO SO.OO 
268 36.299 -35.SS2 95.944 OO 51.35 
268 37.510 -35.879 96.691 OO 53.41 
268 38.332 -36.923 95.940 OO 55.13 
268 37.589 -38.222 95.692 OO 59.90 
268 38.264 -39.115 94.650 OO 618O 
268 37.689 -40.179 94.332 OO 62.83 
268 39.358 -38.756 94.154 OO 62.29 
268 38.381 -34.672 96.964 OO 53.78 
268 38.293 -34.046 98.023 OO 54.54 
269 39.232 -34.35S 96.OOO OO 53.53 
269 40.139 -33.231 96.132 OO 53.58 
269 41564 -33.689 95.841 OO 55.20 
269 41.923 -35.009 96.487 OO 57.76 
269 43.335 -3S4SO 96.151 OO 59.84 
269 43.678 -36.621 96.416 OO 59.87 
269 44.109 -34.623 95.626 OO 62.O7 
269 39.746 -32.126 95.162 OO 52.41 
269 38.749 -32.2S2 94.452 OO S3.19 
ATOM 926 N AL 270 40.530 -31.049 95.138 OO S.O.34 
ATOM 927 CA AL 270 40.269 -29.926 94.241 OO 48.54 
ATOM 928. CB AL 270 41.091 -28.663 94.633 OO 47.63 
ATOM 929 CG1 AL 270 41.172 -27.707 93.467 OO 45.74 
ATOM 930 CG2 VAL 270 40.424 -27.9SO 95.806 OO 47.67 
ATOM 931 C VAL 270 40.631 -30.337 92.823 OO 47.45 
ATOM 932 O VAL 270 41.651 -30.994 92.606 OO 47.66 
ATOM 933 N VAL 271 39.790 -29.948 91.864 OO 45.27 
ATOM 934 CA VAL 271 40.012 -30.29O 90.461 OO 42.45 
ATOM 935 CB VAL 271 38.878 -31.202 89.925 OO 41.54 
ATOM 936 CG1 VAL 271 39.220 -31.677 88.S30 OO 39.33 
ATOM 937 CG2 VAL 271 38.663 -32.380 90.857 OO 40.44 
ATOM 938 C VAL 271 40.123 - 29.071, 89.53S OO 40.87 
ATOM 939 O. VA 271 39.324 -28.132 89.623 OO 41.07 
ATOM 940 N ILE 272 41.130 -29.096 88.662 OO 37.99 
ATOM 941 CA ILE 272 41.342 -28.035 87.691 OO 35.44 
ATOM 942 CB ILE 272 42.724 -27.352 87.867 OO 32.95 
ATOM 943 CG2 ILE 272 42.894 -26.892 89.3O2 OO 30.53 
ATOM 944 CG1 ILE 272 43.857 -28.308 87.528 OO 3OSO 
ATOM 945 CD1 ILE 272 45.218 -27.694 87.759 OO 28.89 
ATOM 946 C ILE 272 41.226 -28.705 86.329 OO 36.01 
ATOM 947 O ILE 272 41.804 -29.76O 86.104 OO 36.26 
ATOM 948 N ARG 273 40.436 -28.1OO 85.444 OO 36.70 
ATOM 949 CA ARG 273 40.173 -28.629 84.107 OO 36.68 
ATOM 950 CB ARG 273 38.711 - 29.077 83.996 OO 34.08 
ATOM 951 CG ARG 273 38.209 -30.O3S 85.056 OO 32.56 
ATOM 952 CD ARG 273 36.708 -30.273 84.871 OO 32.51 
ATOM 953 NE ARG 273 36.253 -31.508 85.5O2 OO 31.47 
ATOM 954 CZ ARG 273 36.149 -31.672 86.811 OO 32.01 
ATOM 955 NH1 ARG 273 36.458 -30.672 87.615 OO 34.75 
ATOM 956 NH2 ARG 273 35.771 -32.83S 87.323 OO 30.95 
ATOM 957 C ARG 273 40.409 -27.566 83.030 OO 39.20 
ATOM 958 O ARG 273 40.272 -26.364 83.288 OO 41.19 
ATOM 959 N SER 274 40.757 -28.013 81823 OO 40.06 
ATOM 960 CA. SER 274 40.969 -27.114 80.691 OO 40.76 
ATOM 961 CB SER 274 42.332 -26.436 80.763 OO 36.8O 
ATOM 962 OG SER 274 42.480 -25.540 79.681 OO 32.87 
ATOM 963 C SER 274 40.867 -27.899 79.399 OO 43.92 
ATOM 964 O SER 274 41.114 -29.1OO 79.372 OO 4539 
ATOM 965 N CYS 275 40.480 -27.230 78.32S OO 47.15 
ATOM 966 CA CYS 275 40.377 -27.916 77.055 OO 51.92 
ATOM 967 C CYS 275 41.737 -27.968 76.403 OO 52.82 
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TABLE 1-continued 
The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
ATOM 968 O CYS 275 41.890 -28.48S 75.303 OO 5444 
ATOM 969 CB CYS 275 39.375 -27.207 76.154 OO 55.95 
ATOM 970 SG CYS 275 37.681 -27.472 76.771 OO 66.91 
ATOM 971 N ASN 276 42.730 -27-439 77.106 OO 53.33 
ATOM 972 CA. ASN 276 44.104 -27.397 76.624 OO 52.97 
ATOM 973 CB ASN 276 44.161 -26.855 75.186 OO 55.96 
ATOM 974 CG ASN 276 45.584 -26.683 74.685 OO 61.01 
ATOM 975 OD1 ASN 276 46.331 -25.861 75.210 OO 63.58 
ATOM 976 ND2 ASN 276 45.980 -27.48S 73.701 OO 64.98 
ATOM 977 C ASN 276 44-864 -26.47S 77.571 OO 51.50 
ATOM 978 O. ASN 276 44.876 -25.251 77.398 OO SO.11 
ATOM 979 N PHE 277 45.483 -27.074 78.584 OO 49.28 
ATOM 980 CA PHE 277 46.235 -26.309 79.570 OO 47.85 
ATOM 981 CB PHE 277 46.763 -27.231 80.675 OO 46.32 
ATOM 982 CG PHE 277 45.689 -27.794 81567 OO 44.69 
ATOM 983 CD1 PHE 277 45.136 -29.OSO 81.321 OO 43.74 
ATOM 984 CD2 PHE 277 45.235 -27.070 82.667 OO 43.64 
ATOM 985 CE1 PHE 277 44.149 -29.577 82.163 OO 41.58 
ATOM 986 CE2 PHE 277 44.249 -27.590 83.511 OO 42.49 
ATOM 987 CZ PHE 277 43.707 -28.848 83.258 OO 40.91 
ATOM 988 C PHE 277 47.397 -25.526 78.959 OO 47.27 
ATOM 989 O PHE 277 47.758 -24.456 79.451 OO 46.87 
ATOM 990 N THR 278 47.972 -26.069 77.890 OO 47.46 
ATOM 991 CA. THR 278 49.103 -25.462 77.1.89 OO 48.47 
ATOM 992 CB THR 278 49.612 -26.414 76.092 OO 4842 
ATOM 993 OG1 THR 278 SO.438 -27.41S 76.691 OO 48.33 
ATOM 994 CG2 THR 278 SO.410 -25.659 75.038 OO 49.75 
ATOM 995 C THR 278 48.784 -24.103 76.562 OO 48.99 
ATOM 996 O THR 278 49.596 -23.168 76.609 OO 48.8O 
ATOM 997 N ASP 279 47.6OO -24.021 75.964 OO 48.66 
ATOM 998 CA. ASP 279 47.094 - 22.816 75.315 OO 48.23 
ATOM 999 CB ASP 279 45.819 -23.178 74S47 OO SO.23 
ATOM OOO CG ASP 279 45.261 -22.O2S 73.742 OO 51.68 
ATOM OO1 OD1 ASP 279 44.294 -22.275 72.986 OO 51.77 
ATOM OO2 OD2 ASP 279 45.778 -20.890 73.870 OO 51.55 
ATOM OO3 C ASP 279 46.792 -21.8O1 76.414 OO 47.1.2 
ATOM OO4 O ASP 279 45.827 -21.958 77.168 OO 47.67 
ATOM 005 N ASN 28O 47.609 -20.758 76.507 OO 43.96 
ATOM O06 CA. ASN 28O 47.410 -19.775 77.559 OO 41.43 
ATOM OO7 CB ASN 28O 48.671 -18.910 77.722 OO 39.74 
ATOM OO8 CG ASN 28O 49.OO7 -18.101 76.485 OO 36.68 
ATOM O09 OD1 ASN 28O 48.7SS -18.525 75.364 OO 36.56 
ATOM O10 ND2 ASN 28O 49.604 - 16.931 76.692 OO 33.53 
ATOM O11 C ASN 28O 46.174 -18.916 77.364 OO 41.24 
ATOM O12 O ASN 28O 45.970 -17.927 78.058 OO 40.99 
ATOM O13 N ALA 281 45.321 -19.315 76.434 OO 41.19 
ATOM 014 CA ALA 281 44.117 -18.547 76.192 OO 40.89 
ATOM O15 CB ALA 281 44.119 -18.045 74.777 OO 42.27 
ATOM O16 C ALA 281 42.859 -19.356 76.463 OO 40.32 
ATOM O17 O ALA 281 41.764 -18.949 76.090 OO 41.07 
ATOM O18 N LYS 282 43.012 -2O.SOO 77.1.15 OO 39.16 
ATOM O19 CA LYS 282 4.1.864 -21.334 77.423 OO 38.60 
ATOM O2O CB LYS 282 42.116 - 22.773 76.970 OO 39.99 
ATOM O21 CG LYS 282 41.897 - 22.990 75.479 OO 41.46 
ATOM O22 CD LYS 282 40.523 - 22.473 75.048 OO 43.09 
ATOM O23 CE LYS 282 40.172 - 22.87S 73.625 OO 41.82 
ATOM O24 NZ LYS 282 39.986 -24.349 73.519 OO 42.86 
ATOM O25 C LYS 282 41.488 -21.310 78.897 OO 37.93 
ATOM O26 O LYS 282 42.336 -21.477 79.777 OO 38.22 
ATOM O27 N THR 283 40.2OO -21.110 79.149 OO 36.68 
ATOM O28 CA. THR 283 39.648 -21.049 80.494 OO 35.31 
ATOM O29 CB THR 283 38.117 -20.944 80.447 OO 34.66 
ATOM O3O OG1 THR 283 37.745 -19.702 79.850 OO 37.62 
ATOM O31 CG2 THR 283 37.523 -21.018 81.833 OO 34.32 
ATOM O32 C THR 283 39.982 -22.263 81.340 OO 35.03 
ATOM O33 O THR 283 39.808 -23.396 80.896 OO 35.94 
ATOM O34 N ILE 284 40.461 -22.026 82.558 OO 33.55 
ATOM O3S CA ILE 284 40.7SO -23.11S 83.481 OO 32.06 
ATOM O36 CB ILE 284 42087 -22.926 84.220 OO 29.94 
ATOM O37 CG2 ILE 284 42.264 -24.025 85.253 OO 2S.OO 
ATOM O38 CG1 ILE 284 43.234 -22.964 83.225 OO 28.55 
ATOM O39 CD1 ILE 284 44.563 - 22.787 83.859 OO 28.55 
ATOM O40 C ILE 284 39.609 -23.124 84.5O2 OO 33.37 
ATOM O41 O ILE 284 39.398 -22.149 85.237 OO 32.79 
ATOM O42 N. ILE 285 38.867 -24227 84.516 OO 33.28 
ATOM O43 CA ILE 285 37.740 -24.413 85.412 OO 32.89 
ATOM O44 CB ILE 285 36.657 -25.259 84.734 OO 31.95 
ATOM O4S CG2 ILE 285 35.537 -25.555 85.697 OO 32.46 
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The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
ATOM O46 CG1 ILE 285 36.113 -24.517 83.527 OO 32.81 
ATOM O47 CD1 ILE 285 34.981 -25.242 82.844 OO 35.28 
ATOM O48 C ILE 285 38.158 -25.122 86.695 OO 34.13 
ATOM O49 O ILE 285 38.440 -26.313 86.690 OO 35.08 
ATOM 050 N VAL 286 38.206 -24.398 87.799 OO 34.62 
ATOM OS1 CA VAL 286 38.566 -25.024 89.056 OO 34.98 
ATOM OS2 CB VAL 286 39.403 -24.051 89.931 OO 34.50 
ATOM OS3 CG1 VAL 286 39.593 -24.6OO 91.335 OO 31.43 
ATOM OS4 CG2 VAL 286 40.743 -23.843 89.292 OO 34.26 
ATOM 055 C VAL 286 37.276 -25413 89.788 OO 36.26 
ATOM OS6 O VAL 286 36.276 -24.683 89.736 OO 36.24 
ATOM 057 N GLN 287 37.290 -26.581 90.425 OO 35.78 
ATOM OS8 CA GLN 287 36.151 -27.041 91.210 OO 36.32 
ATOM OS9 CB GLN 287 35.441 -28.214 90.547 OO 35.89 
ATOM O60 CG GLN 287 34.369 -28.83O 91.444 OO 35.81 
ATOM O61 CD GLN 287 33.732 -30.067 90.834 OO 35.51 
ATOM 062 OE1 GLN 287 34.394 -30.838 90.141 OO 34.61 
ATOM O63 NE2 GLN 287 32.446 -30.269 91.102 OO 34.71 
ATOM O64 C GLN 287 36.673 -27.444 92.595 OO 36.79 
ATOM O6S O GLN 287 37.691 -28.131 92.728 OO 35.75 
ATOM O66 N LE 288 35.955 -27.011 93.623 OO 37.06 
ATOM O67 CA LE 288 36.357 -27.248 94.996 OO 37.17 
ATOM O68 CB LE 288 36.146 -25.962 95.805 OO 34.97 
ATOM O69 CG LE 288 36.614 -24.63O 95.2O6 OO 32.83 
ATOM O70 CD1 LE 288 35.969 -23.494. 95.955 OO 31.53 
ATOM O71 CD2 LE 288 38.12O -24.514 95.268 OO 31.88 
ATOM O72 C LE 288 35.653 -28.4OS 95.707 OO 38.46 
ATOM O73 O LE 288 34.SS3 -28.817 95.334 OO 38.22 
ATOM O74 N ASN 289 36.322 -28.898 96.748 OO 39.95 
ATOM O75 CA. ASN 289 35.855 - 29.984 97.6OS OO 40.45 
ATOM O76 CB ASN 289 37.057 -30.772 98.117 OO 4.O.S.S 
ATOM O77 CG ASN 289 38.027 - 29.893 98.867 OO 42.68 
ATOM O78 OD1 ASN 289 38.080 -28.692 98.6OO OO 43.84 
ATOM O79 ND2 ASN 289 38.797 -30.451 99.798 OO 45.54 
ATOM O80 C ASN 289 35.136 - 29.342 98.793 OO 40.56 
ATOM O81 O ASN 289 34426 -30.011 99.534 OO 41.39 
ATOM O82 N THR 290 35.334 -28.037 98.971 OO 40.82 
ATOM O83 CA. THR 290 34.716 -27.293 100.075 OO 39.80 
ATOM O84 CB THR 290 35.738 -26.968 101.168 OO 40.22 
ATOM O85 OG1 THR 290 36.425 -28.160 101.564 OO 40.45 
ATOM O86 CG2 THR 290 35.038 -26.345 102.361 OO 40.96 
ATOM O87 C THR 290 34.141 -25.953 99.630 OO 38.45 
ATOM O88 O THR 290 34.790 -25.211 98.898 OO 38.51 
ATOM O89 N SER 291 32.941 -25.626 100.093 OO 37.41 
ATOM O90 CA. SER 291 32.334 -24.349 99.735 OO 36.56 
ATOM O91 CB SER 291 3O834 -24.367 100.019 OO 37.11 
ATOM O92 OG SER 291 30.126 -25.014. 98.978 OO 40.14 
ATOM O93 C SER 291 32.96S -23.232 100.537 OO 35.66 
ATOM O94 O SER 291 33.504 -23.480 101604 OO 36.84 
ATOM O95 N VAL 292 32.919 -22012 100.OO2 OO 35.35 
ATOM O96 CA VAL 292 33.432 -20.806 100.682 OO 34.01 
ATOM O97 CB VAL 292 34.734 -20.239 100.018 OO 32.71 
ATOM O98 CG1 VAL 292 35.059 -18.859 100.597 OO 27.63 
ATOM O99 CG2 VAL 292 35.907 -21.193 100.257 OO 29.57 
ATOM OO C VAL 292 32.306 -19.784 100.537 OO 33.54 
ATOM O1 O VAL 292 31.983 -19.374 99.426 OO 33.35 
ATOM O2 N GLU 293 31.691 -19.379 101.639 OO 33.37 
ATOM O3 CA GLU 293 30.580 -18.440 101.519 OO 34.15 
ATOM O4 CB GLU 293 29.834 -18.262 102.846 OO 37.09 
ATOM OS CO GLU 293 29.612 - 19536 103.649 OO 44.11 
ATOM O6 CD GLU 293 3O893 -20.OOO 104.321 OO SO.19 
ATOM O7 OE1 GLU 293 31.452 - 1921 6 105.13S OO 53.93 
ATOM O8 OE2 GLU 293 31.350 -21.131 104.033 OO 51.72 
ATOM 09 C GLU 293 31.013 -17.077 101.036 OO 32.44 
ATOM 10 O GLU 293 32.131 - 16.632 101.270 OO 32.48 
ATOM 11 N ILE 294 30.112 - 16.419 100.334 OO 31.24 
ATOM 12 CA ILE 294 30.371 -15.08.0 99.858 OO 31.02 
ATOM 13 CB ILE 294 30.909 - 15.06O 98.407 OO 28.57 
ATOM 14 CG2 ILE 294 29.896 -15.631. 97.459 OO 28.94 
ATOM 1S CG1 ILE 294 31.228 - 13.627 97.999 OO 26.61 
ATOM 16 CD1 ILE 294 31.771 -13.513 96.622 OO 26.35 
ATOM 17 C ILE 294 29.018 - 14.391 99.953 OO 32.34 
ATOM 18 O ILE 294 28.050 - 14.78S 99.293 OO 3174 
ATOM 19 N ASN 295 28.943 - 13.381 100.811 OO 33.69 
ATOM 2O CA. ASN 295 27.694 - 12.666 101.OO2 OO 36.46 
ATOM 21 CB ASN 295 27.305 - 12.678 102.484 OO 36.40 
ATOM 22 CG ASN 295 27.390 - 14.059 103.099 OO 36.18 
ATOM 23 OD1 ASN 295 26.783 -1S.O2S 102.619 OO 32.60 
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ATOM 24 ND2 ASN 295 28.148 -14.155 104.18O OO 37.07 
ATOM 25 C ASN 295 27.801 - 11.230 10O.S13 OO 37.74 
ATOM 26 O ASN 295 28.729 -1O.S12 100.889 OO 37.01 
ATOM 27 N CYS 296 26.852 - 10.822 99.672 OO 39.54 
ATOM 28 CA CYS 296 26.853 -9467 99.142 OO 40.74 
ATOM 29 C CYS 296 25.546 -8.761 99.438 OO 39.17 
ATOM 30 O CYS 296 24554 -9.388 99.804 OO 37.88 
ATOM 31. CB CYS 296 27.051 -9.468 97.637 OO 43.38 
ATOM 32 SG CYS 296 28.393 -10504 96.984 OO SO.13 
ATOM 33 N. THR 297 25.548 -74SO 99.241 OO 38.11 
ATOM 34 CA 297 24.368 -6.654 99.498 OO 38.11 
ATOM 35 CB 297 24.326 -6.2OO 100.953 OO 39.36 
ATOM 36 OG1 297 23.087 -S.S22 101.209 OO 40.89 
ATOM 37 CG2 297 25.5OO -5.261 101.241 OO 37.42 
ATOM 38 C 297 24.348 -5.412 98.629 OO 37.88 
ATOM 39 O 297 25.400 -4.82O 98.356 OO 37.71 
ATOM 40 N 298 23.144 -5.011 98.218 OO 36.98 
ATOM 41 CA 298 22.990 -3.829 97.389 OO 36.14 
T 
T 
T 
T 
T 
T 
G 
G 
ATOM 42 C GLY 298 23.541 -2.583 98.058 OO 35.8O 
ATOM 43 O GLY 298 23.479 -1.486 97.499 OO 35.86 
ATOM 44 N ALA 299 24.079 -2.752 99.262 OO 35.67 
ATOM 45 CA ALA 299 24.648 -1644 100.018 OO 34.99 
ATOM 46 CB ALA 299 24.757 -2.OO1 101.506 OO 35.85 
ATOM 47 C ALA 299 26.014 -1.346 99.450 OO 34.21 
ATOM 48 O ALA 299 26.628 -0.354 99.809 OO 34.18 
ATOM 49 N GLY 329 26.503 -2.232 98.591 OO 34.17 
ATOM SO CA GLY 329 27.785 -1988 97.96S OO 35.52 
ATOM 51 C GLY 329 28.940 -2.931 98.199 OO 36.98 
ATOM 52 O GLY 329 30.059 -2.611 97.805 OO 37.25 
ATOM 53 N. HIS 330 28.709 -4.086 98.817 OO 39.63 
ATOM S4 CA HIS 330 29.827 -S.OO2 99.058 OO 40.25 
ATOM SS CB HIS 330 30.600 -4.559 100.305 OO 39.30 
ATOM S6 CG HIS 330 29.818 -4.666 101.578 OO 40.8O 
ATOM 57 CD2 HIS 330 30.171 -5.1OS 102.807 OO 42.OO 
ATOM S8 ND1 HIS 330 28.516 -4.227 101.693 OO 41.71 
ATOM S9 CE1 HIS 330 28.105 -4.386 102.936 OO 41.88 
ATOM 60 NE2 HIS 330 29.090 -4.918 103636 OO 42.53 
ATOM 61 C HIS 330 29.536 -6.504 99.162 OO 40.37 
ATOM 62 O HIS 330 28.388 -6.961 99.125 OO 38.87 
ATOM 63 N CYS 331 30.630 - 7.2SS 99.255 OO 41.78 
ATOM 64 CA CYS 331 30.62O -8.702 99.394 OO 42.53 
ATOM 65 C CYS 331 31.656 -9.068 100.444 OO 41.74 
ATOM 66 O CYS 331 32.783 -8.569 100.418 OO 40.56 
ATOM 67 CB CYS 331 31.022 -9.387 98.1 OS OO 44.95 
ATOM 68 SG CYS 331 29.923 -9.199 96.679 OO 48.68 
ATOM 69 N ASN 332 31.273 -9.945 101.359 OO 40.38 
ATOM 70 CA. ASN 332 32.189 - 10.364 102.386 OO 4012 
ATOM 71 CB ASN 332 31.SS6 -10.224 103.766 OO 42.37 
ATOM 72 CG ASN 332 31.322 -8.777 104.151 OO 44.33 
ATOM 73 OD1 ASN 332 32.169 -7.911 103.909 OO 44.82 
ATOM 74 ND2 ASN 332 30.175 -8.509 104.768 OO 44.71 
ATOM 75 C ASN 332 32.586 -11.795 102.141 OO 39.72 
ATOM 76 O ASN 332 31.793 - 12.607 101.661 OO 38.64 
ATOM 77 N. ILE 333 33.834 -12088 102.472 OO 40.OO 
ATOM 78 CA ILE 333 34.387 - 13.416 102.317 OO 40.51 
ATOM 79 CB ILE 333 35.109 - 13.544 100.985 OO 40.85 
ATOM 80 CG2 ILE 333 35.936 -14.821 100.957 OO 42.34 
ATOM 81 CG1 ILE 333 34.089 - 13.52O 99.855 OO 40.11 
ATOM 82 CD1 ILE 333 34.709 - 13.314 98.515 OO 41.51 
ATOM 83 C ILE 333 35.381 - 13.647 103.432 OO 40.36 
ATOM 84 O ILE 333 36.201 - 12.780 103.723 OO 40.87 
ATOM 85 N ALA 334 35.299 - 14.812 104.060 OO 39.60 
ATOM 86 CA. ALA 334 36.204 - 15.156 105.147 OO 38.54 
ATOM 87 CB ALA 334 35.762 - 16.471 105.757 OO 41.22 
ATOM 89 C ALA 334 37.614 - 15.275 104.590 OO 36.87 
ATOM 90 O ALA 334 37.883 -16.097 103.715 OO 33.76 
ATOM 91 N ARG 335 38.510 -14.444 105.102 OO 36.58 
ATOM 92 CA ARG 335 39.883 -14.434 104.628 OO 37.37 
ATOM 93 CB ARG 335 40.669 -13333 105.326 OO 36.39 
ATOM 94 CG ARG 335 42,094 - 13.213 104.847 OO 38.55 
ATOM 95 CD ARG 335 428O1 - 12.047 105.516 OO 42.33 
ATOM 96 NE ARG 335 42.268 - 10.762 105.079 OO 44.44 
ATOM 97 CZ. ARG 335 42.375 - 10.3OS 103.837 OO 45.53 
ATOM 98 NH1 ARG 335 42.999 -11.034 102.924 OO 46.03 
ATOM 99 NH2 ARG 335 41.856 -9.127 103.509 OO 46.38 
ATOM 2OO C ARG 335 40.558 - 15.774 104.855 OO 38.44 
ATOM 2O1 O ARG 335 41.318 - 16.259 104.012 OO 39.73 
ATOM 2O2 N ALA 336 40.276 - 16.37S 106.OOO OO 38.31 
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ATOM 2O3 CA ALA 336 40.849 -17.664 106.347 OO 38.08 
ATOM 204 CB ALA 336 40.436 -18.O2S 107.7SO OO 38.47 
ATOM 205 C ALA 336 40.393 -18.754 105.371 OO 38.68 
ATOM 2O6 O ALA 336 41.214 - 19420 104.728 OO 37.19 
ATOM 2O7 N LYS 337 39.078 -18.934 105.271 OO 39.27 
ATOM 208 CA LYS 337 38.523 -19932 104.376 OO 39.56 
ATOM 209 CB LYS 337 37.003 -19.839 104.339 OO 40.15 
ATOM 210 CG LYS 337 36.316 -20.161 105.642 OO 4229 
ATOM 211 CD LYS 337 34.875 -2O.S64 105.373 OO 44.78 
ATOM 212 CE LYS 337 34.130 -20.917 106.647 OO 46.19 
ATOM 213 NZ LYS 337 32.829 -21.58O 106.331 OO 47.33 
ATOM 214 C LYS 337 39.066 -19744 102.974 OO 39.65 
ATOM 215 O LYS 337 39.464 -20.699 102.329 OO 39.54 
ATOM 216 N TRP 338 39.086 -18.506 102.5O1 OO 41.16 
ATOM 217 CA TRP 338 39.585 -18.2S2 101.159 OO 43.17 
ATOM 218 CB TRP 338 39.319 -16.817 100.725 OO 40.60 
ATOM 219 CG TRP 338 39.685 - 16.593 99.290 OO 37.38 
ATOM 220 CD2 TRP 338 38.950 - 17.042 98.154 OO 36.44 
ATOM 221 CE2 TRP 338 39.646 -16.608 97.004 OO 36.35 
ATOM 222 CE3 TRP 338 37.765 - 17.774. 97.993 OO 35.17 
ATOM 223 CD1 TRP 338 40.777 - 15.928 98.803 OO 36.91 
ATOM 224 NE1 TRP 338 40.761 -15.93O 97.427 OO 35.85 
ATOM 225 CZ2 TRP 338 39.194 - 16.878 95.714 OO 36.13 
ATOM 226 CZ3 TRP 338 37.316 -18.044 96.712 OO 34.19 
ATOM 227 CH2 TRP 338 38.028 -17.596 95.588 OO 35.36 
ATOM 228 C TRP 338 41.069 -18.515 101.032 OO 46.01 
ATOM 229 O TRP 338 41523 -19.094 100.045 OO 46.74 
ATOM 230 N ASN 339 41.836 -18.083 102.02O OO 48.56 
ATOM 231 CA. ASN 339 43.260 -18.298 101.949 OO 51.16 
ATOM 232 CB ASN 339 43.957 - 17.688 103.143 OO 56.16 
ATOM 233 CG ASN 339 45.435 - 17.890 103.08O OO 63.56 
ATOM 234 OD1 ASN 339 46.073 -17.445 102.132 OO 6419 
ATOM 23S ND2 ASN 339 45.995 - 18.566 104.079 OO 71.86 
ATOM 236 C ASN 339 43.6OS -19.777 101.860 OO SO.86 
ATOM 237 O ASN 339 44597 -20.144 101.242 OO 50.87 
ATOM 238 N ASN 340 428OO -20.634 102.478 OO SO.99 
ATOM 239 CA. ASN 340 43.071 - 22.067 102.407 OO 51.70 
ATOM 24O CB ASN 340 42.192 -22.862 103.371 OO 54.49 
ATOM 241 CG ASN 340 42.634 -22.724 104.808 OO 58.41 
ATOM 242 OD1 ASN 340 43.787 -23.014 105.151 OO 60.24 
ATOM 243 ND2 ASN 340 41.719 -22.288 105.666 OO 6O46 
ATOM 244 C ASN 340 42.781 -22.540 101.004 OO 50.85 
ATOM 245 O ASN 340 43.537 -23.331 100.433 OO 51.84 
ATOM 246 N THR 341 41.669 -22.058 100.456 OO 48.01 
ATOM 247 CA. THR 341 41.269 -22.434 99.116 OO 45.14 
ATOM 248. CB THR 341 39.989 -21.678 98.686 OO 44.64 
ATOM 249 OG1 THR 341 38.964 -21.883 99.667 OO 42.76 
ATOM 2SO CG2 THR 341 39.488 -22.189 97.334 OO 4230 
ATOM 251 C THR 341 42.416 -22.124 98.163 OO 44.38 
ATOM 252 O THR 341 42.821 - 22.977 97.377 OO 42.42 
ATOM 253 N. LEU 342 42.959 -20.911 98.249 OO 44.37 
ATOM 254 CA LEU 342 44.061 -20.531. 97.373 OO 44.41 
ATOM 255 CB LEU 342 44.506 -19.087 97.63S OO 43.85 
ATOM 2S6 CG LEU 342 43.507 - 17.9SO 97.33S OO 44.37 
ATOM 257 CD1 LEU 342 44.162 - 16.606 97.623 OO 43.63 
ATOM 2S8. CD2 LEU 342 43.OSO -17.996 95.894 OO 43.05 
ATOM 259 C LEU 342 45.245 -21.489 97.514 OO 44.72 
ATOM 260 O LEU 342 45.858 -21.851 96.515 OO 45.32 
ATOM 261 N LYS 343 45.567 -21.917 98.73S OO 44.30 
ATOM 262 CA LYS 343 46.678 -22.854 98.921 OO 43.59 
ATOM 263 CB LYS 343 46.928 -23.141 100.406 OO 44.40 
ATOM 264 CG LYS 343 48.240 -23.898 100.658 OO 46.15 
ATOM 26S CD LYS 343 48.4.13 -24.323 102.114 OO 49.16 
ATOM 266 CE LYS 343 48.578 -23.136 103.08O OO 52.93 
ATOM 267 NZ LYS 343 49.893 -224OO 103.01.1 OO 53.31 
ATOM 268 C LYS 343 46.388 -24.173 98.2O6 OO 42.93 
ATOM 269 O. LYS 343 47.242 -24.709 97.493 OO 42.92 
ATOM 270 N GLN 344 45.179 -24.693 98.396 OO 42.56 
ATOM 271 CA GLN 344 44.778 -25.957 97.777 OO 42.99 
ATOM 272 CB GLN 344 43.385 -26.373 98.241 OO 41.89 
ATOM 273 CG GLN 344 43.168 -26.344 99.725 OO 42.51 
ATOM 274 CD GLN 344 41.735 -26.664 100.081 OO 43.88 
ATOM 275 OE1 GLN 344 41.243 -27.736 99.7SS OO 45.09 
ATOM 276 NE2 GLN 344 41.052 -25.728 100.744 OO 44.66 
ATOM 277 C GLN 344 44.762 -25.908 96.254 OO 43.37 
ATOM 278 O. GLN 344 44.870 -26.952 95.612 OO 44.99 
ATOM 279 N ILE 345 44.602 -24.714 95.679 OO 43.39 
ATOM 280 CA ILE 345 44.559 -24.567 94.218 OO 42.52 
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ATOM 281 CB ILE 345 43.705 -23.359 93.765 OO 40.62 
ATOM 282 CG2 ILE 345 43.479 -23.434 92.28O OO 39.28 
ATOM 283 CG1 ILE 345 42.332 -23.377 94.419 OO 40.32 
ATOM 284 CD1 ILE 345 41.517 -22.134 94.104 OO 40.02 
ATOM 285 C ILE 345 45.946 -24.394 93.611 OO 43.06 
ATOM 286 O ILE 345 46.281 -25.OSO 92.626 OO 42.31 
ATOM 287 N ALA 346 46.745 -23.496 94.184 OO 44.37 
ATOM 288 CA ALA 346 48.097 -23.273 93.683 OO 45.42 
ATOM 289 CB ALA 346 48.836 - 22.275 94.556 OO 43.26 
ATOM 290 C ALA 346 48.771 -24.63O 93.743 OO 46.84 
ATOM 291 O ALA 346 49.582 -24.981 92.886 OO 47.39 
ATOM 292 N SER 347 48.408 -25.396 94.765 OO 47.70 
ATOM 293 CA. SER 347 48.950 -26.722 94.934 OO 49.50 
ATOM 294 CB SER 347 48.337 -27.376 96.160 OO 51.28 
ATOM 295 OG SER 347 48.850 -28.68S 96.317 OO 56.57 
ATOM 296 C SER 347 48.662 -27.558 93.683 OO 49.94 
ATOM 297 O SER 347 49.586 -28.029 93.030 OO S.O.34 
ATOM 298 N LYS 348 47.382 -27.728 93.351 OO 50.78 
ATOM 299 CA LYS 348 46.962 -28.494 92.17O OO 51.63 
ATOM 3OO CB LYS 348 45.432 -28.577 92.098 OO 51.50 
ATOM 301 CG LYS 348 44.791 -29.584 93,032 OO 51.75 
ATOM 302 CD LYS 348 45.064 -30.988 92.556 OO 50.85 
ATOM 3O3 CE LYS 348 44.542 -32.004 93.543 OO SO.69 
ATOM 3O4 NZ LYS 348 44.944 -33.37S 93.137 OO SO.94 
ATOM 305 C LYS 348 47.463 -27.869 90.869 OO 52.28 
ATOM 306 O LYS 348 47.585 -28.53S 89.840 OO 52.16 
ATOM 307 N LE 349 47.738 -26.579 90.908 OO 53.08 
ATOM 3O8 CA 
ATOM 309 CB 
ATOM 31 O CG 
ATOM 311 CD1 
ATOM 312 CD2 
ATOM 313 C 
ATOM 314 O 
ATOM 315 N 
ATOM 316 CA 
ATOM 317 CB 
ATOM 318 CG 
ATOM 319 CD 
ATOM 320 NE 
ATOM 321 CZ 
ATOM 322 NH1 
ATOM 323 NH2 
ATOM 324 C 
ATOM 325 O 
ATOM 326 N 
ATOM 327 CA 
ATOM 328 CB 
ATOM 329 CG 
ATOM 330 CD 
ATOM 331 OE1 
ATOM 332 OE2 
ATOM 333 C 
ATOM 334 O 
ATOM 335 N 
ATOM 336 CA 
ATOM 337 CB 
ATOM 338 CG 
ATOM 339 CD 
ATOM 340 OE1 
ATOM 341 NE2 
349 48.203 -25.921 89.713 OO 55.10 
349 48.OO2 -24.402 89.824 OO S388 
349 46.572 -23.8SS 89.720 OO 50.78 
349 46.6OO -22.369 89.985 OO 49.11 
349 45.977 -24.134 88.345 OO 47.99 
349 49.655 -26.259 89.4O2 OO 57.08 
349 49.959 -26.62O 88.270 OO 57.54 
350 S.O.SSS -26.159 90.383 OO 59.82 
350 51.961 -26.476 90.114 OO 63.18 
350 52.866 -26.042 91.266 OO 64.31 
RG 350 52.410 -26.471 92.624 OO 68.34 
RG 350 53.595 -26.54O 93.563 OO 72.56 
RG 350 54.525 -25427 93.375 OO 76.31 
RG 350 SS.714 -25.343 93.974 OO 78.63 
RG 350 56.113 -26.3O8 94.798 OO 78.98 
RG 350 56.511 -24.301 93.751 OO 79.29 
RG 350 52.125 -27.968 89.851 OO 64.33 
RG 350 53.102 -28.405 89.234 OO 65.71 
LU 351 51.148 -28.741 90.312 OO 64.SS 
LU 351 51.126 -30.18O 90.112 OO 63.62 
LU 351 49.963 -30.778 90.898 OO 66.10 
351 49.896 -32.29O 90.914 OO 70.44 
LU 351 48.652 -32.811 91.628 OO 72.67 
LU 351 47.536 -32.631. 91.090 OO 74.72 
LU 351 48.787 -33.397 92.726 OO 73.74 
LU 351 50.941 -30.456 88.615 OO 61.98 
LU 351 51.096 -31.588 88.162 OO 61.SS 
LN 352 50.602 -29.409 87.861 OO 60.65 
LN 352 S.O.397 -29 SOS 86.415 OO 59.13 
LN 352 48.942 -29.191 86.053 OO 56.49 
LN 352 48.699 -29.115 84.545 OO 53.84 
LN 352 47.5O1 -29.931 84.092 OO 52.61 
LN 352 47.280 -30.122 82.895 OO 49.99 
LN 352 46.722 -30.416 85.048 OO 52.71 
U 
ATOM 342 C LN 352 51.320 -28.619 85.563 OO 59.46 
ATOM 343 O. LN 352 S1494 -28.873 84.375 OO 58.99 
ATOM 344 N PHE 353 S1908 -27.585 86.152 OO 6032 
ATOM 345 CA PHE 353 52.796 -26.714 85.390 OO 62.O7 
ATOM 346 CB PHE 353 52.262 -25.277 85.366 OO 61.62 
ATOM 347 CG PHE 353 SO.957 -25.129 84.641 OO 61.43 
ATOM 348 CD1 PHE 353 49.752 -25.258 85.316 OO 61.91 
ATOM 349 CD2 PHE 353 SO.930 -24.905 83.268 OO 62.10 
ATOM 350 CE1 PHE 353 48.532 -25.168 84.633 OO 62.04 
ATOM 351 CE2 PHE 353 49.717 -24.815 82.576 OO 61.69 
ATOM 352 CZ. PHE 353 48.516 -24.948 83.261 OO 61.58 
ATOM 353 C PHE 353 54.229 -26.713 85.915 OO 64.18 
ATOM 3S4 O PHE 353 SS.O46 -25.880 85511 OO 65.29 
ATOM 355 N GLY 3S4 54.540 -27.642 86.812 OO 64.51 
ATOM 356 CA GLY 3S4 SS.888 -27.697 87.340 OO 65.83 
ATOM 357 C GLY 3S4 S5.948 -27.5O1 88.838 OO 67.15 
ATOM 358 O GLY 3S4 55.746 -26.395 89.346 OO 67.01 
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TABLE 1-continued 
The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
ATOM 359 N ASN 355 56.237 -28.589 89.544 OO 67.83 
ATOM 360 CA. ASN 355 56.329 -28.576 90.994 OO 68.59 
ATOM 361 CB ASN 355 56.573 - 29.995 91.513 OO 70.55 
ATOM 362 CG ASN 355 SS.301 -30.841 91.533 OO 72.72 
ATOM 363 OD1 ASN 355 SS.353 -32.048 91.776 OO 74.24 
ATOM 364 ND2 ASN 355 S4.155 -30.208 91.290 OO 72.93 
ATOM 365 C ASN 355 57.4.13 -27.644 91.509 OO 68.43 
ATOM 366 O ASN 355 57.574 -27.48O 92.716 OO 69.01 
ATOM 367 N ASN 356 S8.1SS -27.032 90.597 OO 67.89 
ATOM 368 CA. ASN 356 59.214 -26.114 90.988 OO 67.81 
ATOM 369 CB ASN 356 60.495 -26.427 90.209 OO 68.67 
ATOM 370 CG ASN 356 61:021 -27.836 90.475 OO 68.82 
ATOM 371 OD1 ASN 356 62.067 -28.223 89.956 OO 68.37 
ATOM 372 ND2 ASN 356 60.294 -28.605 91.282 OO 69.10 
ATOM 373 C ASN 356 S8.756 -24.690 90.698 OO 67.61 
ATOM 374 O ASN 356 59.399 -23.719 91.109 OO 68.06 
ATOM 375 N LYS 357 57.632 -24.588 89.989 OO 66.72 
ATOM 376 CA LYS 357 57.028 -23.308 89.603 OO 64.44 
ATOM 377 CB LYS 357 SS.979 -23.528 88.503 OO 6555 
ATOM 378 CG LYS 357 56.524 -23.915 87.138 OO 66.86 
ATOM 379 CD LYS 357 57.287 - 22.758 86.511 OO 68.57 
ATOM 380 CE LYS 357 57.563 - 22.990 85.033 OO 69.07 
ATOM 381 NZ LYS 357 56.297 -23.017 84.2SO OO 69.35 
ATOM 382 C LYS 357 56.353 - 22.582 90.769 OO 61.58 
ATOM 383 O LYS 357 SS. 735 -23.211 91.630 OO 61.43 
ATOM 384 N TH 358 56.463 -21.257 90.778 OO 57.89 
ATOM 385 CA 
ATOM 386 CB 
ATOM 387 OG1 
ATOM 388 CG2 
ATOM 389 C 
ATOM 390 O. 
ATOM 391 N 
ATOM 392 CA 
ATOM 393 CB 
ATOM 394 CG2 
ATOM 395 CG1 
ATOM 396 CD1 
ATOM 397 C 
ATOM 398 O 
ATOM 399 N 
ATOM 400 CA 
ATOM 401 CB 
ATOM 402 CG2 
ATOM 403 CG1 
ATOM 404 CD1 
ATOM 40S C 
ATOM 4O6 O 
358 SS.851 -20.434 
358 56.721 -19.218 
358 57.983 -19666 
358 56.045 - 18.358 
358 54.500 -19.944 
358 54.412 - 19332 
359 53.452 -20.221 
359 52.1OO -19832 
359 51.054 -20.849 
359 49.667 -20.470 
359 S1.387 - 22.258 
359 51.461 -22383 
359 S1.732 - 18.4SO 
359 S1.703 -18.231 
360 S1.451 -17.528 
360 51.058 - 16.163 
360 51.930 -15.086 
360 51.486 -13.711 
360 53.401 -15.28O 
360 54.176 -15.839 
360 49.620 -15898 
360 49.205 - 16.3O2 
.817 OO 54.10 
2.155 OO 53.27 
2.659 OO 52.66 
3.2O2 OO S3.26 
317 OO 51.75 
0.257 OO 51.73 
2.084 OO 48.72 
707 OO 45.84 
2.247 OO 44.27 
.782 OO 43.26 
767 OO 4229 
O.264 OO 42.14 
2.228 OO 45.04 
3.438 OO 44-85 
.309 OO 44.16 
667 OO 43.62 
O.968 OO 41.87 
.399 OO 418O 
297 OO 40.OO 
O.143 OO 41.OO 
231 OO 43.95 
O.139 OO 43.81 
ATOM 407 N PH 361 48.859 -15.215 92.076 OO 43.88 
ATOM 408 CA PH 361 47.486 - 14886 91.721 OO 4S.O.S 
ATOM 409 CB PH 361 46.510 -15.333 92.818 OO 44.SS 
ATOM 410 CG PH 361 46.421 -16.832 92.991 OO 43.16 
ATOM 411 CD1 PH 361 47.047 - 17.463 94.059 OO 41.83 
ATOM 412 CD2 PH 361 45.723 -17.609 92.074 OO 41.08 
ATOM 413 CE1 PH 361 46.978 -18.83S 94.2O7 OO 39.99 
ATOM 414 CE2 PH 361 45.650 -18.978 92.216 OO 39.19 
ATOM 415 CZ PH 361 46.280 -19.591 93.284 OO 39.63 
ATOM 416 C PH 361 47.370 - 13.381 91.521 OO 45.78 
ATOM 417 O PH 361 47.599 - 12.619 92.456 OO 48.15 
ATOM 418 N LYS 362 47.O32 - 12.946 90.310 OO 44.97 
ATOM 419 CA LYS 362 46.880 -11.519 90.044 OO 45.08 
ATOM 42O CB LYS 362 47.836 -11.058 88.946 OO 46.05 
ATOM 421 CG LYS 362 49.297 -11.07S 89.307 OO 46.12 
ATOM 422 CD LYS 362 SO.116 - 10.SS9 88.147 OO 44.35 
ATOM 423 CE LYS 362 S1.572 -1O.S16 88.524 OO 45.15 
ATOM 424 NZ LYS 362 S1.752 -9.677 89.742 OO 45.33 
ATOM 42S C LYS 362 45.461 - 11179 89.611 OO 45.45 
ATOM 426 O LYS 362 44.719 - 12.042 89.138 OO 45.50 
ATOM 427 N GLN 363 45.102 -9.907 89.759 OO 45.24 
ATOM 428 CA GLN 363 43.781 -9.411. 89.38O OO 44.82 
ATOM 429 CB GLN 363 43.639 -7.954 89.818 OO 44.59 
ATOM 430 CG GLN 363 44807 - 7.064 89.415 OO 45.02 
ATOM 431 CD GLN 363 44,428 -S.S95 89.372 OO 45.87 
ATOM 432 OE1 GLN 363 43.SSS -5.199 88.6OO OO 47.42 
ATOM 433 NE2 GLN 363 45.079 -4.78O 90.199 OO 44.92 
ATOM 434 C GLN 363 43.527 -9.506 87.872 OO 45.O1 
ATOM 43S O GLN 363 44.459 -9.717 87.090 OO 44.87 
ATOM 436 N SER 364 42.263 -9.3SO 87.470 OO 44.6O 
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TABLE 1-continued 
The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
ATOM 437 CA. SER 364 41.895 -9.394 86.052 OO 43.07 
ATOM 438 CB SER 364 40.444 -8.956 85.850 OO 41.38 
ATOM 439 OG SER 364 40.073 -9.076 84.487 OO 39.74 
ATOM 440 C SER 364 428O3 -8.436 85.297 OO 43.26 
ATOM 441 O SER 364 43.104 -7.347 85.793 OO 43.43 
ATOM 442 N. SER 365 43.234 -8.829 84.102 OO 42.44 
ATOM 443 CA. SER 365 44.116 -7.979 83.312 OO 41.33 
ATOM 444 CB SER 365 45.140 -8.846 82.566 OO 41.58 
ATOM 445 OG SER 365 44.530 -1O.OOO 82.013 OO 44.41 
ATOM 446 C SER 365 43.445 - 6.996 82.328 OO 40.25 
ATOM 447 O SER 365 44.132 -6.413 81.491 OO 42.93 
ATOM 448 N. GLY 366 42.130 -6.794 82.424 OO 36.76 
ATOM 449 CA GLY 366 41.473 -5.86O 81.524 OO 32.OS 
ATOM 450 GLY 366 40.321 -6.445 80.741 OO 31.17 
ATOM 451 GLY 366 40.099 - 7.652 80.762 OO 31.00 
ATOM 452 GLY 367 39.581 -S.S85 80.044 OO 30.27 
ATOM 454 GLY 367 37.117 -5.504 79.777 OO 29.8O 
ATOM 455 GLY 367 37.087 -4.691 80.702 OO 31.08 
ATOM 456 ASP 368 36.015 -5.9S4 79.192 OO 29.13 
ATOM 457 CA. ASP 368 34.699 -SSO7 79.626 OO 31.89 
ATOM 458 CB ASP 368 33.604 -6.3OS 78.909 OO 35.79 
ATOM 459 CG ASP 368 33.588 -6.073 77.397 OO 39.65 
ATOM 460 OD1 ASP 368 32.826 -6.784 76.700 OO 40.OO 
ATOM 461 OD2 ASP 368 34.328 -S.187 76.908 OO 42.73 
ATOM 462 C ASP 368 34.527 -5.663 81.144 OO 32.13 
ATOM 463 O ASP 368 35.139 -6.527 81.757 OO 32.82 
ATOM 464 N PRO 369 33.684 -4.821 81.766 OO 31.85 
ATOM 465 CD PRO 369 32.993 -3.693 81.120 OO 30.96 
ATOM 466 CA PRO 369 33.404 -4.838 83.2O7 OO 31.36 
ATOM 467 CB PRO 369 32.265 -3.842 83.337 OO 31.63 
ATOM 468 CG PRO 369 32.613 -2.833 82.289 OO 31.18 
ATOM 469 C PRO 369 33.007 -6.2O3 83.739 OO 30.91 
ATOM 470 O PRO 369 33.485 -6.649 84.778 OO 31.90 
ATOM 471 N GLU 370 32.112 - 6.858 83.023 OO 30.62 
ATOM 472 CA GLU 370 31.627 -8.162 83.415 OO 31.59 
ATOM 473 CB GLU 370 30.534 -8.585 82.440 OO 32.54 
ATOM 474 CG GLU 370 29.303 - 7.659 82.445 OO 34.81 
ATOM 47S CD GLU 370 29.452 -6.366 81622 OO 34.63 
ATOM 476 OE1 GLU 370 28.495 -S.S67 81.6O1 OO 3416 
ATOM 477 OE2 GLU 370 30.503 -6.142 80.991 OO 3590 
ATOM 478 C GLU 370 32.718 -9.245 83.519 OO 32.22 
ATOM 479 O GLU 370 32.528 - 10.259 84.194 OO 33.09 
ATOM 480 N ILE 371 33.857 -9.016 82.864 OO 31.32 
ATOM 481 CA ILE 371 34.999 -9.943 82.861 OO 28.31 
ATOM 482 CB ILE 371 35.579 -10.085 81.422 OO 28.08 
ATOM 483 CG2 ILE 371 37.098 - 10.089 81.437 OO 27.78 
ATOM 484 CG1 ILE 371 35.037 - 11.343 80.779 OO 28.02 
ATOM 485 CD1 ILE 371 33.SSS -11.407 80.819 OO 30.47 
ATOM 486 C ILE 371 36.133 -9.506 83.797 OO 27.21 
ATOM 487 O ILE 371 36.974 -10.315 84.191 OO 26.14 
ATOM 488 N VAL 372 36.158 -8.224 84.138 OO 26.33 
ATOM 489 CA VAL 372 37.194 - 7.676 85.007 OO 27.67 
ATOM 490 CB VAL 372 37.487 -6.2OO 84.678 OO 27.14 
ATOM 491 CG1 VAL 372 38.468 -5.636 85.687 OO 24.67 
ATOM 492 CG2 VAL 372 38.035 -6.O78 83.258 OO 26.38 
ATOM 493 C VAL 372 36.807 -7.739 86.467 OO 28.75 
ATOM 494 O VAL 372 37.662 -7.792 87.355 OO 29.82 
ATOM 495 N 373 35.506 -7.734 86.709 OO 29.47 
ATOM 496 CA 373 34.983 -7.77O 88.066 OO 28.66 
ATOM 497 CB 373 34.079 -6.554 88.296 OO 27.96 
ATOM 498 OG1 373 32.916 -6.668 87.472 OO 28.85 
ATOM 499 CG2 373 34.801 -5.28S 87.888 OO 26.32 
ATOM 500 C 373 34.166 -9.042 88.221 OO 28.00 
ATOM SO1 O 373 33.806 -9.658 87.211 OO 28.23 
ATOM 502 N 374 33.902 -9.453 89.466 OO 27.55 
ATOM SO3 CA 374 33.075 - 10.642 89.723 OO 26.55 
ATOM SO4 CB 374 33.245 - 11.149 91.162 OO 25.93 
ATOM 505 CO 374 32.187 - 12.121 91.591 OO 26.09 
ATOM SO6 CD2 374 31.358 - 12.121 92.663 OO 26.47 
ATOM 507 ND1 374 31.866 -13.243 90.863 OO 27.70 
ATOM SO8 CE1 374 3O881 - 13.892 91.463 OO 25.87 
ATOM 509 NE2 374 30.555 - 13.232 92.557 OO 25.26 
ATOM 510 C 374 31.654 -10.153 89.476 OO 25.07 
ATOM 511 O 374 31,071 -9.423 90.268 OO 25.98 
ATOM 512 N 375 31.132 -10546 88.332 OO 24.08 
ATOM S13 CA 375 29.829 -10.142 87.866 OO 24.74 
ATOM S14 CB 375 29.960 -9.781 86.383 OO 2SO4 
C 
O 
N 
ATOM 453 CA GLY 367 38.441 - 6.04O 79.258 OO 29.70 
C 
O 
N 
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TABLE 1-continued 
The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
ATOM 515 CO TRP 375 28.702 -9.478 85.662 OO 25.75 
ATOM 516 CD2 TRP 375 28.096 -10271 84.645 OO 25.29 
ATOM 517 CE2 TRP 375 26.916 -9.609 84.235 OO 24.75 
ATOM 518 CE3 TRP 375 28.430 - 11488 84.037 OO 26.21 
ATOM 519 CD1 TRP 375 27.896 -8.390 85.828 OO 26.87 
ATOM 520 NE1 TRP 375 26.819 -8.457 84.972 OO 25.73 
ATOM 521 CZ2 TRP 375 26.075 - 10.111 83.256 OO 25.28 
ATOM 522 CZ3 TRP 375 27.591 - 11.996 83.057 OO 25.89 
ATOM 523 CH2 TRP 375 26.424 -11.307 82678 OO 26.36 
ATOM 524 C TRP 375 28.844 -11268 88.060 OO 26.93 
ATOM 525 O TRP 375 29.098 - 12.411. 87.687 OO 27.40 
ATOM 526 N PHE 376 27.707 - 10.946 88.646 OO 28.62 
ATOM 527 CA PHE 376 26.693 -11.954 88.863 OO 31.15 
ATOM 528 CB PHE 376 26.989 - 12.736 90.130 OO 30.11 
ATOM 529 CG PHE 376 27.135 - 11.877 91.332 OO 30.51 
ATOM 530 CD1 PHE 376 28.310 -11162 91.547 OO 30.86 
ATOM 531. CD2 PHE 376 26.090 -11754 92.241 OO 30.19 
ATOM 532 CE1 PHE 376 28.448 -10.331 92.652 OO 29.71 
ATOM 533 CE2 PHE 376 26.209 -10.929 93.352 OO 30.22 
ATOM S34 CZ PHE 376 27.393 -10.213 93.560 OO 30.89 
ATOM 535 C PHE 376 25.355 - 11.279 88.996 OO 32.83 
ATOM S36 O PHE 376 25.280 -10.086 89.252 OO 33.02 
ATOM 537 N ASN 377 24.299 -12051 88.809 OO 3569 
ATOM S38 CA. ASN 377 22.963 -11.521 88.929 OO 40.61 
ATOM 539 CB ASN 377 22.046 -12.178 87.913 OO 44.38 
ATOM S4O CG ASN 377 20.647 -11.597 87.940 OO 48.66 
ATOM S41 OD1 ASN 377 20.426 -10443 87.542 OO 48.26 
ATOM S42 ND2 ASN 377 19.689 - 12.393 88.420 OO 51.13 
ATOM 543 C ASN 377 22.491 - 11.8SS 90.327 OO 42.23 
ATOM S44 O ASN 377 22.892 - 12.864 90.876 OO 44.30 
ATOM 545 N CYS 378 21643 -11.009 90.901 OO 44.SS 
ATOM 546 CA CYS 378 21.117 - 11.22O 92251 OO 45.14 
ATOM 547 C CYS 378 9.934 -10.282 92.488 OO 43.OO 
ATOM S48 O CYS 378 20.075 -9.066 92.377 OO 41.28 
ATOM S49 CB 378 22.2O3 -10.9SO 93.3O2 OO 49.09 
ATOM 550 SG 378 21.506 -11.015 94.982 OO 57.12 y s 
ATOM 551 N LY 379 8.773 - 10.842 92.819 OO 41.22 
ATOM SS2 CA LY 379 7.600 - 10.011 93.025 OO 40.83 
ATOM 553 C LY 379 7.246 -9.244 91.753 OO 40.79 
ATOM SS4 O LY 379 6.556 -8.222 91.784 OO 41.26 
ATOM 555 N. LY 380 7.718 -9.738 90.619 OO 39.72 
ATOM SS6 CA LY 380 7.442 -9.059 89.372 OO 39.79 
ATOM 557 C LY 380 8.461 -7.986 89.005 OO 39.81 
ATOM 558 O LY 380 8.544 -7.578 87.842 OO 39.98 
ATOM 559 N 381 9.243 -7.524 89.979 OO 39.10 
ATOM S60 CA 
ATOM 561 CB 
ATOM 562 CG 
ATOM S63 CD 
ATOM S64 OE1 
ATOM 565 OE2 
ATOM 566 C 
ATOM 567 O 
ATOM 568 N 
ATOM 569 CA 
ATOM 570 CB 
ATOM 571 CO 
ATOM 572 CD1 
ATOM 573 CD2 
ATOM 574 CE1 
ATOM 575 CE2 
ATOM 576 CZ 
ATOM 577 C 
ATOM 578 O. 
ATOM 579 N 
ATOM S80 CA 
ATOM 581 CB 
ATOM 582 CG 
ATOM 583 CD1 
ATOM S84 CD2 
ATOM 585 CE1 
ATOM 586 CE2 
ATOM 587 CZ 
ATOM 588 C 
ATOM S89 O 
ATOM 590 N TY 
ATOM 591 CA TY 
ATOM 592 CB TY 
381 2O.244 -6.489 89.712 OO 38.16 
381 20.440 -5.6O7 90.940 OO 38.52 
381 9.162 -5139 91.6O1 OO 41.28 
381 8.327 -4.226 90.728 OO 43.40 
381 8.904 -3.42O 89.963 OO 44.79 
381 7.083 -4.303 90.827 OO 44.94 
381 21.583 -7.123 89.353 OO 36.75 
381 21.890 -8.228 89.796 OO 34.31 
382 22.382 -6.421 88.556 OO 34.93 
382 23.684 -6.937 88.174 OO 34:11 
382 23.955 -6.685 86.699 OO 35.03 
382 23.062 -74SO 85.796 OO 35.63 
382 21868 -6.901 85.351 OO 37.48 
382 23.392 -8.740 8541S OO 37.08 
382 21.007 -7.628 84.534 OO 38.27 
382 22.543 -9.482 84.600 OO 38.30 
382 21.343 -8.924 84.156 OO 38.8O 
382 24.8OO -6.316 88.992 OO 33.85 
382 25.066 -5.122 88.892 OO 33.66 
383 25.463 -7.145 89.788 OO 33.72 
383 26. SS7 -6.694 90.628 OO 33.09 
383 26.646 -7.546 91895 OO 34.99 
383 25.462 -7.409 92.806 OO 38.33 
383 24.183 -7.73O 92.364 OO 39.48 
383 25619 -6.928 94.103 OO 4O16 
383 23.079 -7.568 93.195 OO 39.96 
383 24.517 -6.762 94.942 OO 39.80 
383 23.247 -7.08.2 94484 OO 40.07 
383 27.876 -6.77S 89.887 OO 31.86 
383 28.064 - 7.627 89.024 OO 30.97 
384 28.779 -S.87O 90.233 OO 31.42 
384 30.102 -5.818 89.646 OO 32.51 
384 30.197 -4.673 88.643 OO 33.51 
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The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
ATOM 593 CG TYR 384 29.3SO -4.8SO 87.399 OO 35.33 
ATOM 594 CD1 TYR 384 27.961 -4.728 87.451 OO 36.88 
ATOM 595 CE1 TYR 384 27.177 -4.891 86.311 OO 36.38 
ATOM 596 CD2 TYR 384 29.938 -5.145 86.170 OO 35.34 
ATOM 597 CE2 TYR 384 29.16S -5.311 85.023 OO 36.36 
ATOM 598. CZ TYR 384 27.784 -S.185 85.102 OO 37.21 
ATOM 599 OH TYR 384 27.008 -5.351 83.971 OO 37.53 
ATOM 600 C TYR 384 31.033 -SSS8 90.815 OO 33.55 
ATOM 601 O TYR 384 31.207 -4.404 91.217 OO 32.94 
ATOM 602 N CYS 385 31.619 -6.631. 91356 OO 34.77 
ATOM 603 CA CYS 385 32.509 -6.549 92.525 OO 34.65 
ATOM 604 C CYS 385 33.971 -6.626 92.216 OO 34.20 
ATOM 60S O CYS 385 34.433 - 7.SS8 91.565 OO 35.22 
ATOM 606 CB CYS 385 32.217 - 7.658 93.521 OO 34.87 
ATOM 607 SG CYS 385 30.526 - 7.663 94.168 OO 40.52 
ATOM 608 N ASN 386 34.705 -5.653 92.727 OO 33.25 
ATOM 609 CA. ASN 386 36.129 -5.598 92.521 OO 33.13 
ATOM 61O CB ASN 386 36.645 -4.259 93.01.1 OO 35.09 
ATOM 611 CG ASN 386 38.103 -4.104 92.775 OO 39.37 
ATOM 612 OD1 ASN 386 38.880 -4.983 93.117 OO 41.53 
ATOM 613 ND2 ASN 386 38.506 -2.99O 92.194 OO 43.99 
ATOM 614 C ASN 386 36.802 -6.744 93.28O OO 32.07 
ATOM 615 O 386 36.891 -6.718 94.507 OO 33.16 A. S N 
ATOM 616 N SE 387 37.288 -7.746 92.SSS OO 30.06 
ATOM 617 CA SE 387 37.922 -8.895 93.196 OO 29.26 
ATOM 618 CB SER 387 37. SOS -10.178 92.478 OO 28.12 
ATOM 619 OG SER 387 37.730 - 10.093 91.087 OO 26.31 
ATOM 620 C SER 387 39.443 -8.867 93.337 OO 29.50 
ATOM 621 O SER 387 40.063 -9.889 93.624 OO 29.39 
ATOM 622 N THR 388 40.045 - 7.702 93.159 OO 29.97 
ATOM 623 CA. THR 388 41.488 -7.586 93.273 OO 31.62 
ATOM 624 CB THR 388 41.929 -6.116 93.190 OO 32.8O 
ATOM 625 OG1 THR 388 41.734 -5.63O 91.849 OO 31.68 
ATOM 626 CG2 THR 388 43.392 -5.980 93.590 OO 31.85 
ATOM 627 C THR 388 42038 -8.194 94.561 OO 33.05 
ATOM 628 O THR 388 43.1OO -8.816 94.553 OO 33.91 
ATOM 629 N GLN 389 41.320 -8.027 95.667 OO 34.67 
ATOM 630 CA GLN 389 41792 -8574 96.944 OO 37.35 
ATOM 631 CB GLN 389 40.957 -8.065 98.124 OO 36.04 
ATOM 632 CG GLN 389 40.860 -6.578 98.266 OO 34.05 
ATOM 633 CD GLN 389 39.773 -6.202 99.241 OO 34.91 
ATOM 634 OE1 GLN 389 39.964 -6.271 100.451 OO 37.19 
ATOM 63S NE2 GLN 389 38.609 -S.826 98.720 OO 36.2O 
ATOM 636 C GLN 389 41.779 -10.101 97.01.1 OO 38.08 
ATOM 637 O GLN 389 42.422 -10.687 97.882 OO 40.01 
ATOM 638 N LEU 390 41,042 - 10.752 96.124 OO 37.43 
ATOM 639 CA 390 40.994 - 12.199 96.175 OO 38.01 
ATOM 640 CB 390 39.663 - 12.699 95.613 OO 37.92 
ATOM 641 CG U 390 38.396 -12318 96.392 OO 37.01 
ATOM 642 CD1 LEU 390 37.175 - 12.76S 95.614 OO 35.68 
ATOM 643 CD2 LEU 390 38.399 - 12.959 97.764 OO 35.67 
ATOM 644 C LEU 390 42.163 - 12.816 95.415 OO 39.31 
ATOM 645 O LEU 390 42.692 - 13.863 95.8O1 OO 40.54 
ATOM 646 N. PHE 391 42.583 -12.15O 94.347 OO 39.70 
ATOM 647 CA PHE 391 43.680 - 12.644 93.528 OO 38.54 
ATOM 648 CB PHE 391 43.2O6 -12.794 92.092 OO 37.22 
ATOM 649 CG PHE 391 41.913 - 13.532 91.984 OO 37.31 
ATOM 650 CD1 PHE 391 40.707 - 12.871 92.177 OO 38.01 
ATOM 651 CD2 PHE 391 41.897 -14.907 91.784 OO 37.44 
ATOM 652 CE1 PHE 391 39.507 - 13.56S 92.179 OO 37.83 
ATOM 653 CE2 PHE 391 40.699 - 15.613 91.786 OO 37.13 
ATOM 654 CZ PHE 391 39.5O1 - 14.939 91.986 OO 38.34 
ATOM 655 C PHE 391 44.848 -11691 93.622 OO 39.15 
ATOM 656 O PHE 391 45.093 - 10.874 92.724 OO 37.81 
ATOM 657 N ASN 392 45.554 -11.8O8 94.742 OO 40.04 
ATOM 658 CA. ASN 392 46.709 - 10.98O 95.038 OO 40.61 
ATOM 659 CB ASN 392 46.243 -9.647 95.650 OO 40.52 
ATOM 660 CG ASN 392 47.401 -8.713 95.990 OO 42.11 
ATOM 661 OD1 ASN 392 48.388 -8.643 95.255 OO 42.90 
ATOM 662 ND2 ASN 392 47.272 -7.978 97.093 OO 42.11 
ATOM 663 C ASN 392 47.615 - 11.736 96.OO6 OO 40.17 
ATOM 664 O ASN 392 47.771 -11.336 97.148 OO 40.62 
ATOM 66S N SER 393 48.205 - 12.837 95.558 OO 40.28 
ATOM 666 CA. SER 393 49.085 -13.598 96.436 OO 41.43 
ATOM 667 CB SER 393 48.261 - 14448 97.403 OO 40.63 
ATOM 668 OG SER 393 47.328 - 15.262 96.718 OO 40.8O 
ATOM 669 C SER 393 SO.077 - 14479 95.687 OO 42.79 
ATOM 670 O SER 393 49.819 - 14.908 94.556 OO 42.31 
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TABLE 1-continued 
The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
ATOM 671 N 
ATOM 672 CA T 
ATOM 673 CB T 
ATOM 674 OG1 T 
ATOM 675 CG2 T 
ATOM 676 C 
ATOM 677 O 
ATOM 678 N 
ATOM 679 CA T 
ATOM 680 CB T 
ATOM 681 CG T 
ATOM 682 CD2 T 
ATOM 683 CE2 T 
ATOM 684 CE3 T 
ATOM 685 CD1 T 
ATOM 686 NE1 T 
ATOM 687 CZ2 T 
ATOM 688. CZ3 T 
ATOM 689 CH2 T 
ATOM 690 C 
394 51.212 - 14.737 96.333 OO 43.79 
394 52.277 - 15.551 95.756 OO 45.04 
394 53.574 -14.737 95.642 OO 45.96 
394 53.333 - 13.573 94.833 OO 46.10 
394 54.688 -15.584 95.026 OO 45.27 
394 52.541 - 16.79O 96.6O2 OO 45.64 
394 S2.906 - 16.684 97.769 OO 44.76 
395 S2.378 - 17.964 95.996 OO 47.09 
395 52.548 -19.228 96.705 OO 47.76 
395 S1.288 -20.068 96.527 OO 41.92 
395 SO.107 -19.326 96.976 OO 38.28 
395 49.405 -19.506 98.205 OO 36.22 
395 48.415 -18.5O3 98.268 OO 36.46 
395 49.514 -20.414 99.258 OO 33.85 
395 49.532 - 18.258 96.357 OO 37.38 
395 48.517 - 17.754 97.126 OO 36.41 
395 47.539 -18.387 99.348 OO 34.01 
395 48.647 -20.297 100.324 OO 33.66 
395 47.670 -19.290 100.361 OO 33.40 
395 53.761 -20.066 96.339 OO S1.43 
ATOM 691 O 395 S4.159 -20.124 95.170 OO 52.73 
ATOM 692 N PH 396 S4.339 -20.71O 97.358 OO 54.22 
ATOM 693 CA PH 396 SS.491 -21.589 97.190 OO 56.04 
ATOM 694 CB PH 396 55.138 -22.681 96.186 OO 54.94 
ATOM 695 CG PH 396 53.790 -23.3OS 96.422 OO 55.63 
ATOM 696 CD1 PH 396 53.083 -23.883 95.373 OO 56.03 
ATOM 697 CD2 PH 396 S3.226 -23.325 97.699 OO 56.08 
ATOM 698 CE1 PH 396 51.830 -24.48O 95.591 OO 56.77 
ATOM 699 CE2 PH 396 S1.974 -23.917 97.930 OO 56.41 
ATOM 700 CZ, PH 396 51.275 -24.495 96.872 OO 56.06 
ATOM 701 C PH 396 56.708 -20.813 96.713 OO 58.81 
ATOM 702 O PH 396 57.523 -21.322 95.938 OO 59.35 
ATOM 703 N ASN 397 56.815 -19.57O 97.172 OO 61.45 
ATOM 704 CA. ASN 397 57.932 - 18.717 96.802 OO 63.89 
ATOM 705 CB ASN 397 57.462 -17.262 96.713 OO 65.82 
ATOM 706 CG ASN 397 58.568 - 16.31 O 96.270 OO 68.51 
ATOM 707 OD1 ASN 397 58.333 -15.112 96.O75 OO 69.99 
ATOM 708 ND2 ASN 397 59.782 - 16.839 96.110 OO 68.62 
ATOM 709 C ASN 397 59.052 - 18.854 97.837 OO 64.94 
ATOM 710 O ASN 397 59.583 -19.946 98.06S OO 64.91 
ATOM 711 N GLY 410 45.948 -11180 107.879 OO 61.02 
ATOM 712 CA GLY 45.413 -9.847 107.656 OO 62.50 
ATOM 713 C GLY 44.155 -9569 108.466 OO 62.44 
ATOM 714 O GLY 44.097 -9.849 109.668 OO 63.35 
ATOM 715 N SER 43.145 -9.007 107.814 OO 61.14 
ATOM 716 CA. SER 
ATOM 717 CB SER 
ATOM 718 OG SER 
ATOM 719 C SER 
ATOM 720 O SER 
ATOM 721 N AS 
ATOM 722 CA AS 
ATOM 723 CB AS 
ATOM 724 CG AS 
ATOM 725 OD1 AS 
ATOM 726 OD2 AS 
ATOM 727 C AS 
ATOM 728 O AS 
ATOM 729 N TH 
ATOM 730 CA. TH 
ATOM 731. CB TH 
ATOM 732 OG1 TH 
ATOM 733 CG2 TH 
ATOM 734 C TH 
ATOM 735 O TH 
ATOM 736 N IL 
ATOM 737 CA IL 
ATOM 738 CB IL 
ATOM 739 CG2, IL 
ATOM 740 CG1 IL 
ATOM 741 CD1 IL 
ATOM 742 C IL 
ATOM 743 O. IL 
ATOM 744 N TH 
ATOM 745 CA. TH 
ATOM 746 CB TH 
ATOM 747 OG1 TH 
ATOM 748 CG2 TH 
41.893 -8.720 108.488 OO 60.04 
41.252 -7.461 107.913 OO 61.29 
39.982 -7.232 108.499 OO 62.93 
40.959 -9.902 108.295 OO 59.15 
40.857 - 10448. 107.197 OO 59.05 
40.278 - 10.28S 109.369 OO 57.82 
39.338 - 11.406 109.376 OO 56.24 
38.36O -11213 110.532 OO 59.37 
37.032 - 11.908 110.298 OO 63.07 
37.031 - 13.136 110.041 OO 64.07 
35.990 -11214 110.371 OO 65.25 
38.556 -11.681 108.082 OO 53.55 
38.694 - 12.746 107.475 OO 52.85 
37.715 - 10.73S 107.68O OO SO45 
36.918 - 10.892 106.472 OO 46.99 
35.415 - 10.527 106.742 OO 46.65 
34.929 -9.666 105.703 OO 46.90 
35.247 -9.813 108.078 OO 4453 
37.456 - 10.014 105.337 OO 44.78 
38.021 -8.9S4 105.58O OO 45.19 
37.311 - 10.471 104.099 OO 41.90 
37.744 -9.684 102.949 OO 39.73 
38.299 -10564 101.813 OO 38.13 
38.798 -9.697 10O.690 OO 36.56 
39.464 -11.408 102.316 OO 37.94 
39.966 -12.403 101.3OO OO 34.67 
36.474 -9.007 102.444 OO 39.45 
35.541 -9.682 102.OO8 OO 38.16 
36.420 - 7.683. 102.526 OO 39.33 
35.237 -6.956 102.071 OO 39.02 
34.868 -5.782 103.045 OO 4.O.S.S 
34.451 -6.313 104.313 OO 41.85 
33.731 -4.942 102.483 OO 39.85 
C 
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TABLE 1-continued 
The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
ATOM 749 C THR 
ATOM 750 O THR 
ATOM 751. N E 
ATOM 752 CA 
ATOM 753 CB 
ATOM 754 CG LE 
ATOM 755 CD1 LE 
ATOM 756 CD2 LE 
35.487 -6.410 100.671 OO 37.52 
36.386 -S.S92 100.458 OO 36.96 
34.683 - 6.887 99.722 OO 35.70 
34.772 -6.48O 98.323 OO 33.93 
34.459 - 7.669 97.422 OO 35.45 
35.609 -8.553 96.946 OO 36.03 
36.708 -8.616 98.004 OO 35.17 
35.046 -9.933 96.61O OO 35.12 
ATOM 757 C LE 33.831 -5.34O 97.949 OO 31.99 
ATOM 758 O LE 32.631 -5.392 98.222 OO 31.87 
ATOM 759 N PRO 34.366 -4.285 97.319 OO 29.92 
ATOM 760 CD PRO 35.782 -3.96S 97.067 OO 27.19 
ATOM 761 CA PRO 33.507 -3.169 96.929 OO 28.26 
ATOM 762 CB PRO 34.509 -2.052 96.705 OO 24.49 
ATOM 763 CG PRO 35.678 -2.776 96.162 OO 23.69 
ATOM 764 C PRO 32.747 -3.548 95.654 OO 28.94 
ATOM 765 O PRO 33.305 -4.21S 94.781 OO 29.04 
ATOM 766 N CYS 
ATOM 767 CA CYS 
ATOM 768 C CYS 
ATOM 769 O. CYS 
ATOM 77O CB CYS 
ATOM 771 SG CYS 
ATOM 772 N ARG 
ATOM 773 CA ARG 
ATOM 774 CB ARG 
ATOM 77S CG ARG 
ATOM 776 CD ARG 
ATOM 777 NE ARG 
ATOM 778. CZ ARG 
ATOM 779 NH1 ARG 
ATOM 780 NH2 ARG 
ATOM 781 C ARG 
31.476 -3.166 95.SS3 OO 30.16 
30.702 -3.472 94.348 OO 33.10 
29.782 -2.338 93.978 OO 32.71 
29.610 -1.387 94.731 OO 33.13 
29.808 -4.704 94-510 OO 35.70 
30.459 -6.095 95.454 OO 40.35 
29.167 -2.479 92.812 OO 33.12 
28.226 -1.499 92.315 OO 3348 
28.937 -0.474 91.418 OO 35.57 
28.028 O.673 91.009 OO 42.11 
28.395 1.296 89.654 OO 47.71 
29.270 2.464 89.754 OO SO.S4 
30.576 2.412 90.009 OO SO.62 
31.178 1240 90.1.89 OO 50.07 
31.279 3.538 90.093 OO 49.54 
27.163 -2.223 91...SO1 OO 31.21 
ATOM 782 O ARG 9 27.453 -3.223 90.848 OO 28.57 
ATOM 783 N LE 420 25.929 -1.736 91.567 OO 30.97 
ATOM 784 CA LE 420 24.845 -2.301 90.759 OO 31.92 
ATOM 785 CB LE 420 23.459 -2.2SS 91.482 OO 31.58 
ATOM 786 CG2 ILE 420 22.341 -2.527 90.491 OO 29.56 
ATOM 787 CG1 ILE 420 23.396 -3.3O8 92.583 OO 32.48 
ATOM 788 CD1 ILE 420 24.525 -3.201 93.579 OO 35.47 
ATOM 789 C LE 420 24.793 - 1.378 89.542 OO 31.56 
ATOM 790 O. LE 420 24.866 -0.161 89.687 OO 31.84 
ATOM 791 N LYS 421 24.687 -1938 88.349 OO 30.80 
ATOM 792 CA LYS 421 24.626 -1.104 87.163 OO 31.04 
ATOM 793 CB LYS 421 25.808 - 1418 86.259 OO 32.69 
ATOM 794 CG LYS 421 27.164 -1.194 86.883 OO 32.84 
ATOM 795 CD LYS 421 28.220 - 1.316 85.790 OO 33.11 
ATOM 796 CE LYS 421 29.583 -0.872 86.271 OO 32.74 
ATOM 797 NZ LYS 421 30.553 -0.859 85.147 OO 32.81 
ATOM 798 C LYS 421 23.32O -133O 86.4O1 OO 30.54 
ATOM 799 O LYS 421 22.72O -2.408 86.503 OO 30.70 
ATOM 800 N GLN 422 22.879 -0.319 85.651 OO 29.64 
ATOM 801 CA GLN 422 21.652 -0.428 84.859 OO 30.52 
ATOM 802 CB GLN 422 20.803 O.838 84.969 OO 30.67 
ATOM 8O3 CG GLN 422 20.06S O.997 86.279 OO 32.13 
ATOM 804 CD GLN 422 20.998 1.157 87.466 OO 33.77 
ATOM 805 OE1 GLN 422 21.823 2.081 87.514 OO 30.92 
ATOM 806 NE2 GLN 422 20.869 O.2SS 88.438 OO 34.85 
ATOM 807 C GLN 422 21.989 -0.669 83.395 OO 31.34 
ATOM 808 O GLN 422 21.162 -1.159 82.630 OO 31.50 
ATOM 809 N 423 23.213 -0.321 83.017 OO 32.09 
ATOM 810 CA 423 23.681 -0.5O1 81.650 OO 31.47 
ATOM 811 CB 423 24.22O O.82S 81.125 OO 30.44 
ATOM 812 CG2 IL 423 24.767 0.662 79.725 OO 29.43 
ATOM 813 CG1 IL 423 23.084 1842 81151 OO 29.90 
ATOM 814 CD1 IL 423 23.454 3.193 80.628 OO 30.47 
ATOM 815 C 423 24.727 - 1.62S 81.564 OO 32.OO 
ATOM 816 O 423 25.905 - 1.453 81.856 OO 33.10 
ATOM 817 N 424 24.241 -2.785 81.149 OO 33.21 
ATOM 818 CA 424 24.995 -4.022 81.017 OO 33.92 
ATOM 819 CB 424 24.055 -5.212 81.346 OO 34.97 
ATOM 820 CG2 IL 424 24.828 -6.487 81.526 OO 35.83 
ATOM 821 CG1 IL 424 23.264 -4.900 82.605 OO 37.56 
ATOM 822 CD1 IL 424 24.141 -4.483 83.764 OO 40.47 
ATOM 823 C 424 25.529 -4.276 79.609 OO 33.77 
ATOM 824 O 424 25.094 -3.670 78.644 OO 34.71 
ATOM 825 N ASN 425 26.481 -5.194 79.515 OO 34.13 
ATOM 826 CA. ASN 425 27.033 -5.649 78.244 OO 33.45 
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TABLE 1-continued 
The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
ATOM 827 CB ASN 425 28.559 -5.655 78.279 OO 33.20 
ATOM 828 CG ASN 425 29.174 -4.SS6 77.438 OO 32.66 
ATOM 829 OD1 ASN 425 28.619 -4.149 76.414 OO 30.45 
ATOM 830 ND2 ASN 425 30.346 -4.087 77.855 OO 32.53 
ATOM 831 C ASN 425 26.536 - 7.081 78.347 OO 33.79 
ATOM 832 O ASN 425 27.053 -7.826 79.167 OO 33.77 
ATOM 833 N MET 426 25.539 -74.71 77.554 OO 35.05 
ATOM 834 CA MET 426 24.974 -8.827 77.653 OO 36.48 
ATOM 835 CB MET 426 23.788 -8.98O 76.698 OO 37.46 
ATOM 836 CG MET 426 22.690 -7.9S4 76.921 OO 42.17 
ATOM 837 SD MET 426 21.033 -8496 76.443 OO 47.19 
ATOM 838 CE MET 426 21.110 -8.248 74.701 OO 47.57 
ATOM 839 C MET 426 25.928 - 10.006 77.447 OO 37.83 
ATOM 840 O MET 426 27.017 -9.867 76.885 OO 37.54 
ATOM 841 N TRP 427 25.506 - 11:176 77.916 OO 39.73 
ATOM 842 CA TRP 427 26.304 - 12.386 77.770 OO 41.17 
ATOM 843 CB TRP 427 26.323 - 13.179 79.085 OO 42.99 
ATOM 844 CG TRP 427 24.959 -13.SS6 79.621 OO 45.82 
ATOM 845 CD2 TRP 427 24.303 - 14.822 79.485 OO 46.8O 
ATOM 846 CE2, TRP 427 23.034 -14.709 80.100 OO 47.OO 
ATOM 847 CE3 TRP 427 24.662 - 16.044 78.899 OO 47.97 
ATOM 848 CD1 TRP 427 24.087 -12.748 80.300 OO 47.O3 
ATOM 849 NE1 TRP 427 22.929 -13.434 80.591 OO 47.49 
ATOM 850 CZ2 TRP 427 22.124 -15763 80.143 OO 47.71 
ATOM 851 CZ3 TRP 427 23.756 -17.097 78.944 OO 48.88 
ATOM 852 CH2 TRP 427 22.500 - 16.947 79.562 OO 49.07 
ATOM 853 C TRP 427 25.812 - 13.284 76.632 OO 41.19 
ATOM 854 O TRP 427 26.607 - 13.964 76.000 OO 41.60 
ATOM 855 N. CYS 428 24.509 - 13.272 76.363 OO 42.OO 
ATOM 856 CA CYS 428 23.922 - 14.101 75.308 OO 44.36 
ATOM 857 C CYS 428 24410 - 13.749 73.917 OO 44.OO 
ATOM 858 O CYS 428 24.887 - 14.616 73.176 OO 44.48 
ATOM 859 CB CYS 428 22.394 -14.O23 75.381 OO 47.62 
ATOM 860 SG CYS 428 21.874 -14.854 76.914 OO 57.16 
ATOM 861 N LYS 429 24.290 - 12.479 73.SS7 OO 43.21 
ATOM 862 CA LYS 429 24.7SO - 12.01S 72.263 OO 41.60 
ATOM 863 CB LYS 429 23.569 -11.882 71.307 OO 42.35 
ATOM 864 CG LYS 429 22.384 -11.156 71.883 OO 43.72 
ATOM 865 CD LYS 429 21.248 -11.148 70.901 OO 45.78 
ATOM 866 CE LYS 429 2O.OS3 -10.418 71.475 OO 47.56 
ATOM 867 NZ LYS 429 18.901 - 10.4OS 70.517 OO SO.92 
ATOM 868 C LYS 429 25.423 -10.673 72.495 OO 40.41 
ATOM 869 O LYS 429 25.256 - 10.073 73.SS3 OO 40.49 
ATOM 870 N VAL 430 26.193 -10.213 71.521 OO 39.52 
ATOM 871 CA VAL 430 26.879 -8.944 71.645 OO 39.11 
ATOM 872 CB VAL 430 27.937 -8.791 70.532 OO 37.84 
ATOM 873 CG1 VAL 430 28.489 -7.380 70.507 OO 39.67 
ATOM 874 CG2 WAL 430 29.073 -9.761 70.743 OO 35.62 
ATOM 875 C VAL 430 25.914 -7.764 71.573 OO 40.33 
ATOM 876 O VAL 430 25.783 -7.136 7.O.S39 OO 42.24 
ATOM 877 N. CYS 431 25.211 -747O 72.657 OO 41.16 
ATOM 878 CA CYS 431 24.291 -6.326 72.682 OO 43.40 
ATOM 879 C CYS 431 24499 -S.S3O 73.970 OO 42.17 
ATOM 880 O CYS 431 25.OOO -6.O62 74.964 OO 43.09 
ATOM 881 CB CYS 431 22.835 -6.780 72.668 OO 48.10 
ATOM 882 SG CYS 431 22.257 -7.836 71.299 OO 60.95 
ATOM 883 N LYS 432 24.119 -4.2S7 73.960 OO 38.87 
ATOM 884 CA LYS 432 24.226 -3.454 75.164 OO 36.15 
ATOM 885 CB LYS 432 24.86O -2.104 74.846 OO 35.67 
ATOM 886 CG LYS 432 25.975 - 1.723 75.807 OO 37.19 
ATOM 887 CD LYS 432 26.857 -0.647 75.192 OO 39.70 
ATOM 888 CE LYS 432 28.075 -0.33S 76.058 OO 42.82 
ATOM 889 NZ LYS 432 28.992 - 1.509 76.255 OO 42.87 
ATOM 890 C LYS 432 22.794 -3.297 75.680 OO 35.02 
ATOM 891. O LYS 432 21.888 -3.024 74.909 OO 35.60 
ATOM 892 N ALA 433 22.574 -3497 76.972 OO 33.36 
ATOM 893 CA. ALA 433 21.226 -3.385 77.500 OO 33.09 
ATOM 894 CB ALA 433 20.714 -4.753 77.881 OO 33.61 
ATOM 895 C ALA 433 21.156 -246O 78.696 OO 34.02 
O 
N 
ATOM 896 ALA 433 22.129 -2.309 79.420 OO 35.31 
ATOM 897 MET 434 2O.OO6 -1830 78.908 OO 34.39 
ATOM 898 CA MET 434 19.853 -0.927 80.043 OO 34.19 
ATOM 899 CB MET 434 19.688 0.522 79.577 OO 34.29 
ATOM 900 CG MET 434 19.537 1.519 80.722 OO 35.19 
ATOM 901 SD MET 434 18.772 3.088 80.230 OO 38.57 
ATOM 902 CE MET 434 17.017 2.778 80598 OO 37.43 
ATOM 903 C MET 434 18.626 -1328 80.841 OO 34.05 
ATOM 904 O MET 434 17.522 - 1.387 80.307 OO 35.74 
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TABLE 1-continued 
The structural coordinates of an exemplary stabilized form of gp120 at atomic resolution 
ATOM 905 N TYR 435 8.817 -1.602 82.123 OO 32.51 
ATOM 906 CA TYR 435 7.709 -1984 82.973 OO 30.96 
ATOM 907 CB TYR 435 8.106 -3.184 83.822 OO 29.29 
ATOM 908 CG TYR 435 8.339 -4.417 82.992 OO 25.84 
ATOM 909 CD1 TYR 435 9.560 -4.636 82.365 OO 25.45 
ATOM 910 CE1 TYR 435 9.745 -5.711. 81.524 OO 24.61 
ATOM 911. CD2 TYR 435 7.311 -5.314 82.760 OO 23.29 
ATOM 912 CE2 TYR 435 7.482 -6.382 81924 OO 24.52 
ATOM 913. CZ TYR 435 8.699 -6.581 81.305 OO 24.68 
ATOM 914 OH TYR 435 8.847 - 7.648 80.450 OO 26.95 
ATOM 915 C TYR 435 7.313 -0.828 83.859 OO 32.33 
ATOM 916 O TYR 435 8.OO1 O.195 83.892 OO 33.56 
ATOM 917 N ALA 436 6.2O3 -0.984 84.576 OO 32.62 
ATOM 918 CA ALA 436 5.736 OO67. 85.473 OO 33.64 
ATOM 919 CB ALA 436 4.236 -0.064 85.698 OO 31.13 
ATOM 920 C ALA 436 6.494 -0.003 86.813 OO 35.55 
ATOM 921 O ALA 436 7.025 - 1.058 87.199 OO 36.85 
ATOM 922 N PRO 437 6.580 1.132 87.527 OO 35.03 
ATOM 923 CD PRO 437 6.171 2.473 87.084 OO 34.29 
ATOM 924 CA PRO 437 7.270 1198 88.817 OO 34.44 
ATOM 925 CB PRO 437 7.150 2.66S 89.182 OO 35.20 
ATOM 926 CG PRO 437 7.130 3.339 87.833 OO 35.19 
ATOM 927 C PRO 437 6.572 O.287 89.825 OO 35.06 
ATOM 928 O PRO 437 S.471 -0.2OO 89.562 OO 36.23 
ATOM 929 N PRO 438 7.188 O.OS1 90.994 OO 33.79 
ATOM 930 CD PRO 438 8.576 O.364 91.356 OO 33.35 
ATOM 931 CA PRO 438 6.587 -0.82O 92.008 OO 34.09 
ATOM 932 CB PRO 438 7.729 -1.028 92.994 OO 33.97 
ATOM 933 CG PRO 438 8.947 -0.849 92.167 OO 33.01 
ATOM 934 C PRO 438 5.343 -0.263 92.694 OO 3S4O 
ATOM 935 O PRO 438 S.116 O.945 92.706 OO 35.71 
ATOM 936 N LE 439 4.524 -1.151 93.253 OO 36.30 
ATOM 937 CA LE 439 3.333 -0.707 93.962 OO 36.39 
ATOM 938 CB LE 439 2008 -1.142 93.261 OO 34.37 
ATOM 939 CG2 ILE 439 2.OO3 -0.699 91.836 OO 34.23 
ATOM 940 CG1 ILE 439 1845 -2.653 93.288 OO 3539 
ATOM 941 CD1 ILE 439 O469 -3.098 92.843 OO 34.29 
ATOM 942 C LE 439 3.367 -1.242 95.393 OO 37.68 
ATOM 943 O. LE 439 2.507 -0.911 96.204 OO 39.13 
ATOM 944 N SER 440 4.364 -2.062 95.705 OO 37.37 
ATOM 945 CA. SER 440 4491 -2.584 97.057 OO 39.32 
ATOM 946. CB SER 440 4.604 -4.104 97.054 OO 40.44 
ATOM 947 OG SER 440 4.933 -4.568 98.362 OO 40.66 
ATOM 948 C SER 440 S.707 - 2011 97.774 OO 40.33 
ATOM 949 O SER 440 6.679 -1.597 97.13S OO 41.36 
ATOM 950 N GLY 441 5.646 -1994 99.102 OO 40.54 
ATOM 951 CA GLY 441 6.752 -1.482 99.890 OO 42.17 
ATOM 952 C GLY 441 7.425 -2.604 100.659 OO 43.06 
ATOM 953 O GLY 441 8.367 -2.392 101.437 OO 42.78 
ATOM 954 N. GLN 442 6.920 -3.811 100.439 OO 43.64 
ATOM 9.SS CA GLN 442 7.445 -4.997 101.085 OO 44.67 
ATOM 956 CB GLN 442 6.475 -S.47S 102.175 OO 45.38 
ATOM 957 CG GLN 442 6.864 -SO3O 103.587 OO 47.90 
ATOM 958 CD GLN 442 5.7SO -5.219 104.621 OO 49.44 
ATOM 959 OE1 GLN 442 4.751 -4.495 104.599 OO SO.66 
ATOM 960 NE2 GLN 442 S.921 -6.190 105.530 OO 47.39 
ATOM 961 C GLN 442 7.679 -6.080 100.035 OO 44.84 
ATOM 962 O GLN 442 6.909 - 7.032 99.904 OO 44.57 
ATOM 963 N ILE 443 8.755 -5.908 99.278 OO 45.49 
ATOM 964 CA ILE 443 9.132 - 6.851 98.236 OO 46.47 
ATOM 965 CB ILE 443 9.492 - 6.092 96.941 OO 45.56 
ATOM 966 CG2 ILE 443 20.064 - 7.039 95.908 OO 44.09 
ATOM 967 CG1 ILE 443 8.238 -5.392 96.411 OO 4S.O7 
ATOM 968 CD1 ILE 443 8.433 -4.604 95.153 OO 44.19 
ATOM 969 C ILE 443 20.328 - 7.651 98.744 OO 47.21 
ATOM 970 O ILE 443 21449 -7.142 98.782 OO 47.84 
ATOM 971 N ARG 444 20.087 -8.899 99.13S OO 47.05 
ATOM 972 CA ARG 444 21.1SO -9.732 99.681 OO 48.36 
ATOM 973 CB ARG 444 20.856 -10.036 101.152 OO SO.OO 
ATOM 974 CG ARG 444 20.436 -8.837 101.994 OO 52.86 
ATOM 975 CD ARG 444 21.439 -8.53S 103.105 OO SS.04 
ATOM 976 NE ARG 444 20.951 -7.5OO 104.017 OO 59.88 
ATOM 977 CZ ARG 444 20.629 -6.2SS 103.659 OO 61.86 
ATOM 978 NH1 ARG 444 20.193 -5.391 104.570 OO 62.57 
ATOM 979 NH2 ARG 444 20.741 -5.862 102.395 OO 6240 
ATOM 980 C ARG 444 21.361 -11.052 98.948 OO 48.73 
ATOM 981 O ARG 444 20.405 -11.671 98.481 OO 49.67 
ATOM 982 N CYS 445 22.619 -11479 98.849 OO 48.63 
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ATOM 983 CA CYS 445 22.956 -12749 98.212 OO 47.62 
ATOM 984 C CYS 445 24.029 - 13.5O2 98.946 OO 45.78 
ATOM 985 O CYS 445 25.207 - 13.129 98.931 OO 45.76 
ATOM 986 CB CYS 445 23.392 - 12.574 96.762 OO SO.80 
ATOM 987 SG CYS 445 21.966 -12871 95.692 OO 57.24 
ATOM 988 N SER 446 23.595 - 14.574 99.589 OO 42.24 
ATOM 989 CA. SER 446 24.471 -15438 100.339 OO 39.56 
ATOM 990 CB SER 446 23.764 -1588S 101.600 OO 40.45 
ATOM 991 OG SER 446 22.870 -14.868. 102.024 OO 43.28 
ATOM 992 C SER 446 24.667 - 16.613 99.417 OO 37.50 
ATOM 993 O SER 446 23.767 - 17424 99.252 OO 37.85 
ATOM 994 N SER 447 25.833 - 16.693 98.795 OO 34.81 
ATOM 995 CA. SER 447 26.095 - 17.78O 97.881 OO 33.45 
ATOM 996 CB SER 447 26.331 - 17.227 96.485 OO 34.56 
ATOM 997 OG SER 447 25.323 - 16.307 96.128 OO 36.68 
ATOM 998 C SER 447 27.300 -18.588 98.300 OO 32.91 
ATOM 999 O SER 447 28.088 -18.178 99.151 OO 33.16 
ATOM 2000 N ASN 448 27.432 - 19.7SS 97.697 OO 32.65 
ATOM 2001 CA. ASN 448 28.561 -20.62O 97.970 OO 33.16 
ATOM 2002 CB ASN 448 28.088 -22O19 98.361 OO 3597 
ATOM 2003 CG ASN 448 27.950 - 22.184 99.852 OO 41.24 
ATOM 2004 OD1 ASN 448 28.938 -22.162 100.574 OO 42.95 
ATOM 2005 ND2 ASN 448 26.727 - 22.357 100.331 OO 46.28 
ATOM 2006 C ASN 448 29.444 -20.7O6 96.731 OO 31.71 
ATOM 2007 O ASN 448 29.005 -21.162 95.668 OO 30.58 
ATOM 2008 N ILE 449 30.675 -20.222 96.862 OO 29.84 
ATOM 2009 CA ILE 449 31.645 -20.292 95.772 OO 27.37 
ATOM 2010 CB ILE 449 32.980 -19.595 96.137 OO 25.12 
ATOM 2011 CG2 ILE 449 34.005 -19.817 95.040 OO 24.87 
ATOM 2012 CG1 ILE 449 32.766 -18.11O 96.374 OO 22.91 
ATOM 2013 CD1 ILE 449 34.006 - 17435 96.882 OO 2004 
ATOM 2014 C ILE 449 31.929 -21.784 95.734 OO 27.61 
ATOM 2015 O ILE 449 32.2O3 - 22.373 96.785 OO 29.12 
ATOM 2016 N THR 450 31.854 -22409 94.567 OO 25.09 
ATOM 2017 CA. THR 450 32.134 -23.836 94.5O1 OO 24.31 
ATOM 2018 CB THR 450 30.832 -24.667 94.295 OO 24.01 
ATOM 2019 OG1 THR 450 30.135 -24.223 93.121 OO 23.07 
ATOM 2020 CG2 THR 450 29.927 -24.523 95.489 OO 22.78 
ATOM 2021 C THR 450 33.108 -24.109 93.368 OO 24.60 
ATOM 2022 O THR 450 33.469 -25.248 93.088 OO 23.80 
ATOM 2023 N GLY 451 33.542 -23.042 92.718 OO 2SO4 
ATOM 2024 CA GLY 451 34.470 -23.2OO 91.62O OO 26.73 
ATOM 2025 C GLY 451 34.924 -21.855 91.118 OO 26.65 
ATOM 2026 O GLY 451 34.370 -20.828 91...SOS OO 27.30 
ATOM 2027 N LEU 452 35.945 -21.851 90.273 OO 26.29 
ATOM 2028 CA 
ATOM 2029 CB 
ATOM 2030 CG 
ATOM 2031 CD1 
ATOM 2032 CD2 LE 
ATOM 2033 C LE 
ATOM 2034 O LE 
452 36.439 -20.592 89.739 OO 27.72 
452 37.798 -20.211 90.351 OO 2SO3 
452 37.865 -19.937 91.850 OO 23.22 
452 37.792 -21.248 92.592 OO 22.91 
452 39.1SO -19.225 92.198 OO 2212 
452 36.602 -20.72O 88.249 OO 27.91 
452 36.381 -21.784 87.678 OO 30.44 
453 36.983 -1962O 87.626 OO 25.60 
453 37.223 -19.6OS 86.211 OO 24.90 
453 36.071 -18.936 85.473 OO 21.07 
453 34.724 - 19.652 85.532 OO 16.96 
453 33.754 -18.93O 84.649 OO 17.51 
453 34.850 -21.061 85.077 OO 13.58 
453 38.485 -18.79O 86.124 OO 27.06 
453 38.458 -17.568 86.262 OO 28.02 
454 39.602 - 1948O 85.936 OO 28.63 
454 40.889 -18.809 85.862 OO 30.83 
454 41898 -19.483 86.789 OO 29.19 
454 41.646 -19.667 88.277 OO 28.21 
454 42.802 -20.46O 88.863 OO 28.15 
454 41.527 -18.331 88.961 OO 28.25 
454 41.474 -18.815 84.465 OO 32.86 
LEU 
ATOM 2035 N 
ATOM 2036 CA 
ATOM 2037 CB 
ATOM 2038 CG 
ATOM 2039 CD1 
ATOM 2040 CD2 
ATOM 2041 C 
ATOM 2042 O 
ATOM 2043 N 
ATOM 2044 CA 
ATOM 204S CB 
ATOM 2046 CG 
ATOM 2047 CD1 
ATOM 2048 CD2 
ATOM 2049 C 
ATOM 2050 O LEU 454 41.103 -19631 83.622 OO 33.87 
ATOM 2051 N THR 455 42.415 -17.904 84.248 OO 34.41 
ATOM 2052 CA THR 455 43.123 -17.791 82.984 OO 37.13 
ATOM 2053 CB THR 455 42.759 -16.519 82.2SO OO 38.41 
ATOM 2054 OG1 THR 455 41.340 - 16.467 82.075 OO 41.71 
ATOM 2055 CG2 THR 455 43.438 - 16.491 80.893 OO 38.74 
ATOM 2056 C THR 455 44591 -17.716 83.344 OO 38.29 
ATOM 2057 O THR 455 44.943 -17.138 84.367 OO 38.34 
ATOM 2058 N ARG 456 45.450 -18.289 82.508 OO 39.99 
ATOM 2059 CA. ARG 456 46.881 - 18.277 82.783 OO 41.61 
ATOM 2060 CB ARG 456 47.424 -19.698 82.719 OO 42.OO 
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48.889 
49.323 
49.147 
50.117 
49.857 
51.348 
47.664 
47.66S 
48.333 
49.124 
49.969 
49.169 
49.798 
47.921 
SO.OS1 
49.941 
50.975 
S1898 
52.751 
53.043 
S3.145 
53.980 
SS.443 
55.830 
56.254 
57.694 
58.357 
57.866 
56.884 
S8.543 
58.409 
58.412 
S9.021 
59.771 
58.858 
59.608 
60.368 
59.649 
61.682 
62.399 
63.877 
64.408 
64320 
64.963 
62.248 
62.664 
61.648 
61.379 
60.737 
60.656 
60.296 
60.976 
60.392 
59.372 
60.684 
59.788 
60.598 
61.323 
62.120 
62.812 
62.OSS 
58.765 
S8.986 
57.639 
56.516 
56.918 
57.130 
55.356 
55.526 
54.184 
52.994 
52.200 
S2.956 
S3.221 
54:153 
52.492 
S2.110 
52.057 
-19811 
-21:250 
-21.774 
-21.842 
-22.331 
-21439 
-17389 
-17.626 
-16.371 
-15-451 
-14.515 
-13.352 
-12.434 
- 13.3SS 
-16.199 
-16.088 
-16.959 
-17.712 
-16.795 
-15659 
-17.288 
-16.494 
-16.727 
-16.889 
-16.73S 
-16.954 
-16.575 
-17.426 
-18.16.1 
-17.323 
-16.242 
-15.010 
-17.051 
-16.582 
-15.82O 
-15.227 
-17.804 
-18.579 
-17.979 
-19101 
-19.043 
-17.626 
-16.891 
-17.230 
-19.078 
-21.833 
-22.608 
-23.814 
-24.457 
-24.121 
-20185 
-2O303 
- 19.677 
-19.200 
-17974 
-16.853 
-18.818 
-18O16 
- 19.397 
-19.126 
-20.413 
-21470 
-21.049 
-21.608 
-2O165 
-18.087 
-18O15 
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39 N 
40 CA 
41 CB 
42 CG2 
43 CG1 
44 CD1 
45 C 
46 O 
47 N 
48 CA 
49 CB 
SO CG 
S1 CD1 
52 CD2 
53 CE1 
54 CE2 
55 CZ 
56 
57 
58 
S9 CA 
6O CB 
61 CG 
62 CD 
63 NE 
64 CZ 
6S NH1 
66 NH2 
67 C 
68 O 
69 N 
70 CD 
71 CA 
72 CB 
73 CO 
74 C 
75 O 
76 N 
77 CA 
78 
79 
8O 
81 
82 
83 
84 
85 
86 
87 
88 
89 CA 
90 CB 
91 CG 
92 OD1 
93 OD2 
94 C 
95 O 
96 N 
97 CA 
98 CB 
2199 CG 
2200 SD 
22O1 CE 
22O2 C 
22O3 O 
2204 N 
2205 CA 
2206 CB 
2207 CG 
2208 CD 
2209 NE 
221 O CZ 
2211 NH1 
2212 NH2 
2213 C 
2214 O 
2215 N 
2216 CA 
e 
C 
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51419 
S.O.S43 
SO.903 
SO.1.89 
52.410 
52.829 
49.1OO 
48.817 
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ATOM 2295 CD LYS 485 29.109 -35.779 87.115 OO 
ATOM 2296 CE LYS 485 28.091 -34.913 87.862 OO 
ATOM 2297 NZ LYS 485 28.190 -35.067 89.3SO OO 
ATOM 2298 C LYS 485 29.230 -36. SS7 82.686 OO 
ATOM 2299 O LYS 485 28.637 -37.547 83.1OS OO 
ATOM 2300 N TYR 486 28.876 -35.931 81.568 OO 
ATOM 2301 CA TYR 486 27.7SO -36.389 80.767 OO 
ATOM 2302 CB TYR 486 26.523 -35.492 80.970 OO 
ATOM 23O3 CG TYR 486 25.915 -35.521 82.350 OO 
ATOM 2304 CD1 TYR 486 26.240 -34.5SO 83.299 OO 
ATOM 2305 CE1 TYR 486 25.677 -34.577 84.576 OO 
ATOM 2306 CD2 TYR 486 25.011 -36.514 82.709 OO 
ATOM 2307 CE2 TYR 486 24.445 -36.5SO 83.979 OO 
ATOM 2308. CZ TYR 486 24.777 -35.583 84.904 OO 
ATOM 2309 OH TYR 486 24.22O -35.624 86.158 OO 
ATOM 2310 C TYR 486 28.089 -36.382 79.291 OO 
ATOM 2311 O TYR 486 29.078 -35.796 78.866 OO 
ATOM 2312 N LYS 487 27.249 -37.041 78.509 OO 
ATOM 2313 CA LYS 487 27.413 -37.090 77.070 OO 
ATOM 2314 CB LYS 487 28.638 -37.91S 76.670 OO 
ATOM 2315 CG LYS 487 28.399 -39.4O1 76.615 OO 
ATOM 2316 CD LYS 487 29.518 -40.088 75.855 OO 
ATOM 2317 CE LYS 487 29.612 -39594 74.405 OO 
ATOM 2318. NZ LYS 487 30.745 -40.213 73.638 OO 
ATOM 2319 C LYS 487 26.149 -37.724 76.527 OO 
ATOM 2320 O LYS 487 25.597 -38.640 77.1.28 OO 
ATOM 2321 N VAL 488 25.682 -37.217 75.400 OO 
ATOM 2322 CA VAL 488 24.475 -37.729 74.790 OO 
ATOM 2323 CB VAL 488 23.SS8 -36.554 74.409 OO 
ATOM 2324 CG1 VAL 488 24.209 -35.72O 73.338 OO 
ATOM 2325 CG2 WAL 488 22.214 -37.OS6 73.966 OO 
ATOM 2326 C VAL 488 24.864 -3.8.554 73.SS7 OO 
ATOM 2327 O VAL 488 25.888 -38.290 72.927 OO 
ATOM 2328 N VAL 489 24.07O -39.57O 73.223 OO 
ATOM 2329 CA VAL 489 24.383 -40.403 72.060 OO 
ATOM 233O CB VAL 489 25.341 -41.573 72.438 OO 
ATOM 2331 CG1 VAL 489 24.659 -42.513 73.409 OO 
ATOM 2332 CG2 WAL 489 25.783 -42.316 71.178 OO 
ATOM 2333 C VAL 489 23.161 -40.983 71.344 OO 
ATOM 2334 O VAL 489 22.115 -41.249 71.956 OO 
ATOM 2335 N LYS 490 23.317 -41.163 70.033 OO 
ATOM 2336 CA LYS 490 22.272 -41.708 69.179 OO 
ATOM 2337 CB LYS 490 22.757 -41.833 67.729 OO 
ATOM 2338 CG LYS 490 23.172 -40.539 67.031 OO 
ATOM 2339 CD LYS 490 24493 -39.974 67.570 OO 
ATOM 2340 CE LYS 490 25.132 -38.975 66.597 OO 
ATOM 2341 NZ LYS 490 24.183 -37.926 66.111 OO 
ATOM 2342 C LYS 490 21928 -43.094 69.671 OO 
ATOM 2343 O LYS 490 22.825 -43.917 69.873 OO 
ATOM 2344 N LE 491 20.642 -43.364 69.868 OO 
ATOM 2345 CA LE 491 20.237 -44.697 70.303 OO 
ATOM 2346 CB LE 491 18.861 -44.685 70.982 OO 
ATOM 2347 CG2 ILE 491 18.641 -45.994 71.698 OO 
ATOM 2348 CG1 ILE 491 18.776 -43.545 71.983 OO 
ATOM 2349 CD1 ILE 491 17.409 -43.403 72594 OO 
ATOM 23SO C LE 491 20.144 -45.57O 69.045 OO 
ATOM 23S1 O LE 491 19.728 -45.038 67.989 OO 
ATOM 2352 OXT ILE 491 20.478 -46.769 69.127 OO 
END 
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VII. Crystals of gp120 with an Extended V3 Loop 
The present disclosure further relates to the crystal struc 
ture of gp120 in which the V3 loop is in an extended confor 
mation. The present disclosure also relates to the crystals 
obtained from a gp120 polypeptide with an extended V3 loop. 
The three-dimensional coordinates of a gp120 polypeptide 
with an extended V3 loop, three-dimensional structures of 
models of a gp120 polypeptide with an extended V3 loop, and 
uses of these models. The amino acid sequence of a gp120 
polypeptide with an extended V3 loop variant is set forth as 
SEQID NO: 2. 
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The structure of a gp120 polypeptide with an extended V3 
loop was solved in complex with the X5 Fab and the d1 d2 
domain of the CD4 receptor. Analysis of the structure 
revealed that the V3 loop was present in an elongated confor 
mation that was previously not seen in other complexes 
involving the gp120 protein. An advantageous feature of this 
crystal structure over previous structures is the organization 
of the V3 loop in an elongated conformation, compatible with 
the elicitation of immunodominant antibody response. Table 
2 provides the atomic coordinates of the crystal structure of 
the polypeptide disclosed in SEQID NO: 2. 
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The structural coordinates of an exemplary gp120 with an ex 
313 
314 
315 
316 
317 
3.18 
319 
320 
321 
322 
323 
324 
325 
326 
327 
328 
329 
330 
331 
332 
333 
334 
335 
336 
337 
338 
339 
340 
341 
342 
343 
344 
345 
346 
347 
348 
349 
350 
351 
352 
353 
3S4 
355 
356 
357 
358 
359 
360 
361 
362 
363 
364 
365 
366 
367 
368 
369 
370 
371 
372 
373 
374 
375 
376 
377 
378 
379 
380 
381 
382 
383 
384 
385 
386 
387 
388 
389 
390 
O 
CB 
CG 
CD 
CE 
NZ 
N 
CA 
C 
O 
CB 
CG 
CD1 
CD2 
CA 
CB 
OG1 
CA 
CB 
CD 
CA 
CB 
CD1 
CD2 
CA 
CB 
SG 
CA 
CB 
LYS 
LYS 
LYS 
LYS 
LYS 
LYS 
EU 
EU 
EU 
EU 
EU 
EU 
EU 
EU 
HR 
HR 
HR 
HR 
HR 
HR 
HR 
RO 
RO 
RO 
RO 
RO 
RO 
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TABLE 2-continued 
21 
21 
21 
21 
21 
21 
22 
22 
22 
22 
22 
22 
22 
22 
23 
23 
23 
23 
23 
23 
23 
24 
24 
24 
24 
24 
24 
24 
25 
25 
25 
25 
25 
25 
25 
25 
26 
26 
26 
26 
26 
26 
27 
27 
27 
27 
27 
27 
27 
28 
28 
28 
28 
29 
29 
29 
29 
29 
30 
30 
30 
30 
95 
95 
95 
95 
95 
95 
96 
96 
96 
96 
96 
96 
97 
97 
97 
97 
81,131 
81.033 
81.448 
80.779 
81.061 
80.615 
83.233 
83473 
83.757 
84.701 
84657 
84.274 
83.608 
85.521 
82.938 
83.092 
83.058 
82.259 
81.968 
81.834 
82.256 
83.927 
83.953 
82.656 
82.392 
85.163 
86.068 
85.075 
81.838 
80.575 
80.861 
80624 
79.648 
78.192 
77.403 
77.599 
81.378 
81708 
80.573 
80.494 
82.901 
84.494 
79.696 
78.566 
78.834 
79.182 
77.241 
77.304 
76.075 
78.684 
78.941 
80.436 
81.051 
81.009 
82.439 
83.240 
84.144 
82.632 
82.913 
83.615 
84.OOS 
83.255 
85.182 
85.705 
84.590 
83.538 
86.570 
87.524 
84.830 
83.821 
83.992 
84.973 
83.720 
84.469 
83.008 
82.992 
82.935 
82.951 
21.337 
24.260 
25.664 
26.073 
27.533 
27.906 
21.767 
2O394 
20.376 
21.010 
9.785 
8.875 
9.695 
8.189 
9.641 
9.563 
8.134 
ended V3 loop 
36.959 
36.099 
35.700 
34.387 
34.049 
32.674 
36.290 
35.863 
34.371 
33.905 
36.611 
37.779 
38.873 
38.306 
33.629 
32.186 
31.670 
32.126 
31.489 
32.076 
30.011 
30.700 
30.148 
29.415 
28.346 
29.211 
29.882 
30.199 
29.994 
29.366 
28.2SO 
28.406 
30.398 
29.992 
30.161 
3O874 
27.1.28 
26.O16 
25.057 
23.953 
25.236 
26.046 
25.497 
24.693 
24.326 
25.187 
25.483 
26.721 
24.595 
23.048 
22.614 
22.541 
23.527 
21.367 
21.102 
22.232 
22.787 
19819 
22.558 
23.621 
24.763 
25.104 
25.341 
26.454 
27.275 
27.495 
27.345 
26.567 
27.740 
28.490 
30.010 
30.58O 
27.931 
26.286 
30.649 
32.095 
32.366 
31431 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
76.19 
72.94 
75.20 
77.11 
78.09 
79.45 
76.38 
79.17 
81.74 
82.55 
79.45 
78.85 
77.90 
79.94 
85.43 
90.13 
93.59 
94.38 
91.32 
93.24 
912S 
97.34 
OO.80 
O3S1 
O4.31 
OO.91 
OO.12 
98.73 
O7.90 
12.76 
16.09 
16.30 
1340 
13.32 
14.30 
14.10 
1958 
22.9S 
25.81 
26.35 
22.36 
21.90 
29.15 
31.76 
32.26 
32.30 
32.38 
33.33 
33.20 
31.94 
31.82 
31.76 
31.75 
31.69 
31.75 
32.17 
32.86 
31.22 
31.78 
30.67 
30.19 
30.65 
28.61 
26.30 
25.16 
25.28 
25.36 
21.97 
22.96 
20.58 
1842 
1788 
20.97 
22.59 
15:33 
1291 
11.21 
1148 
116 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
The structural coordinates of an exemplary gp120 with an ex 
391 
392 
393 
394 
395 
396 
397 
398 
399 
400 
401 
402 
403 
404 
40S 
406 
407 
408 
409 
410 
411 
412 
413 
414 
415 
416 
417 
418 
419 
420 
421 
422 
423 
424 
425 
426 
427 
428 
429 
430 
431 
432 
433 
434 
435 
436 
437 
438 
439 
440 
441 
442 
443 
444 
445 
446 
447 
448 
449 
450 
451 
452 
453 
454 
455 
456 
457 
458 
459 
460 
461 
462 
463 
464 
465 
466 
467 
468 
CB 
CG 
OD1 
OD2 
N 
CA 
C 
O 
CB 
OG1 
CG2 
CA 
CB 
OG 
CA 
CA 
CA 
CA 
CB 
CG 
CD 
OE1 
NE2 
ASP 
ASP 
ASP 
ASP 
THR 
THR 
THR 
THR 
THR 
THR 
THR 
SER 
SER 
SER 
SER 
SER 
SER 
VAL 
VAL 
VAL 
VAL 
VAL 
VAL 
VAL 
ILE 
ILE 
ILE 
ILE 
ILE 
ILE | E. 
LA 
N 
117 
US 8,715,686 B2 
TABLE 2-continued 
97 
97 
97 
97 
98 
98 
98 
98 
98 
98 
98 
99 
99 
99 
99 
99 
99 
2OO 
2OO 
2OO 
2OO 
2OO 
2OO 
2OO 
2O1 
2O1 
2O1 
2O1 
2O1 
2O1 
2O1 
2O1 
2O2 
2O2 
2O2 
2O2 
2O2 
2O2 
2O2 
2O3 
2O3 
2O3 
2O3 
2O3 
2O3 
2O3 
2O3 
2O3 
204 
204 
204 
204 
204 
205 
205 
205 
205 
205 
205 
2O6 
2O6 
2O6 
2O6 
2O6 
2O6 
2O6 
2O7 
2O7 
2O7 
2O7 
2O7 
2O7 
2O7 
2O7 
2O7 
208 
208 
208 
81.766 
81916 
82.826 
81,132 
82.848 
82.796 
81.395 
80627 
83.760 
83441 
85.190 
81.071 
79.765 
79.905 
80.584 
79.113 
77.821 
79.247 
79.331 
78.074 
76.954 
79.568 
80.051 
80.568 
78.270 
77.164 
77.483 
78.516 
76.904 
76.600 
75.733 
77.830 
76.600 
76.812 
75.852 
74.653 
76.575 
75.243 
77.549 
76.384 
75.571 
76.077 
77.208 
75.548 
76.918 
76.859 
76.167 
77.589 
75.232 
75.593 
76.718 
76.692 
74.366 
77.702 
78.808 
79.087 
79.822 
80.083 
80.806 
78.506 
78.691 
80.095 
80.606 
77.621 
76.607 
77497 
80.719 
82.064 
82.101 
82.701 
82.851 
83.462 
84.876 
85.454 
84.868 
81.466 
81.482 
82.668 
0.273 
ended V3 loop 
32.701 
34.191 
34.563 
34.98O 
33.633 
33.987 
34.392 
34.988 
35.144 
36.263 
34.729 
34.068 
34.395 
35.444 
35.216 
33.130 
33.406 
36.584 
37.664 
37.797 
37.747 
39.012 
40.045 
38.831 
37.976 
38.132 
39.234 
39.197 
36.840 
35.666 
37.055 
35.047 
40.216 
41.299 
41.137 
40.906 
42.667 
42.725 
42.901 
41.249 
41.104 
41.977 
42.457 
39.63S 
38.979 
37.514 
36.714 
37.157 
42.181 
43.003 
42.355 
41.156 
43.209 
43.149 
42.609 
43.328 
44.314 
42.558 
44.146 
42.826 
43416 
43.099 
42004 
42.719 
42.2S3 
41757 
44.044 
43.823 
43.241 
43.830 
45.139 
45.466 
44.916 
45.044 
44.051 
42.091 
41.466 
40.512 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
11440 
116.21 
118.31 
116.81 
108.94 
106.71 
104.11 
105.56 
108.19 
109.13 
108.79 
101.10 
98.61 
96.43 
96.37 
98.18 
96.50 
92.8O 
89.88 
87.32 
86.48 
90.70 
90.81 
91.35 
84.68 
81.86 
79.73 
79.56 
82.08 
85.27 
78.87 
89.69 
78.11 
79.05 
80.92 
81.00 
78.00 
7943 
77.99 
81.69 
81.90 
83.87 
84.27 
80.36 
79.24 
80.19 
79.78 
80.36 
86.42 
87.19 
87.49 
85.76 
86.04 
89.57 
93.38 
96.85 
96.56 
92.11 
93.23 
OO.89 
OSO1 
O9.65 
10.64 
O3.87 
O2.48 
O2.04 
1422 
1919 
23.01 
24.82 
1960 
1901 
1882 
17.77 
16.94 
27.08 
31.24 
32.68 
118 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
A TOM 
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469 
470 
471 
472 
473 
474 
475 
476 
477 
478 
479 
480 
481 
482 
483 
484 
485 
486 
487 
488 
489 
490 
491 
492 
493 
494 
495 
496 
497 
498 
499 
500 
5O1 
502 
503 
SO4 
505 
SO6 
507 
SO8 
509 
510 
511 
512 
513 
S14 
515 
S16 
517 
S18 
519 
52O 
521 
522 
523 
524 
525 
526 
527 
528 
529 
530 
531 
532 
533 
534 
535 
536 
537 
538 
539 
S4O 
541 
S42 
543 
544 
545 
S46 
O 
CB 
CG1 
CG2 
CD1 
N 
CA 
C 
O 
CB 
OG 
N 
CA 
C 
O 
CB 
CG 
CD1 
CD2 
CE1 
CE2 
CZ 
CA 
CB 
CG 
CD 
OE1 
OE2 
CA 
CB 
CG 
CD 
CA 
CA 
CB 
CG 
CD 
CA 
CA 
CB 
CG 
ND1 
CD2 
CE1 
NE2 
CA 
CB 
CG 
CD1 
ILE 
ILE 
ILE 
ILE 
ILE 
SE 
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TABLE 2-continued 
208 
208 
208 
208 
208 
209 
209 
209 
209 
209 
209 
2 
83.143 
80184 
79.995 
78.995 
78.847 
83.138 
84.284 
83.970 
83.009 
84.979 
84.086 
84.798 
84.660 
85.467 
86.687 
85.200 
85.309 
84.170 
86.5SO 
84.266 
86.657 
85.513 
84.774 
85.408 
85.710 
84.856 
84.515 
84.410 
83.07.0 
82.970 
82.114 
86.933 
87.358 
86.618 
87.2O6 
88.858 
89.224 
88.063 
85.327 
84.515 
84.844 
84.751 
83.O2S 
82.170 
82.728 
80.713 
85.234 
85.590 
84.603 
83.390 
85.637 
86.169 
85.294 
85.131 
84.297 
84.606 
85.758 
84.498 
83.798 
83.946 
82.301 
83.567 
83.707 
83.OOS 
81.782 
83.064 
83.602 
84.919 
82.988 
85.091 
83.935 
83.767 
83.154 
82.753 
83.591 
84.159 
83.551 
82.990 
40.004 
41.174 
40.133 
41.165 
40.446 
42.234 
42.480 
42.546 
43.192 
43.779 
44.875 
4.1.869 
41.858 
43.033 
42.9SO 
40.546 
40.538 
40.630 
40.429 
40.612 
40.409 
40.499 
44.126 
45.342 
45.289 
44906 
46.543 
46.875 
47.479 
48106 
47.317 
45.685 
45.686 
46.766 
47.771 
45.974 
45.516 
46.041 
46.SSS 
47.525 
47.553 
46.53S 
47.221 
48.233 
45.797 
48.192 
48.730 
48.929 
48.292 
48.418 
SO449 
SO.848 
SO.O12 
47.609 
46.949 
47.439 
47.432 
45.419 
44.853 
44.775 
45.085 
47.855 
48.337 
47.378 
47.263 
49.719 
50.756 
51164 
S1.5O1 
S2.118 
S2.341 
46.678 
45.78O 
46.675 
47.022 
44.736 
43.677 
42.522 
ended V3 loop 
39.984 
40.682 
39.584 
41.622 
38.6SS 
40.295 
39.429 
37.938 
37.517 
39.850 
39.771 
37.146 
35.694 
35.152 
35.018 
35.121 
33.623 
32.828 
33.003 
31436 
31.614 
30.829 
34.852 
34.347 
32.849 
32,049 
34.648 
36.128 
36.492 
37.568 
35.704 
32.452 
31.OSO 
30.271 
29.876 
31.143 
32.532 
33.324 
30.049 
29.329 
27.836 
27.154 
29.538 
28.78O 
29.093 
29.175 
27.316 
25.907 
24.933 
25.097 
25.787 
27.130 
28.043 
23.922 
22.928 
21.517 
21.089 
22.972 
24.204 
21.712 
24.2O7 
2O.801 
19436 
18487 
18.512 
19.279 
2O.212 
2O.198 
21.161 
21.096 
21.694 
17.657 
16.686 
15.523 
14.699 
16.2O2 
15.308 
15.849 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
33.21 
32.2O 
32.98 
32.23 
34.64 
34.15 
35.70 
37.12 
38.29 
34.98 
35.08 
37.24 
37.12 
38.23 
38.35 
36.15 
35.14 
34.46 
34.03 
33.36 
33.27 
33.06 
39.29 
40.31 
40.01 
39.77 
41.10 
43.21 
44.76 
45.16 
46.11 
39.56 
39.07 
38.18 
38.23 
39.58 
39.85 
39.87 
36.58 
34.44 
33.16 
33.40 
34.18 
33.60 
34.56 
34:43 
31.77 
30.01 
28.02 
26.87 
30.90 
31.42 
31.68 
26.22 
24.39 
23.82 
23.83 
24.52 
24.66 
23.95 
26.40 
22.91 
22.26 
22.82 
22.59 
21.11 
20.49 
20.39 
20.37 
20.82 
20.97 
24.13 
26.48 
29.20 
29.59 
24.57 
23.48 
23.73 
120 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
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A 
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A 
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A 
A 
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TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
A TOM 
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547 
S48 
549 
550 
551 
552 
553 
554 
555 
556 
557 
558 
559 
S60 
S61 
S62 
563 
S64 
565 
566 
567 
568 
569 
570 
571 
572 
573 
574 
575 
576 
577 
578 
579 
S8O 
581 
582 
583 
S84 
585 
S86 
587 
S88 
589 
590 
591 
592 
593 
594 
595 
596 
597 
598 
599 
600 
6O1 
6O2 
603 
604 
60S 
606 
607 
608 
609 
610 
611 
612 
613 
614 
615 
616 
617 
618 
619 
62O 
621 
622 
623 
624 
CD2 
CE1 
CE2 
CZ 
OH 
N 
CA 
C 
O 
CB 
SG 
N 
CA 
CD1 
CD2 
CE1 
CE2 
CA 
CB 
CG 
CD1 
CD2 
TYR 
TYR 
TYR 
TYR 
TYR 
CYS 
CYS 
CYS 
CYS 
CYS 
CYS 
ALA 
ALA 
ALA 
ALA 
ALA 
PRO 
PRO 
PRO 
PRO 
PRO 
PRO 
PRO 
ALA 
ALA 
ALA 
ALA 
ALA 
GLY 
GLY 
GLY 
GLY 
PHE 
PHE 
PHE 
PHE 
PHE 
PHE 
PHE 
PHE 
PHE 
PHE 
PHE 
ALA 
ALA 
ALA 
ALA 
ALA 
LE 
LE 
LE 
LE 
LE 
LE 
LE 
LE 
LEU 
LEU 
LEU 
LEU 
LEU 
LEU 
LEU 
LEU 
LYS 
LYS 
LYS 
LYS 
LYS 
LYS 
LYS 
LYS 
LYS 
CYS 
CYS 
CYS 
CYS 
CYS 
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TABLE 2-continued 
: 
220 
220 
220 
220 
220 
221 
221 
221 
221 
221 
222 
222 
222 
222 
223 
223 
223 
223 
223 
223 
223 
223 
223 
223 
223 
224 
224 
224 
224 
224 
225 
225 
225 
225 
225 
225 
225 
225 
226 
226 
226 
226 
226 
226 
226 
226 
227 
227 
227 
227 
227 
227 
227 
227 
227 
228 
228 
228 
228 
228 
83.531 
82.427 
82.969 
82.42O 
81.86S 
81.486 
81.054 
80.480 
8O.OSO 
79.996 
80.410 
80.464 
79.953 
78.437 
77.887 
80.656 
77.747 
76.292 
75.88O 
76.725 
75.973 
77147 
78.287 
74.58O 
74.079 
74.302 
73.748 
72.603 
75.115 
75.396 
76.792 
77.2O1 
77.526 
78.890 
79.777 
79.291 
78.894 
78.252 
78.935 
76.967 
78.352 
76.371 
77.067 
81.08.1 
82.038 
83.350 
83.741 
82.28O 
84.028 
85.296 
86.481 
86.477 
85.293 
84767 
84.438 
85.843 
87.488 
88.692 
89.778 
90.048 
89.233 
88.416 
88.412 
89.000 
90.405 
91.465 
92.802 
93.016 
91.1.37 
92.124 
92.021 
93.166 
93.253 
93.701 
95.013 
95.858 
96.285 
95.704 
43831 
41.541 
42.858 
41.715 
40.755 
47.070 
47.947 
47.158 
46.011 
48.934 
49.952 
47.790 
47.18O 
47.322 
48.416 
47.793 
46.211 
46.186 
46.886 
47.227 
44.688 
44.054 
44845 
47.099 
47.743 
46.806 
45.708 
48.056 
47.243 
46.417 
45.835 
45.OSO 
46.238 
45.777 
46.927 
47.921 
44.670 
43.397 
42.528 
43.061 
41.337 
41871 
41.007 
46.784 
47.806 
47.160 
46.125 
48.763 
47.771 
47.238 
48.096 
49.316 
47.094 
48.369 
45.910 
49.311 
47.442 
48.108 
48.170 
47.181 
47.360 
47.465 
46.134 
48.571 
49.333 
49.518 
49.761 
SO.822 
50.710 
50.907 
52.297 
52.535 
S3.948 
48.782 
48.931 
49.909 
49.591 
47.560 
ended V3 loop 
3.921 
S.O33 
3.096 
3.658 
2.843 
5.462 
4.38O 
3.2O2 
3.357 
4.866 
6.317 
2.031 
O.806 
O.652 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
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A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
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A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
A 
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TOM 
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TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
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TOM 
TOM 
TOM 
TOM 
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TOM 
TOM 
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625 
626 
627 
628 
629 
630 
631 
632 
633 
634 
635 
636 
637 
638 
639 
640 
641 
642 
643 
644 
645 
646 
647 
648 
649 
6SO 
651 
652 
653 
654 
655 
656 
657 
658 
659 
660 
661 
662 
663 
664 
665 
666 
667 
668 
669 
670 
671 
672 
673 
674 
675 
676 
677 
678 
679 
68O 
681 
682 
683 
684 
685 
686 
687 
688 
689 
690 
691 
692 
693 
694 
695 
696 
697 
698 
699 
700 
701 
702 
SG 
N 
CA 
C 
O 
CB 
CG 
OD1 
ND2 
CA 
CB 
CG 
OD1 
OD2 
CA 
CB 
CG 
CD 
CE 
NZ 
CA 
CA 
CB 
CG 
CD1 
CD2 
CE1 
CE2 
CZ 
CA 
CB 
CG 
OD1 
ND2 
CYS 
ASN 
ASN 
ASN 
ASN 
ASN 
ASN 
ASN 
ASN 
ASP 
ASP 
ASP 
ASP 
ASP 
ASP 
ASP 
ASP 
LYS 
LYS 
LYS 
LYS 
LYS 
LYS 
LYS 
LYS 
LY S 
s N 
ASN 
ASN 
ASN 
ASN 
ASN 
ASN 
GLY 
GLY 
GLY 
GLY 
LYS 
LYS 
LYS 
LYS 
LYS 
LYS 
LYS 
LYS 
LYS 
GLY 
GLY 
GLY 
GLY 
PRO 
PRO 
PRO 
PRO 
PRO 
PRO 
PRO 
CYS 
CYS 
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TABLE 2-continued 
228 
229 
229 
229 
229 
229 
229 
229 
229 
230 
230 
230 
230 
230 
230 
230 
230 
231 
231 
231 
231 
231 
231 
231 
231 
231 
232 
232 
232 
232 
232 
232 
232 
233 
233 
233 
233 
233 
233 
233 
233 
233 
233 
233 
234 
234 
234 
234 
234 
234 
234 
234 
235 
235 
235 
235 
236 
236 
236 
236 
236 
236 
236 
236 
236 
237 
237 
237 
237 
238 
238 
238 
238 
238 
238 
238 
239 
239 
97.4O1 
96.082 
96.859 
98.350 
99.019 
96.331 
95.052 
93.960 
95.185 
98.873 
OO.298 
O1112 
OO.792 
OO611 
OO.772 
99.829 
O1844 
O2.174 
O3.034 
O3.705 
O3.862 
O4.103 
O3.545 
O2.981 
O2.249 
O1640 
O4.1OO 
O4.7SO 
O4.170 
O4627 
O6.264 
O6.807 
O6.956 
O3.162 
O2SO6 
O2.979 
O3.185 
OO.990 
OO.211 
OO413 
99.267 
99.687 
98.534 
98.744 
O3.137 
O3.606 
O2.497 
O2.776 
O4.479 
O3.667 
O3.832 
O2.791 
O1246 
OO.152 
99.372 
98.186 
OO.O23 
99.361 
OO.036 
O1.238 
99.386 
OO.774 
OO.770 
OO.766 
OO.848 
99.254 
99.797 
99.066 
97.921 
99.693 
99.075 
99.297 
100.427 
99.759 
100.463 
10O886 
98.228 
98.361 
47.576 
S1.103 
52.135 
52.104 
53.135 
53.533 
53.874 
53.472 
54.612 
SO.931 
SO.803 
S1040 
SOSO1 
49.413 
49.400 
49.813 
48.972 
S1832 
52.142 
SO.890 
50.762 
53.164 
54.525 
SS.296 
56.559 
57.279 
49.970 
48.738 
47.577 
47.283 
48.791 
49.976 
47.583 
46.923 
45.798 
44,482 
44.394 
45.927 
45.067 
45.170 
44.163 
44.386 
43.372 
43.485 
43455 
42.163 
41.209 
40.083 
41.463 
40.844 
39.666 
41.636 
41649 
40.784 
40.177 
40.456 
39.334 
38.704 
39.113 
39.357 
37.177 
36.597 
35.068 
34.390 
32.901 
39.183 
39.569 
40.755 
41.018 
41.487 
42.651 
43.951 
44.267 
42.702 
41.336 
41.069 
44.703 
45.976 
ended V3 loop 
O6.702 
O7.768 
O8.452 
O8.15S 
O8.224 
O8.114 
O8.855 
O8.4S5 
O9.953 
O7.822 
O7.541 
O8.808 
O9.867 
O6.994 
OS-486 
O4.784 
OSO12 
O8.693 
O9.833 
10.406 
1162O 
O942O 
O8.994 
10.185 
O9.747 
10.904 
O9.531 
O9.960 
O9.173 
O8.072 
O9.698 
10.286 
10.304 
O9.741 
09.086 
O9.689 
10.897 
O9240 
O8.293 
O6.922 
O8.766 
06.031 
O7.885 
O6. S13 
O8.857 
O9.353 
O9.789 
10.195 
O8.305 
O7.184 
O6.859 
O6.581 
O9.711 
10.119 
O8.967 
O8.808 
O8.171 
O7.031 
O5.726 
OS.693 
O7.169 
O7412 
O7.512 
O6.146 
O6.254 
O4.654 
O3.364 
O2.767 
O3.138 
O1838 
O12OO 
O1.98S 
O2.353 
99.827 
99.685 
O1.093 
O2.245 
O2.959 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
32.08 
25.50 
26.07 
26.43 
26.40 
27.05 
28.07 
29.09 
28.62 
27.09 
28.18 
29.06 
29.47 
28.04 
28.21 
29.16 
27.80 
30.19 
31. SO 
32.11 
32.26 
31.22 
31.29 
31.06 
30.17 
28.78 
32.72 
33.16 
33.64 
34.29 
33.30 
33.19 
34.O1 
33.70 
34.07 
33.22 
33.97 
35.95 
38.56 
39.24 
39.44 
40.27 
40.8O 
40.90 
32.11 
31.12 
30.16 
30.18 
31.40 
31.18 
30.27 
30.32 
28.79 
27.79 
27.12 
26.69 
26.63 
26.89 
28.87 
29.74 
24.81 
22.07 
2O.19 
1890 
1647 
3O44 
32.18 
33.46 
34.O2 
33.68 
33.81 
33.94 
33.93 
33.77 
34.36 
34.13 
34.81 
36.32 
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TOM 
TOM 
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TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
TOM 
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937 
938 
939 
940 
941 
942 
943 
944 
945 
946 
947 
948 
949 
950 
951 
952 
953 
954 
955 
956 
957 
958 
959 
96.O 
961 
962 
963 
964 
96S 
966 
967 
968 
969 
970 
971 
972 
973 
974 
975 
976 
977 
978 
979 
98O 
981 
982 
983 
984 
985 
986 
987 
988 
989 
990 
991 
992 
993 
994 
995 
996 
997 
998 
999 
1OOO 
1001 
10O2 
10O3 
1004 
1005 
1006 
1007 
1008 
1009 
1010 
1011 
1012 
1013 
1014 
CA 
CA 
CB 
CG 
CD 
NE 
CZ 
NH1 
NH2 
CA 
CB 
OG 
CA 
CB 
CG 
OD1 
OD2 
CA 
CB 
CG 
OD1 
ND2 
CA 
CB 
CG 
CD1 
CD2 
CE1 
CE2 
CZ 
CA 
CB 
OG1 
CG2 
N 
CA 
C 
O 
CB 
CG 
OD1 
ND2 
N 
CA 
C 
VAL 
VAL 
VAL 
VAL 
VAL 
VAL 
VAL 
VAL 
ILE 
ILE 
ILE 
ILE 
ILE 
ILE 
ILE 
ILE 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
ARG 
SER 
SER 
SER 
SER 
SER 
SER 
ASP 
ASP 
ASP 
ASP 
ASP 
ASP 
ASP 
ASP 
ASN 
ASN 
ASN 
ASN 
ASN 
ASN 
A s N 
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TABLE 2-continued 
270 
271 
271 
271 
271 
271 
271 
271 
272 
272 
272 
272 
272 
272 
272 
272 
273 
273 
273 
273 
273 
273 
273 
273 
273 
273 
273 
274 
274 
274 
274 
274 
274 
275 
275 
275 
275 
275 
275 
275 
275 
276 
276 
276 
276 
276 
276 
276 
276 
277 
277 
277 
277 
277 
277 
277 
277 
277 
277 
277 
278 
278 
278 
278 
278 
278 
278 
279 
279 
279 
279 
279 
279 
279 
279 
28O 
28O 
28O 
O8.621 
O6.598 
06.313 
O5.937 
O4.888 
OS.168 
O5.713 
O4.117 
O6.804 
O6.572 
O5.975 
06.352 
O7.887 
O9.042 
O8.2O3 
09.082 
OS.040 
O4.405 
O3.923 
O3.487 
O3.254 
O2.587 
O2.311 
O1683 
O1400 
O1691 
OO.82S 
O4.018 
O3.618 
O3.131 
O3.519 
O4.814 
O4.457 
O2.285 
O1.764 
O2.906 
O2.898 
OO.742 
99.978 
OO.457 
98.907 
O3.885 
05.053 
O6.182 
06.209 
O4.764 
O5.951 
O6.983 
O5.817 
O7.098 
O8.223 
O9.164 
O9.851 
09.021 
O8.616 
O7.662 
O9.177 
O7.274 
O8.797 
O7.843 
09.205 
10,082 
O9.545 
10.298 
10.194 
1O.S12 
11.299 
O8.237 
O7.588 
O7.553 
07.075 
O6.168 
O5.527 
O6.104 
O4.322 
O8.059 
08.107 
O6.785 
46.755 
45.520 
44.636 
43.226 
43.009 
45.198 
46.225 
45.838 
42.272 
40.872 
40.139 
40.394 
40.177 
40.617 
40.507 
39.944 
39.232 
38. SOO 
37.100 
36.845 
39.339 
40.260 
41.625 
42.560 
43.826 
44.310 
44.6O7 
36.199 
34.81O 
34.296 
34.816 
33.974 
32.617 
33.274 
32.718 
32.161 
32.283 
3.1626 
31.168 
30.241 
31748 
31.547 
30.984 
30.957 
30.097 
29.56S 
28.957 
28.684 
28.752 
31.915 
32.013 
30.82O 
30.543 
33.282 
34.440 
35.352 
34.606 
36.416 
35.661 
36.568 
30.113 
28.9S4 
27.821 
26.961 
28.471 
29.583 
27.432 
27.836 
26.823 
27.290 
28.384 
26.570 
25.362 
24.276 
25.540 
26.451 
26.780 
26.592 
ended V3 loop 
20.395 
6.668 
5.547 
5.975 
6.581 
4.68O 
3.699 
5.573 
S.656 
5.990 
4.795 
3.652 
6.415 
5.512 
7.860 
4.157 
5.052 
3.967 
4.334 
5.455 
3.401 
4.417 
3.795 
4.726 
4.433 
3.234 
5.337 
3.363 
3.531 
2.184 
1140 
4.003 
4.198 
2.205 
O966 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
OO 
30.81 
28.20 
26.00 
23.76 
23.89 
27.31 
27.47 
28.06 
21.03 
18.57 
16.72 
16.74 
1870 
1992 
1821 
20.90 
14.52 
12.62 
12.88 
13.04 
10.31 
O6.44 
O4.49 
O2.8O 
O153 
99.91 
OO.38 
13.32 
14.33 
1569 
15.97 
14.12 
14.92 
17.50 
1982 
22.54 
23.77 
1948 
1915 
1947 
1952 
24.54 
26.17 
26.16 
27.07 
27.69 
3O48 
31.45 
33.41 
25.51 
24.73 
24.32 
24.52 
24.97 
24.70 
2433 
25.19 
24.54 
25.18 
24.26 
23.74 
23.33 
22.48 
22.37 
23.77 
22.39 
24.71 
21.41 
20.64 
1986 
19.77 
22.36 
23.19 
24.95 
23.66 
1887 
18.01 
1708 
132 














































